

(51) International Patent Classification:

A61K 48/00 (2006.01) C12N 9/02 (2006.01)
C12N 15/864 (2006.01) C12N 9/78 (2006.01)
A61P 25/16 (2006.01) A61K 31/713 (2006.01)

(21) International Application Number:

PCT/GB2021/053191

(22) International Filing Date:

07 December 2021 (07.12.2021)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

2019286.0 08 December 2020 (08.12.2020) GB

(71) Applicant: **MAAVRX LTD** [GB/GB]; c/o CMB Partnership Limited, 7 Wey Court, Mary Road, Guildford Surrey GU1 4QU (GB).

(72) Inventor: **MCDONALD, Michael**; 41 Fairway, Guildford Surrey GU1 1XW (GB).


(74) Agent: **HUTTER, Anton**; Venner Shipley LLP, The Surrey Research Park, 5 Stirling House, Stirling Road, Guildford Surrey GU2 7RF (GB).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,

(54) Title: EXPRESSION VECTORS COMPOSITION

Figure 6



(57) Abstract: The invention relates to expression vectors, and pharmaceutical compositions, and kits comprising the vectors, and, in particular, their use in methods for treating Parkinson's disease (PD), DOPA responsive dystonia, vascular parkinsonism, side effects associated with L-DOPA treatment for Parkinson's disease, L-DOPA induced dyskinesia, Segawa syndrome, or genetic dopamine receptor abnormalities.

TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
KM, ML, MR, NE, SN, TD, TG).

Published:

- *with international search report (Art. 21(3))*
- *with sequence listing part of description (Rule 5.2(a))*

EXPRESSION VECTORS COMPOSITION

The present invention relates to expression vectors, and pharmaceutical compositions, and kits comprising the vectors, and, in particular, their use in methods for treating Parkinson's disease (PD), DOPA responsive dystonia, vascular parkinsonism, side
5 effects associated with L-DOPA treatment for Parkinson's disease, L-DOPA induced dyskinesia, Segawa syndrome, or genetic dopamine receptor abnormalities.

Parkinson's disease is a neurodegenerative disease associated with the loss of dopamine-producing cells in the striatum. Three enzymes are necessary for the
10 production of dopamine by brain cells: tyrosine hydroxylase (TH), GTP cyclohydrolase 1 (GCH1) and aromatic amino acid decarboxylase (AADC). TH and GCH1 regulate the production of L-DOPA (a precursor to dopamine) from tyrosine, and AADC converts L-DOPA to dopamine. The current treatment options for Parkinson's disease include oral
15 administration of L-DOPA, which, in contrast to dopamine, is absorbed across the blood-brain barrier. This treatment is efficacious because AADC is still present in the brains of patients with Parkinson's disease.

However, a problem with oral L-DOPA therapy is that it can lead to side effects, such as abnormal movement. These side effects are believed to be due to the fluctuation of
20 levels of L-DOPA in the blood and brain caused by the short half-life of L-DOPA and the variable absorption across the gut mucosa and blood brain barrier resulting from competition with other amino acids for active transport (Lees, April 2008, The Importance of Steady-State plasma DOPA levels in reducing motor fluctuations in Parkinson's disease, Expert Roundtable Supplement, CNS Spectr 13:4 (Suppl 7) P4-7).

25 Many attempts have been made to formulate L-DOPA into a sustained release oral product that will deliver steady blood and brain levels of L-DOPA. These have not been successful. Currently, the most effective method for delivering steady plasma L-DOPA level requires constant slow infusion of a gel formulation of L-DOPA directly into the
30 patient's jejunum via a tube through the patient's abdominal wall. The more stable plasma levels of L-DOPA result in significantly improved symptomatic control and reduced dyskinesias (Olanow et al Continuous intrajejunal infusion of levodopa-carbidopa intestinal gel for patients with advanced Parkinson's disease: a randomised, controlled, double-blind, double-dummy study. The Lancet Neurology Vol 13 February
35 2014). However the lifelong requirement for a tube through the abdominal wall (with adverse events including dislodgement, kinking, blockage and infection), to carry a

large pump and to refresh the supply of gel daily restrict use of this therapy and make it suboptimal especially for elderly patients with PD.

Many attempts, therefore, have, been made by multiple authors to restore dopamine
5 levels in Parkinson's disease patients by targeting gene therapy directly into the most affected area of the brain, i.e. the striatum. Preclinical and clinical studies have shown some effect with various constructs but none has yet demonstrated sufficient efficacy, safety or the ability to be manufactured at a commercially viable cost to be approved for medicinal use in any country.

10

Efficacy of a formulation of a mixture of three monocistronic single stranded AAV
vectors each encoding either TH, GCH, or AADC demonstrated efficacy in the 1-methyl-
4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) lesioned macaque model of PD. The
contribution of the AAV vector encoding AADC was considered integral to the success
15 of the formulation. This product was never progressed to clinical evaluation (Muramatsu 10 February, 2002, Behavioural Recovery in a Primate Model of Parkinson's disease by Triple Transduction of Striatal Cells with Adeno-Associated Viral (AAV) Vectors Expressing dopamine-Synthesizing Enzymes, Human Gene Therapy, 12: 345-354). The requirement to produce and mix three different AAV
20 vectors and the resulting cost of goods was a factor in the decision not to develop the formulation further.

A single tricistronic Lente vector encoding all three genes demonstrated efficacy in the MPTP macaque model of PD (Azzouz M, Martin-Rendon E, Barber RD, et al.
25 Multicistronic Lentiviral Vector-Mediated Striatal Gene Transfer of Aromatic l-Amino Acid Decarboxylase, Tyrosine Hydroxylase, and GTP Cyclohydrolase I Induces Sustained Transgene Expression, Dopamine Production, and Functional Improvement in a Rat Model of Parkinson's Disease. J Neurosci. 2002;22(23):10302-10312.). Although this was progressed into a clinical trial, the reported efficacy was modest.
30 Approximately one third of treated patients reported no reduction in their oral L-DOPA equivalent daily dose of L-DOPA and dopamine agonists. Remaining patients experienced only a modest reduction in the need for oral L-DOPA or dopamine agonists. The most common reported adverse events remained dyskinesia and on/off fluctuation (Palfi S, Gurru J, Le H, et al. Long-term follow up of a phase 1/2 study of ProSavin, a lentiviral vector gene therapy for Parkinson's disease. Hum Gene Ther Cl
35 Dev. Published online 2018.). Again, the contribution of the AADC was considered

integral to the efficacy of the product. However, AADC may also have contributed to the incidence of dyskinesia by locally amplifying the erratic peaks in L-DOPA levels associated with the continued requirement for oral L-DOPA.

- 5 Rosenblad et al evaluated a bicistronic AAV encoding only TH and GCH1 administered directly to the striatum to produce L-DOPA (WO2013/061076 and WO2010/055209). Although this bicistronic AAV vector resulted in strong expression of TH and GCH1 and complete symptomatic improvement of motor deficit in the 6-hydroxydopamine (6-OHDA) lesioned rat model of PD, it did not result in the expected increase in striatal
10 TH expression (assessed by immunohistochemistry) or sufficient motor improvement in the MPTP lesioned macaque model of PD leading the inventors to write “This issue should be resolved prior to proceeding towards clinical trials.” (Cederfjäll E, Nilsson N, Sahin G, et al. Continuous DOPA synthesis from a single AAV: dosing and efficacy in models of Parkinson’s disease. Sci Rep-uk. 2013;3(1).). Furthermore, the inventors
15 stated “we cannot exclude that this property of our vector is due to some feature of its design” (Rosenblad C, Li Q, Pioli EY, et al. Vector-mediated l-3,4-dihydroxyphenylalanine delivery reverses motor impairments in a primate model of Parkinson’s disease. Brain. 2019;142(8):2402-2416.).
- 20 Despite this prior art, there clearly remains an unmet clinical need for an effective gene therapy to treat PD.

The inventors investigated novel expression vectors for treating PD, and found that using a combination of two monocistronic vectors, which separately encode GCH1 and
25 TH1, results in surprising levels of gene expression. This approach is superior to that of Rosenblad as, in contrast to the Rosenblad bicistronic vector, it resulted in TH expression which was readily detected by immunohistochemistry. In contrast to the Muramatsu and Azzouz methods the invention results in improved motor function in the MPTP lesioned macaque model of PD without augmenting AADC.

30 Thus, according to a first aspect of the invention, there is provided a composition comprising first and second expression vectors, wherein the first expression vector comprises a self-complementary coding sequence including a promoter operably linked to a sequence, which encodes tyrosine hydroxylase (TH), and the second expression
35 vector comprises a self-complementary coding sequence including a promoter operably linked to a coding sequence, which encodes GTP cyclohydrolase 1 (GCH1).

Preferably, the composition does not comprise a vector (either the first or second expression vector or any other vector), which encodes aromatic amino acid decarboxylase (AADC).

5

Advantageously, the composition of the invention exhibits the following unique combination of properties:

- a) It does not require the manufacture and mixing of three vectors (it only requires two vectors), thus simplifying manufacture and reducing cost;
- 10 b) It does not encode AADC, thus reducing the potential for increased AADC expression to exaggerate peak dopamine levels in a patient with a continued requirement for oral L-DOPA (albeit at reduced dosage); and
- c) It results in strong expression of TH, for example in the striatum, thereby resulting in restored levels of endogenously produced L-DOPA and dopamine
- 15 for use in treating Parkinson's disease.

Preferably, in one embodiment, the first expression vector is an AAV vector. Preferably, in one embodiment, the second expression vector is an AAV vector.

- 20 Preferably, in one embodiment, the first expression vector is a self-complementary AAV (scAAV) vector. Preferably, in one embodiment, the second expression vector is a self-complementary AAV vector.

- In another embodiment, the first expression vector is a naked DNA vector. Preferably, 25 the second expression vector is a naked DNA vector.

Preferably, in one embodiment, the second expression vector is a single-stranded AAV (ssAAV) vector.

- 30 In one preferred embodiment, however, the first expression vector is self-complementary AAV vector, and the second expression vector is a ssAAV or naked DNA vector.

- The skilled person would understand that a self-complementary vector is a vector that 35 includes an inverted repeat genome that can fold into dsDNA without the requirement for DNA synthesis or base-pairing between multiple vector genomes. A self-

complementary adeno-associated virus (scAAV) vector is an adeno-associated virus (AAV) vector that carries an inverted repeat genome that can fold into dsDNA without the requirement for DNA synthesis or base-pairing between multiple vector genomes

5 The AAV (first and/or second expression vector) may be derived from AAV-1, AAV-2, AAV-3A, AAV-3B, AAV-4, AAV-5, AAV-6, AAV-7, AAV-8, AAV-9, AAV-10, and/or AAV-11. Preferably, the AAV has tropism to neural tissue. The first and second AAV expression vectors may be different serotypes, but more preferably are the same serotype. In a preferred embodiment, the AAV (first and/or second expression vector)
10 may be derived from AAV1, AAV5, or AAV9, and more preferably, AAV5.

As described in the Examples, and as shown in Figures 17-19, using a 1:1 mixture of scAAV5-human truncated TH and scAAV5-GCH1 (both using CBh promoters) resulted in very clear expression of human truncated TH. Thus, AAV5 is most preferred for the
15 first and/or second expression vector. The skilled person would understand that the truncated TH lacks the regulatory domain of TH.

The composition is preferably a combination or mixture of the first and second expression vectors. The TH-encoding vector is preferably self-complementary AAV
20 (scAAV). The GCH-encoding vector may be either self-complementary or single stranded. Preferably, however, the second vector is also self-complementary. Therefore, in a most preferred embodiment, the first expression vector is scAAV and the second expression vector is scAAV.

25 It should be appreciated that based on prior art it was not at all predictable or expected that administration of two different vectors would result in sufficient coinfection of sufficient cells at an effective ratio throughout a sufficient volume of the primate striatum to achieve sufficient new transduced L-DOPA production to achieve improved motor function in the MPTP macaque model of PD. Furthermore, the use
30 of scAAVs results in significantly lower doses being required due to their high expression levels, which reduces the cost of the treatment, which is very important given the high price of AAVs.

The composition may comprise the two vectors supplied individually (e.g. in a vial or
35 syringe) and mixed immediately prior to, or at the time of, administration, or may be supplied as a single pre-mixed formulation. The ratio of the first vector to second vector

may preferably be about 50:50, but could be 5:95, 10:90, 20:80, 30:70 60:40, 40:60, 70:30, 80:20, 90:10 or 95:5.

In one embodiment, the coding sequence, which encodes TH, encodes human TH,
5 which is referred to herein as SEQ ID No: 1, as set out below:

atgcccacccccgacgccaccacgccacaggccaagggcttccgcagggccggtgtctgagctggacgccaagcaggca
gaggccatcatgtccccgcgggttcattggggcgcaggcagagcctcatcgaggacgcccgcgaaggagcgggaggcggcg
gtggcagcagcggccgctgcagtccttcggagcccggggacccccctggaggctgtggcctttgaggagaaggagggg
10 aaggccgtgctaaacctgctcttctccccgagggccaccaagccctcggcgctgtcccgagctgtgaaggtgtttgag
acgtttgaagccaaaatccaccatctagagacccggcccgccagaggccgcgagctgggggccccccacctggagtac
ttcgtgcgctcgagggtgcgccgaggggacctggccgcccctgctcagtggtgtgcccagggtgtcagaggacgtgcgc
agccccgcggggcccaaggtcccctggttcccaagaaaagtgtcagagctggacaagtgtcatcacctggtcaccaag
15 ttcgacctgacctggacttggaccacccgggcttctcggaccagggtgtaccgccagcgcaggaagctgattgctgag
atcgcttccagtacaggcacggcgacccgattccccgtgtggagtacaccgccgaggagattgccacctggaaggag
gtctacaccacgctgaagggcctctacgccacgcacgcctgcggggagcacctggaggcctttgctttgctggagcgc
ttcagcggctaccgggaagacaatatccccagctggaggacgtctcccgttctgaaggagcgcacgggcttccag
ctgcggcctgtggccggcctgctgtccgcccgggacttctggccagcctggccttccgcgtgttccagtgcacccag
20 tatatccgccacgcgtcctcgcccatgcactcccctgagccggactgctgccacgagctgctggggcacgtgcccatg
ctggccgaccgcaccttcgcgcagttctcgcaggacattggcctggcgtccctgggggcctcggatgaggaaattgag
aagctgtccacgctgtactggttcacggtggagtccgggctgtgtaagcagaacggggagggtgaaggcctatggtgcc
gggctgctgtcctcctacggggagctcctgcactgcctgtctgaggagcctgagattcgggccttcgacctgaggct
gcgcccgctgcagccctaccaagaccagacgtaccagtcagtctacttcgtgtctgagagcttcagtgcgccaaggac
25 aagctcaggagctatgcctcacgcacccagcgccttctccgtgaagttcgaccctgacacgctggccatcgacgtg
ctggacagccccagggcgtgcggcgctccctggagggtgtccaggatgagctggacacccttgcccctgagctgagtg
gccattggctag

[SEQ ID NO: 1]

Preferably, therefore, the coding sequence that encodes TH comprises a nucleotide
30 sequence substantially as set out in SEQ ID No: 1, or a fragment or variant thereof.

Human TH may have an amino acid sequence according to NCBI Reference Sequence:
NP_000351.2, which is referred to herein as SEQ ID NO: 2, as set out below:

35 MPTPDATTPQAKGFRRVSELDKQAEAIMSPRFIGRRQSLIEDARKEREA AVAAAAAAVPSEPGDPLEA
VAFEEKEGKAVLNLLFSRATKPSALSRAVKVFETFEAKIHHLETRPAQRPRAGGPHLEYFVRLEVRRGD
LAALLSGVRQVSEDVRSPAGPKVPWFPRKVSELDKCHHLVTKFDPDLDDHPGFSQDVYRQRRKLIAEIA
FQYRHGDPIPRVEYTAEEIATWKEVYTTLKGLYATHACGEHLEAFALLERFSGYREDNIPQLEDVSRFLK
ERTGFQLRPVAGLLSARDFLASLAFRVFQCTQYIRHASSPMHSPEPDCHELLGHVPMLADRTFAQFSQD
40 IGLASLGASDEEIEKLSTLYWFTVEFGLCKQNGEVKAYGAGLLSSYGELLHCLSEEPEIRAFDPEAAAVQ
PYQDQTYQSVYFVSESFSDAKDKLRSYASRIQRPFSVKFDPYTLAIDVLDSPQAVRRSLEGVQDELDTLA
HALSAIG*

[SEQ ID NO: 2]

Preferably, therefore, the coding sequence that encodes TH comprises a nucleotide sequence which encodes an amino acid sequence substantially as set out in SEQ ID No: 2, or a fragment or variant thereof.

- 5 In another embodiment, however, the coding sequence, which encodes TH, encodes human TH, which is referred to herein as SEQ ID No: 21, as set out below:

atgcccacccccgacgccaccacgccacaggccaagggcttccgcagggccgtgtctgagctggacgccaaagcaggca
gaggccatcatgtccccgcggttcattgggcgcaggcagagcctcatcgaggacgcccgcaggagcgggagggcggcg
10 gtggcagcagcggccgctgcagtcacctcgagcccggggacccctggaggctgtggcctttgaggagaaggagggg
aaggccgtgctaaacctgctcttctccccgagggccaccaagccctcggcgctgtcccgagctgtgaaggtgtttgag
acgtttgaagccaaaatccaccatctagagacccggcccgccagaggccgcgagctggggggccccacctggagtac
ttcgtgcgccctcgaggtgcgcgcaggggacctggccgcccctgctcagtggtgtgcgccaggtgtcagaggacgtgcgc
agccccgcggggcccaaggtcccctgggtcccaagaaaagtgtcagagctggacaagtgtcatcacctggtcaccaag
15 ttcgaccctgacctggacttgaccacccgggcttctcgaccaggtgtaccgccagcgcaggaagctgattgctgag
atcgcccttcagtagcaggcacggcgacccgattccccgtgtggagtacaccgccgaggagattgccacctggaaggag
gtctacaccacgctgaagggcctctacgccacgcacgcctgcggggagcacctggaggcctttgctttgctggagcgc
ttcagcggctaccgggaagacaatatccccagctggaggacgtctcccgcttccctgaaggagcgcacgggcttccag
ctgcggcctgtggccggcctgctgtccgcccgggacttccctggccagcctggccttccgcgtgttccagtgcacccag
20 tatatccgccacgcgtcctcgcccatgcactcccctgagccggactgctgccacgagctgctggggcacgtgcccatg
ctggccgaccgcaccttcgcgcagttctcgcaggacattggcctggcgtccctgggggcctcggatgaggaaattgag
aagctgtccacgctgtcatgggttcacgggtggagttcgggctgtgtaagcagaacggggaggtgaaggcctatggtgcc
gggctgctgtcctcctacggggagctcctgcactgcctgtctgaggagcctgagattcgggccttcgacctgaggct
gcggccgtgcagccctaccaagaccagacgtaccagtcagtcacttcgtgtctgagagcttcagtgacgccaaaggac
25 aagctcaggagctatgcctcacgcattccagcgccttctccgtgaagttcgacccgtacacgctggccatcgacgtg
ctggacagccccagggcgtgcggcgctccctggagggtgtccaggatgagctggacacccttgcccatgcgctgagt
gccattggctag

[SEQ ID NO: 21]

- 30 It should be appreciated that SEQ ID No: 21 is exactly the same as SEQ ID No: 1, except for reversing AC (in SEQ ID No: 1) to CA (in SEQ ID No: 21) at positions 1109 and 1110. Preferably, therefore, the coding sequence that encodes TH comprises a nucleotide sequence substantially as set out in SEQ ID No: 21, or a fragment or variant thereof. Human TH encoded by SEQ ID No: 21 may have an amino acid sequence, which is
35 referred to herein as SEQ ID NO: 22, as set out below:

MPTPDATTPQAKGFRRVSELDAKQAEAIMSPRFIGRRQSLIEDARKEREA AVAAAAAVPSEPGDPLEAVAFEEKEG
KAVLNLLFSPRATKPSALSRAVKVFETFEAKIHLETRPAQRPRAGGPHLEYFVRLEVRRGDLAALLSGVRQVSEDVR
SPAGPKVPWFPRKVSELDKCHHLVTKFDPDLDLHDPGFSQVYRQRRKLIAEIAFQYRHGDPIPRVEYTAEEIATWKE
40 VYTTLKGLYATHACGEHLEAFALLERFSGYREDNIPQLEDVSRFLKERTGFQLRPVAGLLSARDFLASLAFRVFQCTQ

YIRHASSPMHSPEPDCCHELLGHVPM LADRTFAQFSQDIGLASLGASDEEIEKLSTLSWFTVEFGLCKQNGEVKAYGA
 GLLSSYGELLHCLSEEP EIRAFDPEAAAVQPYQDQTYQSVYFVSESFSDAKDKLRSYASRIQRPFSVKFDPYTLAIDV
 LDSPQAVRRSLEGVQDELDTLAHALSAIG*

[SEQ ID NO: 22]

5

The A-C translocation at positions 1109 and 1110 (from SEQ ID No: 1 to SEQ ID No: 21) results in a change of amino acid 401 from a tyrosine to a serine. Preferably, therefore, the coding sequence that encodes TH comprises a nucleotide sequence which encodes an amino acid sequence substantially as set out in SEQ ID No: 22, or a fragment or

10

variant thereof.

In another embodiment, however, the coding sequence encoding TH comprises a nucleotide sequence encoding human truncated TH. Human truncated TH is a variant of TH with the regulatory domain removed. Hence, preferably the first vector

15

comprises a coding sequence encoding TH lacking the regulatory domain of TH.

Advantageously, the first expression vector in the composition of the invention does not encode the regulatory domain of TH, and thus limits the potential for the resulting L-DOPA or dopamine to inhibit additional production due to feedback inhibition. It will be appreciated that the preferred embodiment of the construct comprises a nucleotide

20

sequence encoding human truncated TH, because, in some embodiments, the non-truncated version may be too long to optimally fit into a scAAV.

The domains of TH and their roles are described in Daubner *et al.* (Daubner SC, Lohse DL, Fitzpatrick ' PF. Expression and characterization of catalytic and regulatory domains of rat tyrosine hydroxylase. Protein Sci. 1993;2:1452–60). In one

25

embodiment, human truncated TH comprises the nucleotide sequence referred to herein as SEQ ID No: 3, as set out below:

30

atgagccccgcggggcccaagggtccctggttcccaagaaaagtgtcagagctggacaagtgtcatcacctggtcacc
 aagttcgaccctgacctggacttggaccacccgggcttctcgaccagggtgtaccgccagcgcaggaagctgattgct
 gagatcgcttccagtacaggcacggcgaccgcattccccgtgtggagtacaccgccgaggagattgccacctggaag
 gaggtctacaccacgctgaagggcctctacgccacgcacgcctgcggggagcacctggaggcctttgctttgctggag
 cgcttcagcggctaccgggaagacaatatccccagctggaggacgtctcccgcttccctgaaggagcgcacgggcttc
 cagctgcggcctgtggccggcctgctgtccgcccgggacttcctggccagcctggccttcgcgctgttccagtgcacc
 cagtatatccgccacgcgtcctcgcccatgcaactccctgagccggactgctgccacgagctgctggggcacgtgccc
 atgctggccgaccgcaccttcgcgcagttctcgaggacattggcctggcgtccctgggggcctcgcatgaggaaatt
 gagaagctgtccacgctgtactggttcacgggtggagttcgggctgtgtaagcagaacggggaggtgaaggcctatggt
 gccgggctgctgtcctcctacggggagctcctgcactgcctgtctgaggagcctgagattcgggccttcgacctgag
 gctgcggccgtgcagccctaccaagaccagacgtaccagtcagtctacttcgtgtctgagagcttcagtgcagccaag
 gacaagctcaggagctatgcctcacgcacccagcgccttctccgtgaagttcgacctgacacgctggccatcgac
 gtgctggacagccccagggcgtgcggcgctccctggagggtgtccaggatgagctggacacccttgcccatgcgctg
 agtgccattggctag

35

40

[SEQ ID NO: 3]

Preferably, therefore, the coding sequence encoding TH (and preferably lacking the regulatory domain of TH) comprises a nucleotide sequence substantially as set out in SEQ ID No: 3, or a fragment or variant thereof.

- 5 In one preferred embodiment, the coding sequence encoding TH comprises a nucleotide sequence encoding human truncated TH. In one embodiment, human truncated TH comprises an amino acid sequence referred to herein as SEQ ID NO: 4, as set out below:

10 MSPAGPKVPWFPRKVSELDKCHHLVTKFDPDLDDHPGFSDQVYRQRRKLIAEIAFQYRHGDPIPRVEYTAEIATWK
EVYTTLKGLYATHACGEHLEAFALLERFSGYREDNIPQLEDVSRFLKERTGFQLRPVAGLLSARDFLASLAFRVFQCT
QYIRHASSPMHSPEPDCCHELLGHVPM LADRTFAQFSQDIGLASLGASDEEIEKLSTLYWFTVEFGLCKQNGEVKAYG
AGLLSSYGELLHCLSEEP EIRAFDPEAAAVQPYQDQTYQSVYFVSESFSDAKDKLRSYASRIQRPFSVKFDPYTLAID
VLDSPQAVRRSLEGVQDELDTLAHALSAIG*

[SEQ ID NO: 4]

15

Preferably, therefore, the coding sequence encoding TH comprises a nucleotide sequence encoding an amino acid sequence substantially as set out in SEQ ID No: 4, or a fragment or variant thereof.

- 20 In another embodiment, human truncated TH (having the AC to CA translocation) comprises the nucleotide sequence referred to herein as SEQ ID No: 23, as set out below:

Atgagccccgcggggccaaggtcccctggttcccaagaaaagtgtcagagctggacaagtgtcatcacctggtcacc
aagttcgaccctgacctggacttgaccacccgggcttctcggaccaggtgtaccgccagcgcaggaagctgattgct
25 gagatcgcttccagtacaggcacggcgacccgattccccgtgtggagtacaccgccgaggagattgccacctggaag
gaggtctacaccacgctgaagggcctctacgccacgcacgcctgcggggagcacctggaggcctttgctttgctggag
cgcttcagcggctaccgggaagacaatatccccagctggaggacgtctcccgcttcctgaaggagcgcacgggcttc
cagctgcggcctgtggcggcctgctgtccgcccgggacttcctggccagcctggccttcgcgctgttccagtgcacc
cagtatatccgccacgcgtcctcgcccatgcactcccctgagccggactgctgccacgagctgctggggcacgtgcc
30 atgctggccgaccgcaccttcgcgcagttctcgcaggacattggcctggcgctccctgggggcctcggatgaggaaatt
gagaagctgtccacgctgtactggttcacgggtggagttcgggctgtgtaagcagaacggggaggtgaaggcctatggt
gccgggctgctgtcctcctacggggagctcctgcactgcctgtctgaggagcctgagattcgggccttcgacctgag
gctgcggccgtgcagccctaccaagaccagacgtaccagtcagtctacttcgtgtctgagagcttcagtgcgccaag
gacaagctcaggagctatgcctcacgcacccagcgccccttctccgtgaagttcgaccctacacgctggccatcgac
35 gtgctggacagccccagggcgtgcggcgctccctggaggggtgtccaggatgagctggacacccttgcccatgcgctg
agtgccattggctag

[SEQ ID NO: 23]

Preferably, the coding sequence encoding TH (and preferably lacking the regulatory domain of TH) comprises a nucleotide sequence substantially as set out in SEQ ID No: 23, or a fragment or variant thereof.

- 5 In another embodiment, human truncated TH (in which amino acid 401 has changed from a tyrosine to a serine) comprises an amino acid sequence referred to herein as SEQ ID NO: 24, as set out below:

10 MSPAGPKVPWFPRKVSELDKCHHLVTKFDPDLDDHPGFSDQVYRQRRKLIAEIAFQYRHGDPIPRVEYTAEIATWK
EVYTTTLKGLYATHACGEHLEAFALLERFSGYREDNIPQLEDVSRFLKERTGFQLRPVAGLLSARDFLASLAFRVFQCT
QYIRHASSPMHSPEPDCCHELLGHVPMPLADRTFAQFSQDIGLASLGASDEEIEKLSTLSWFTVEFGLCKQNGEVKAYG
AGLLSSYGELLHCLSEEP EIRAFDPEAAAVQPYQDQTYQSVYFVSESFSDAKDKLRSYASRIQRPFSVKFDPYTLAID
VLDSPQAVRRSLEGVQDELDTLAHALSAIG

[SEQ ID NO: 24]

15

Preferably, therefore, the coding sequence encoding TH comprises a nucleotide sequence encoding an amino acid sequence substantially as set out in SEQ ID No: 24, or a fragment or variant thereof.

- 20 In an embodiment, the coding sequence encoding GCH1 comprises a nucleotide sequence encoding murine GCH1. The nucleotide sequence encoding murine GCH1 is referred to herein as SEQ ID No: 5, as set out below:

25 ggtgggttttccctttgaaaaacacgatgataatatggccacaaccgcggccgtagatcccgggaccatggagaagccgc
ggggagtcaggtgcaccaatgggttctccgagcgggagctgccgcggcccggggagcccgctgccgagaagtccc
ggccgcccagggccaagggcgccacagccggccgacgcctggaaggcagggcgccaccgcagcagggaggaaaaccagg
tgaacctccccaaactggcggtgcttactcgctccattctgctctcgctgggagaggacccccagcgccaggggctgc
tcaagacgcccctggagggcgccaccgcatgcagtacttcaccaagggataccaggagaccatctcagatgtcctga
atgatgctatatattgatgaagatcatgacgagatgggtgattgtgaaggacatagatatgttctccatgtgtgagcatc
30 acctgttccattttaggaaggggtccatattggctatcttcctaacaagcaagtccttgggtctcagtaaaacttgcca
ggattgtagaaatctacagtagacgactacaagttcaagagcgcctcaccaaaacagattgcggtggccatcacagaag
ccttgccagcctgctggcggttgagtagtgattgaagcgacacacatgtgcatggtaatgcgaggcggtgcagaaaatga
acagcaagactgtcactagcaccatgctgggctgttccgggaagacccaagactcgggaggagttcctcacactaa
tcaggagctgag

35

[SEQ ID NO: 5]

Therefore, the coding sequence may comprise a nucleotide sequence substantially as set out in SEQ ID No: 5, or a fragment or variant thereof.

- 40 In a preferred embodiment, however, the coding sequence encoding GCH1 comprises a nucleotide sequence encoding human GCH1. For example, the nucleotide sequence

encoding human GCH may be the sequence according to GenBank NM 000161.2, which is referred to herein as SEQ ID No: 6, as set out below:

5 atggagaagggccctgtgcgggcaccggcggagaagccgcggggcgccaggtgcagcaatgggttccccg
agcgggatccgcccgcggccccgggcccagcaggccggcggagaagcccccgcgccccgaggccaagagcgc
gcagcccgcggacggctggaagggcgagcggccccgcagcggaggaggataacgagctgaacctccctaac
ctggcagccgcctactcgtccatcctgagctcgtctgggcgagaacccccagcggcaagggtgctcaaga
cgccctggagggcgccctcgcccatgcagttcttcaccaagggtaccaggagaccatctcagatgtcct
aaacgatgctatatatttgatgaagatcatgatgagatgggtgattgtgaaggacatagacatgttttccatg
10 tgtgagcatcacttgggttccatttgttggaagggtccatattgggttatcttcctaacaagcaagtccttg
gcctcagcaaacttgcgaggattgtagaaatctatagtagaagactacaagttcaggagcgccttacaaa
acaaattgctgtagcaatcacggaagccttgcgccctgctggagtcggggtagtggttgaagcaacacac
atgtgtatggtaatgcgagggtgtacagaaaatgaacagcaaaaactgtgaccagcacaatgttgggtgtgt
tccgggaggatccaaagactcgggaagagttcctgactctcattaggagctga
15 [SEQ ID NO: 6]

Preferably, therefore, the coding sequence encoding GCH1 comprises a nucleotide sequence substantially as set out in SEQ ID No: 6, or a fragment or variant thereof.

20 In one preferred embodiment, the coding sequence encoding GCH1 comprises a nucleotide sequence encoding human GCH1. Human GCH1 may have an amino acid sequence according to NCBI Reference Sequence: NP_000152.1. Human GCH1 comprises an amino acid sequence referred to herein as SEQ ID NO: 7, as set out below:

25 MEKGPVRAPAEKPRGARCSNGFPERDPPRPGPSRPAEKPPRPEAKSAQPADGWKGERPRSEEDNELNLPN
LAAAYSSILSSLGENPQRQGLLKTPWRAASAMQFFTKGYQETISDVLNDAIFDEDHDEMIVKIDMFMS
CEHHLVPFVGKVHIGYLPNKQVLGLSKLARIVEIYSRRLQVQERLTKQIAVAITEALRPAGVGVVVEATH
MCMVMRGVQKMNSKTVTSTMLGVFREDPKTREEFLTLIRS*
[SEQ ID NO: 7]

30 Preferably, therefore, the coding sequence encoding GCH1 comprises a nucleotide sequence encoding an amino acid sequence substantially as set out in SEQ ID No: 7, or a fragment or variant thereof.

35 The first and second expression vectors each comprise a promoter which may be any suitable promoter, including a constitutive promoter, an activatable promoter, an inducible promoter, or a tissue-specific promoter. The promoter may be the same in the first construct and the second construct, or different promoters may be used for each construct.

40 In a preferred embodiment, the promoter in the first and second expression vector is one enabling the expression of TH and/or GCH1 in the most suitable tissue or tissues

for treating Parkinson's disease. In an embodiment, therefore, the promoter is one that permits high expression in a subject's neurons, or in the subject's glial cells, or in the subject's neurons and glial cells, or in the subject's neurons and ependymal cells lining the cerebral ventricles, or in the subject's neurons and glial cells and ependymal cells.

5

Preferably, the promoter in the first and/or second expression vector may be the CBh promoter, or a fragment or variant thereof. (Gray SJ, Foti SB, Schwartz JW, et al. Optimizing Promoters for Recombinant Adeno-Associated Virus-Mediated Gene Expression in the Peripheral and Central Nervous System Using Self-Complementary Vectors. *Hum Gene Ther.* 2011;22(9):1143-1153.). As described in the Examples, the inventor has compared different potential constructs and demonstrated surprisingly that despite the limited packaging capacity of self-complementary vectors requiring the use of two different viral vectors (one to transduce TH and one to transduce GCH1), the increased transduction achieved requires a lower total number of vector genome copies than would be required using the optimal single bicistronic viral vector. This is important for at least two reasons: (1) reducing manufacturing cost of goods, and (2) reducing the AAV capsid load for the patients and thus reducing the risk of capsid related toxicity.

20 Either or both promoters in the expression vectors may be the CBh promoter. Preferably, both the first and second expression vector comprises the CBh promoter.

The use of the CBh promoter offers at least four advantages to the constructs for treating PD. Firstly, its short length enables accommodation of the promoter trans gene combination within a self-complementary AAV construct. Second, it is less prone to silencing than the CMV promoter which is widely used in previous monocistronic constructs. Thirdly, its lack of neuronal specificity enables transduction of astrocytes and glia increasing the potential for additional production of DOPA by these cells within the striatum. Fourthly, the CBh promoter contains both a truncated chicken beta-actin intron and a minute virus of mouse (MVM) intron, which, together, act as a spacer, thereby increasing gene expression.

30

In one embodiment, the sequence of the CBh promoter is referred to herein as SEQ ID NO: 8, as follows:

35

CGTTACATAACTTACGGTAAATGGCCCGCCTGGCTGACCGCCCAACGACCCCGCCATTGACGTCAATAGTAACGCCAATAGGGACT
 TTCCATTGACGTCAATGGGTGGAGTATTTACGGTAAACTGCCCACTTGGCAGTACATCAAGTGTATCATATGCCAAGTACGCCCCCTA
 TTGACGTCAATGACGGTAAATGGCCCGCCTGGCATTGTGCCAGTACATGACCTTATGGGACTTTCCTACTTGGCAGTACATCTACGT
 ATTAGTCATCGCTATTACCATGGTCGAGGTGAGCCCCACGTTCTGCTTCACTCTCCCCATCTCCCCCCCCCTCCCCACCCCCAATTTTG
 5 TATTTATTTATTTTTTAATTATTTTGTGCAGCGATGGGGGCGGGGGGGGGGGGGGGGGCGCGCGCCAGGCGGGGCGGGGCGGGGCGAGG
 GGC GGCGGGGCGGGGCGAGGCGGAGAGGTGCGGCGGCAGCCAATCAGAGCGGCGCGCTCCGAAAGTTTCCTTTTATGGCGAGGCGGCGGCG
 GCGGCGGCCCTATAAAAAGCGAAGCGCGCGGGCGGGAGTCGCTGCGCGCTGCCTTCGCCCCGTGCCCGCTCCGCCCGCCCTCG
 CGCCGCCCGCCCCGGCTCTGACTGACCGCGTTACTCCACAGGTGAGCGGGCGGGACGGCCCTTCTCCTCCGGGCTGTAATTAGCTGA
 GCAAGAGGTAAGGGTTTAAGGGATGGTTGGTTGGTGGGGTATTAATGTTTAATTACCTGGAGCACCTGCCTGAAATCACTTTTTTTCA
 10 GGTTGG

[SEQ ID No: 8]

Preferably, therefore, the promoter sequence in the first and/or second expression vector comprises a nucleotide sequence substantially as set out in SEQ ID No: 8, or a fragment or variant thereof.

15

In another embodiment, the promoter in the first and/or second expression vector may be a human synapsin promoter. Either or both promoters in the expression vectors may be the human synapsin promoter. Preferably, the promoter is a human synapsin 1 promoter, which comprises 469 nucleotides. One embodiment of the nucleotide
 20 sequence forming the human synapsin I (SYN I) promoter is referred to herein as SEQ ID NO: 9, as follows:

CTGCAGAGGGCCCTGCGTATGAGTGCAAGTGGGTTTTAGGACCAGGATGAGGCGGGGTGGGGTGCCTACCTGACGACCGACCCCGAC
 CCACTGGACAAGCACCCAACCCCATTTCCCAAATTGCGCATCCCCTATCAGAGAGGGGGAGGGGAAACAGGATGCGGCGAGGCGCGT
 25 GCGCACTGCCAGCTTCAGCACCGCGGACAGTGCCCTTCGCCCCCGCCTGGCGGCGCGCGCCACCGCCGCTCAGCACTGAAGGCGCGCT
 GACGTCACTCGCCGGTCCCCCGAAACTCCCCTTCCCGGCCACCTTGGTCGCGTCCGCGCCGCCCGGCCAGCCGGACCGCACAC
 GCGAGGCGCGAGATAGGGGGGCACGGGCGCGACCATCTGCGCTGCGGCGCCGGCGACTCAGCGCTGCCTCAGTCTGCGGTGGGCAGCG
 GAGGAGTCGTGTCGTGCCTGAGAGCGCAG

[SEQ ID NO: 9]

30 The promoter may comprise a nucleotide sequence substantially as set out in SEQ ID No: 9, or a fragment or variant thereof.

In another embodiment, the promoter in the first and/or second expression vector is the chicken beta actin promoter with a cytomegalovirus enhancer (CB7). Either or both
 35 promoters in the expression vectors may comprise the chicken beta actin promoter with a cytomegalovirus enhancer. One embodiment of this promoter is referred to herein as SEQ ID NO: 10, as follows:

gacattgattattgactagttattaatagtaatacaattacggggtcattagttcatagcccatatatggagttccgcgttacataact
 40 tacggtaaatggccccgcctggctgaccgccccaacgacccccgcccattgacgtcaataatgacgtatgttcccatagtaacgcccaata
 gggactttccattgacgtcaatgggtggagtatTTacggtaaacTgccacttggcagtagcatcaagtgtatcatatgccaaagtacgc

5 cccctattgacgtcaatgacggtaaatggcccgccctggcattatgccagtacatgaccttatgggactttcctacttggcagtacat
 ctacgtattagtcacgcgtattaccatggctcgaggtgagccccacgttctgcttcactctccccatctccccccccctccccacccccca
 attttgatatttatttattttttaattattttgtgcagcgatgggggcggggggggggggggggcgcgcgccaggcggggcggggcggg
 gcgaggggcggggcggggcgagggcggagaggtgcggcggcagccaatcagagcggcgcgctccgaaagtttccttttatggcgagggcg
 gcggcgggcgggccctataaaaaagcgaagcgcgcggcgggcg

[SEQ ID No: 10]

The promoter may comprise a nucleotide sequence substantially as set out in SEQ ID No: 10, or a fragment or variant thereof.

10

In an embodiment, the promoter in the first and/or second expression vector is a Tetracycline-responsive element (TRE) promoter. Either or both promoters in the expression vectors may be the TRE promoter, one embodiment of which is referred to herein as SEQ ID NO: 11, as follows:

15

ACGCGTGGAGCTAGTTATTAATAGTAATCAATTACGGGGTCATTAGTTCATAGCCCATATATGGAGTTCCGCGTTACATAACTTACGG
 TAAATGGCCCGCCTGGCTGACCGCCCAACGACCCCGCCCATTTGACGTCAATAATGACGTATGTTCCCATAGTAACGTCAATAGGGAC
 TTTCCATTGACGTCAATGGGTGGAGTATTTACGGTAAACTGCCCACTTGGCAGTACATCAAGTGTATCATATGCCAAGTACGCCCCCT
 ATTGACGTCAATGACGGTAAATGGCCCGCCTGGCATTATGCCCAGTACATGACCTTATGGGACTTTCCTACTTGGCAGTACATCTACG
 20 TATTAGTCATCGCTATTACCATGGTGATGCGGTTTTGGCAGTACATCAATGGGCGTGGATAGCGGTTTGACTCACGGGGATTTCGAAG
 TCTCCACCCCATTTGACGTCAATGGGAGTTTGTGTTTGCACCAAATCAACGGGACTTTCCAAAATGTCGTAACAACTCCGCCCCATTGA
 CGCAAATGGGCGGTAGGCGGTACGGTGGGAGGTCTATATAAGCAGAGCTCGTTTAGTGAACCGTCAGATCGCCTGGAGACGCCATCC
 ACGCTGTTTTGACCTCCATAGAAGACACCGGGACCGATCCAGCCTCC

[SEQ ID No: 11]

25

The promoter may comprise a nucleotide sequence substantially as set out in SEQ ID No: 11, or a fragment or variant thereof.

The promoter in the first and/or the second expression vector may not be the CMV
 30 promoter, or the CMV enhancer/promoter. However, in some embodiments, the
 promoter in the first and/or second expression vector is a CMV promoter. Either or
 both promoters in the expression vectors may be the CMV promoter, one embodiment
 of which is referred to herein as SEQ ID NO: 25, as follows:

35

TAGTTATTAATAGTAATCAATTACGGGGTCATTAGTTCATAGCCCATATATGGAGTTCCGCGTTACATAA
 CTTACGGTAAATGGCCCGCCTGGCTGACCGCCCAACGACCCCGCCCATTTGACGTCAATAATGACGTATG
 TTCCCATAGTAACGCCAATAGGGACTTTCCATTGACGTCAATGGGTGGAGTATTTACGGTAAACTGCCCA
 CTTGGCAGTACATCAAGTGTATCATATGCCAAGTACGCCCCCTATTGACGTCAATGACGGTAAATGGCCC
 GCCTGGCATTATGCCCAGTACATGACCTTATGGGACTTTCCTACTTGGCAGTACATCTACGTATTAGTCA
 40 TCGCTATTACCATGGTGATGCGGTTTTGGCAGTACATCAATGGGCGTGGATAGCGGTTTGACTCACGGGG
 ATTTCCAAGTCTCCACCCCATTTGACGTCAATGGGAGTTTGTGTTTGGCACCAAATCAACGGGACTTTCCA

AAATGTCGTAACAACCTCCGCCCCATTGACGCAAATGGGCGGTAGGCGTGTACGGTGGGAGGTCTATATAA
GCAGAGCTGGTTTAGTGAACCGTCAGATC

[SEQ ID No: 25]

- 5 The promoter may comprise a nucleotide sequence substantially as set out in SEQ ID No: 25, or a fragment or variant thereof.

Therefore, the promoter in the first and/or second expression vector may comprise a nucleotide sequence substantially as set out in SEQ ID No: 8, 9, 10, 11, or 25 or a
10 fragment or variant thereof. However, most preferably, the promoter may comprise a nucleotide sequence substantially as set out in SEQ ID No: 8, or a fragment or variant thereof, i.e. the CBh promoter. Preferably, the first and second vectors comprise the CBh promoter.

- 15 In some embodiments, the first expression vector comprises an intron disposed between its promoter and the nucleotide encoding TH. In some embodiments, the second expression vector comprises an intron disposed between its promoter and the nucleotide encoding GCH1.

- 20 Introns, as non-coding DNA sequences, have the function to regulation gene expression in eukaryotes by a variety of mechanisms, such as enhancing RNA polymerase II process activity, promoting the interaction between splicing proteins and certain transcription factors, connecting and facilitating multiple types of RNA processing mechanisms and affecting nuclear mRNA export, translational efficiency and RNA
25 decay.

The intron may be at least 25, 50, 75, or 100 nucleotides in length. The intron may be at least 125, 150, 175, or 200 nucleotides in length. The intron may be at least 225, 250, 275, or 300 nucleotides in length.

30

The intron may be selected from a group of introns including: the human growth hormone (hGH) intron; the beta-actin intron; the minute virus of mouse (MVM) intron; the SV40 intron; and the EF-1 alpha intron.

- 35 The intron may be the human growth hormone (hGH) intron. The nucleotide sequence of the hGH intron is referred to herein as SEQ ID NO: 26, as follows:

5 TTGGAACAGGTAAGCGCCCCCTAAAATCCCTTTGGGCACAATGTGTCCTGAGGGGAGAGGCAGCGACCTGT
 AGATGGGACGGGGGCACTAACCCTCAGGTTTGGGGCTTCTGAATGTGAGTATCGCCATGTAAGCCCAGTA
 TTTGGCCAATCTCAGAAAGCTCCTGGTCCCTGGAGGGATGGAGAGAGAAAAACAAACAGCTCCTGGAGCA
 GGGAGAGTGCTGGCCTCTTGCTCTCCGGCTCCCTCTGTTGCCCTCTGGTTTCTCCCCAGGTT

[SEQ ID No: 26]

Hence, the first and/or second expression vector may comprise an intron which
 comprises a nucleotide sequence substantially as set out in SEQ ID No: 26, or a
 10 fragment or variant thereof.

Preferably, the intron is the beta-actin intron and/or the minute virus of mouse (MVM)
 intron. Preferably, the intron is the MVM intron. The nucleotide sequence of the MVM
 intron is referred to herein as SEQ ID NO: 27, as follows:

15

GTAAGGGTTTAAGGGATGGTTGGTTGGTGGGGTATTAATGTTTAATTACCTGGAGCACCTGCCTGAAATC
 ACTTTTTTTCAG

[SEQ ID No: 27]

20 Hence, the first and/or second expression vector may comprise an intron which
 comprises a nucleotide sequence substantially as set out in SEQ ID No: 27, or a
 fragment or variant thereof.

As discussed above, the advantage of using the CBh promoter is that it comprises both
 25 the beta-actin intron and the (MVM) intron, which is believed to contribute to
 improved expression levels of the TH (preferably the truncated TH) and GCH1.

Thus, the first and/or second expression vector may comprise a SYN1 promoter
 followed by an intron, which may be the MVM intron (SEQ ID No: 27) or the human
 30 growth hormone (hGH) intron (SEQ ID No: 26).

Alternatively, the first and/or second expression vector may comprise a chicken beta
 actin promoter with a cytomegalovirus enhancer (CB7) followed by an intron, which
 may be the MVM intron or the human growth hormone (hGH) intron.

35

Alternatively, the first and/or second expression vector may comprise a Tetracycline-
 responsive element (TRE) promoter followed by an intron, which may be the MVM
 intron or the human growth hormone (hGH) intron.

Alternatively, the first and/or second expression vector may comprise a CMV promoter followed by an intron, which may be the MVM intron or the human growth hormone (hGH) intron.

5

In an embodiment, the first and/or second expression vector may further comprise a nucleotide sequence encoding Woodchuck Hepatitis Virus Post-transcriptional Regulatory Element (WPRE), which further enhances the expression of TH1 and/or GCH1, respectively. In some embodiments, the first expression vector does not
10 comprise a nucleotide sequence encoding a WPRE.

Preferably, the second expression vector further comprises a nucleotide sequence encoding Woodchuck Hepatitis Virus Post-transcriptional Regulatory Element (WPRE).

15

Preferably, the WPRE coding sequence is disposed 3' of GCH1 coding sequence on the second expression vector.

One embodiment of the WPRE is 592bp long, including gamma-alpha-beta elements,
20 and is referred to herein as SEQ ID No: 12, as follows:

AATCAACCTCTGGATTACAAAATTTGTGAAAGATTGACTGGTATTCTTAACTATGTTGCTCCTTTTACGCTATGTGGATACGCTGCTT
TAATGCCTTTGTATCATGCTATTGCTTCCCGTATGGCTTTCATTTTCTCCTCCTTGTATAAATCCTGGTTGCTGTCTCTTTATGAGGA
GTTGTGGCCCGTTGTCAGGCAACGTGGCGTGGTGTGCACTGTGTTTGCTGACGCAACCCCCACTGGTTGGGGCATTGCCACCACCTGT
25 CAGCTCCTTTCCGGGACTTTTCGCTTTCCTCCCTATGCCACGGCGGAACTCATCGCCGCCTGCCTTGCCCGCTGCTGGACAGGGG
CTCGGCTGTTGGGCACTGACAATTCCTGCTGTTGTCGGGGAAGCTGACGTCCTTTCCATGGCTGCTCGCCTGTGTTGCCACCTGGAT
TCTGCGCGGGACGTCCTTCTGCTACGTCCCTTCGGCCCTCAATCCAGCGGACCTTCCTTCCCGCGGCCTGCTGCCGGCTCTGCGGCCT
CTTCCGCGTCTTCGCCTTCGCCCTCAGACGAGTCGGATCTCCCTTTGGGCCGCCTCCCCGCCTG

[SEQ ID NO: 12]

30

Preferably, the WPRE comprises a nucleic acid sequence substantially as set out in SEQ ID No: 11, or a fragment or variant thereof.

However, in a preferred embodiment, a truncated WPRE is used, which is 247bp long
35 due to deletion of the beta element, and which is referred to herein as SEQ ID No: 13, as follows:

AATCAACCTCTGGATTACAAAATTTGTGAAAGATTGACTGGTATTCTTAACTATGTTGCTCCTTTTACGC
TATGTGGATACGCTGCTTTAATGCCTTTGTATCATGCTATTGCTTCCCGTATGGCTTTCATTTTCTCCTC

CTTGTATAAATCCTGGTTAGTTCTTGCCACGGCGGAACTCATCGCCGCCTGCCTTGCCCGCTGCTGGACA
GGGGCTCGGCTGTTGGGCACTGACAATTCCGTGGTGT

[SEQ ID NO: 13]

Preferably, the WPRE comprises a nucleic acid sequence substantially as set out in SEQ
5 ID No: 13, or a fragment or variant thereof.

Preferably, the first expression vector comprises a nucleotide sequence encoding a
polyA tail. Preferably, the second expression vector comprises a nucleotide sequence
encoding a polyA tail. Preferably, the polyA tail coding sequence is disposed 3' of the
10 TH and/or GCH1 coding sequence, and preferably 3' of the WPRE coding sequence, if
present in the second vector.

In one embodiment, the polyA tail comprises the simian virus 40 poly-A 224 bp
sequence (i.e. SV40 polyA tail). One embodiment of the SV40 polyA tail is referred to
15 herein as SEQ ID No: 14, as follows:

AGCAGACATGATAAGATACATTGATGAGTTTGGACAAACCACAACCTAGAATGCAGTGAAAAAATGCTTT
ATTTGTGAAATTTGTGATGCTATTGCTTTATTTGTAACCATTATAAGCTGCAATAAACAAGTTAACAACA
ACAATTGCATTCATTTTATGTTTCAGGTTTCAGGGGGAGGTGTGGGAGGTTTTTTAAAGCAAGTAAAACCT
20 CTACAAATGTGGTA

[SEQ ID NO: 14]

Preferably, the polyA tail comprises a nucleic acid sequence substantially as set out in
SEQ ID No: 14, or a fragment or variant thereof.

25

In another embodiment, the polyA tail comprises the bovine growth hormone (BGH)
poly A 208 bp sequence. One embodiment of the BGH polyA tail is referred to herein as
SEQ ID No: 15, as follows:

30 CTGTGCCTTCTAGTTGCCAGCCATCTGTTGTTTGCCCCCTCCCCCGTGCCTTCCTTGACCCTGGAAGGTGC
CACTCCCCTGTCCTTTCTAATAAAAATGAGGAAATTGCATCGCATTGTCTGAGTAGGTGTCATTCTATT
CTGGGGGGTGGGGTGGGGCAGGACAGCAAGGGGGAGGATTGGGAAGAGAATAGCAGGCATGCTGGGGA

[SEQ ID No: 15]

35 Preferably, the polyA tail comprises a nucleic acid sequence substantially as set out in
SEQ ID No: 15, or a fragment or variant thereof.

Preferably, the first expression vector comprises a left and/or a right Inverted Terminal Repeat sequences (ITRs). Preferably, the second expression vector comprises a left and/or a right Inverted Terminal Repeat sequences (ITRs). Preferably, each ITR is disposed at the 5' and/or 3' end of the expression vector.

5

The preferred self-complementary first expression vector comprises one Inverted Terminal Repeat (ITR) sequence and one modified ITR sequence in which the terminal resolution site is deleted. The preferred self-complementary second expression vector comprises one Inverted Terminal Repeat (ITR) sequence and one modified ITR
10 sequence in which the terminal resolution site is deleted. One embodiment of the ITR in which the terminal resolution site is deleted is referred to herein as SEQ ID No:16:

CCACTCCCTCTCTGCGCGCTCGCTCGCTCACTGAGGCCGGGCGACCAAAGGTCGCCCGACGCCCGGGCTT
TGCCCGGGCGGCCTCAGTGAGCGAGCGAGCGCGCAGAGAGGGA

15

[SEQ ID No: 16]

Thus, preferably the first and/or second expression vector comprises an ITR comprising a nucleic acid sequence substantially as set out in SEQ ID No: 16, or a fragment or variant thereof.

20

The first expression vector may comprise a nucleotide sequence encoding a 3' untranslated region (3' UTR). The second expression vector may comprise a nucleotide sequence encoding a 3' untranslated region (3' UTR). Preferably, the 3' UTR coding sequence is disposed 3' of the TH and/or GCH1 coding sequence, and preferably 5' of
25 the poly A tail if present and/or 5' of the WPRE coding sequence, if present.

One embodiment of the 3' UTR coding sequence in the first expression vector (i.e. a 3' UTR of TH) is referred to herein as SEQ ID No: 28:

30

GTGCACGGCGTCCCTGAGGGCCCTTCCCAACCTCCCCTGGTCCTGCACTGTCCCGGAGCTCAGGCCCTGG
TGAGGGGCTGGGTCCCGGGTGCCCCCATGCCCTCCCTGCTGCCAGGCTCCCACTGCCCTGCACCTGCT
TCTCAGCGCAACAGCTGTGTGTGCCCGTGGTGAGGTTGTGCTGCCTGTGGTGAGGTCCTGTCCTGGCTCC
CAGGGTCCTGGGGGCTGCTGCACTGCCCTCCGCCCTTCCCTGACACTGTCTGCTGCCCCAATCACCGTCA
CAATAAAAGAACTGTGGTCTCTA

35

[SEQ ID No: 28]

Thus, preferably the first expression vector comprises a 3' UTR coding sequence comprising a nucleic acid sequence substantially as set out in SEQ ID No: 28, or a fragment or variant thereof.

- 5 The first expression vector may comprise a nucleotide sequence encoding a 5' untranslated region (5' UTR). The second expression vector may comprise a nucleotide sequence encoding a 5' untranslated region (5' UTR). Preferably, the 5' UTR coding sequence is disposed 5' of the TH and/or GCH1 coding sequence, and preferably 3' of the promoter.

10

The 5' UTR coding sequence is preferably a Kozak sequence. One embodiment of the 5' UTR coding sequence in the first and/or second expression vector is referred to herein as SEQ ID No: 29:

15 GCCACC

[SEQ ID No: 29]

Thus, preferably the first and/or second expression vector comprises a 5' UTR coding sequence comprising a nucleic acid sequence substantially as set out in SEQ ID No: 29, or a fragment or variant thereof.

20

In an embodiment, the first expression vector may comprise, in this specified order, a 5' promoter; a sequence encoding TH; and a 3' sequence encoding a poly A tail. In an embodiment, the second expression vector may comprise, in this specified order, a 5' promoter; a sequence encoding GCH1; and a 3' sequence encoding a poly A tail. The use
25 of 5' and 3' described herein indicates that the features are either upstream or downstream, and is not intended to indicate that the features are necessarily terminal features.

In an embodiment, the first expression vector may comprise, in this specified order, a 5'
30 ITR; a promoter; a sequence encoding human truncated TH; a sequence encoding a poly A tail; and a 3' ITR. In an embodiment, the second expression vector may comprise, in this specified order, a 5' ITR; a promoter; a sequence encoding human GCH1; a sequence encoding a poly A tail; and a 3' ITR.

35 In an embodiment, the first expression vector may comprise, in this specified order, a 5' ITR; a promoter; an intron; a sequence encoding human truncated TH; a sequence

encoding a poly A tail; and a 3' ITR. In an embodiment, the second expression vector may comprise, in this specified order, a 5' ITR; a promoter; an intron; a sequence encoding human GCH1; a sequence encoding a poly A tail; and a 3' ITR.

- 5 In an embodiment, the first expression vector may comprise, in this specified order, a 5' ITR; a CBh promoter; a sequence encoding human truncated TH; a sequence encoding a poly A tail; and a 3' ITR. In another embodiment, the second expression vector may comprise, in this specified order, a 5' ITR; a CBh promoter; a sequence encoding GCH1; a sequence encoding WPRE; a sequence encoding a poly A tail; and a 3' ITR.

10

In a preferred embodiment, the first expression vector may comprise, in this specified order, a 5' ITR; a CBh promoter; a sequence encoding human truncated TH; a sequence encoding a poly A tail; and a 3' ITR, in which the terminal resolution site is deleted. In a preferred embodiment, the second expression vector may comprise, in this specified

15 order, 5' ITR; a CBh promoter; a sequence encoding GCH1; a sequence encoding WPRE; a sequence encoding a poly A tail; and a 3' ITR, in which the terminal resolution site is deleted. Preferably, the composition of the first aspect comprises the first and second expression vectors as described herein.

- 20 The following sequence, referred to herein as SEQ ID No: 17 and shown in Figure 6, depicts a vector comprising a CBh promoter operably linked to an htTH (human truncated TH) coding sequence:

AGCGCCCAATACGCAAACCGCCTCTCCCCGCGCGTTGGCCGATTCATTAATGCAGCTGGCACGACAGGTTTCCCGACT

25 GGAAAGCGGGCAGTGAGCGCAACGCAATTAATGTGAGTTAGCTCACTCATTAGGCACCCCAGGCTTTACACTTTATGC

TTCCGGCTCGTATGTTGTGTGGAATTGTGAGCGGATAACAATTTACACAGGAAACAGCTATGACCATGATTACGCCA

AGCTCTCGAGATCTAGAAAGCTTCCCGGGGGGATCTGGGCCACTCCCTCTCTGCGCGCTCGCTCGCTCACTGAGGCCG

GGCGACCAAAGGTCGCCCCGACGCCCGGGCTTTGCCCGGGCGGCCTCAGTGAGCGAGCGCGCAGAGAGGGAGTG

CCAACTCCATCACTAGGGGTTTCTGGAGGGGTGGAGTCGTGACCTAGGCAACTTTGTATAGAAAAGTTGCGTTACATA

30 ACTTACGGTAAATGGCCCGCCTGGCTGACCGCCCAACGACCCCCGCCATTGACGTCAATAGTAACGCCAATAGGGAC

TTTCCATTGACGTCAATGGGTGGAGTATTTACGGTAAACTGCCCACTTGGCAGTACATCAAGTGTATCATATGCCAAG

TACGCCCCCTATTGACGTCAATGACGGTAAATGGCCCGCCTGGCATTGTGCCCAGTACATGACCTTATGGGACTTTCC

TACTTGGCAGTACATCTACGTATTAGTCATCGCTATTACCATGGTCGAGGTGAGCCCCACGTTCTGCTTCACTCTCCC

CATCTCCCCCCCCCTCCCCACCCCCAATTTTGTATTTATTTATTTTAAATTATTTTGTGCAGCGATGGGGGCGGGGG

35 GGGGGGGGGGCGCGCGCCAGGCGGGGCGGGGCGGGGCGAGGGGCGGGGCGGGGCGAGGCGGAGAGGTGCGGCGGCAGC

CAATCAGAGCGGCGCGCTCCGAAAGTTTCTTTTATGGCGAGGCGGCGGCGGCGGCGGCCCTATAAAAAGCGAAGCGC

GCGGCGGGGCGGGAGTCGCTGCGCGCTGCCTTCGCCCCGTGCCCCGCTCCGCCGCCGCTCGCGCCGCCCGCCCCGGCT

CTGACTGACCGCGTTACTCCACAGGTGAGCGGGCGGGACGGCCCTTCTCCTCCGGGCTGTAATTAGCTGAGCAAGAG

GTAAGGGTTTAAGGGATGGTTGGTTGGTGGGGTATTAATGTTTAATTACCTGGAGCACCTGCCTGAAATCACTTTTTT

TCAGGTTGGCAAGTTTGTACAGCCACCATGAGCCCCGCGGGGCCCAAGGTCCCCTGGTTCCCAAGAAAAGTGTGAGAG
CTGGACAAGTGTGTCATCACCTGGTCACCAAGTTCGACCCTGACCTGGACTTGGACCACCCGGGCTTCTCGGACCAGGTG
TACCGCCAGCGCAGGAAGCTGATTGCTGAGATCGCCTTCCAGTACAGGCACGGCGACCCGATTCCCCGTGTGGAGTAC
ACCGCCGAGGAGATTGCCACCTGGAAGGAGGTCTACACCACGCTGAAGGGCCTCTACGCCACGCACGCCTGCGGGGAG
5 CACCTGGAGGCCTTTGCTTTGCTGGAGCGCTTCAGCGGCTACCGGGAAGACAATATCCCCAGCTGGAGGACGTCTCC
CGCTTCCTGAAGGAGCGCACGGGCTTCCAGCTGCGGCCTGTGGCCGGCCTGCTGTCCGCCCCGGGACTTCCTGGCCAGC
CTGGCCTTCCGCGTGTTCAGTGCACCCAGTATATCCGCCACGCGTCCTCGCCCATGCACTCCCCTGAGCCGGACTGC
TGCCACGAGCTGCTGGGGCACGTGCCCATGCTGGCCGACCGCACCTTCGCGCAGTTCTCGCAGGACATTGGCCTGGCG
TCCCTGGGGGCCTCGGATGAGGAAATTGAGAAGCTGTCCACGCTGTACTGGTTCACGGTGGAGTTCGGGCTGTGTAAG
10 CAGAACGGGGAGGTGAAGGCCTATGGTGCCGGGCTGCTGTCTCCTACGGGGAGCTCCTGCACTGCCTGTCTGAGGAG
CCTGAGATTTCGGGCCTTCGACCCTGAGGCTGCGGCCGTGACGCCCTACCAAGACCAGACGTACCAGTCAGTCTACTTC
GTGTCTGAGAGCTTCAGTGACGCCAAGGACAAGCTCAGGAGCTATGCCTCACGCATCCAGCGCCCCCTTCTCCGTGAAG
TTCGACCCGTACACGCTGGCCATCGACGTGCTGGACAGCCCCCAGGCCGTGCGGCGCTCCCTGGAGGGTGTCCAGGAT
GAGCTGGACACCCTTGCCCATGCGCTGAGTGCCATTGGCTAACAGACATGATAAGATACATTGATGAGTTTGGACAAA
15 CCACAACCTAGAATGCAGTGAAAAAATGCTTTATTTGTGAAATTTGTGATGCTATTGCTTTATTTGTAACCATTATAA
GCTGCAATAAACAAGTTAACAACAACAATTGCATTCATTTTATGTTTTCAGGTTTCAGGGGGAGGTGTGGGAGGTTTTTT
AAAGCAAGTAAAACCTCTACAAATGTGGTAACTAGTCCACTCCCTCTCTGCGCGCTCGCTCGCTCACTGAGGCCGGGC
GACCAAAGGTGCGCCGACGCCCCGGGCTTTGCCCGGGCGGCCTCAGTGAGCGAGCGAGCGCGCAGAGAGGGACAGATCC
GGGCCCCGATGCGTCGACAATTCCTGGCCGTCGTTTTTACAACGTCGTGACTGGGAAAACCTGGCGTTACCCAACTT
20 AATCGCCTTGACGACATCCCCCTTTCGCCAGCTGGCGTAATAGCGAAGAGGCCCGCACCCGATCGCCCTTCCCAACAG
TTGCGCAGCCTGAATGGCGAATGGCGCCTGATGCGGTATTTTCTCCTTACGCATCTGTGCGGTATTTACACCCGCATA
TGGTGCACTCTCAGTACAATCTGCTCTGATGCCGCATAGTTAAGCCAGCCCCGACACCCGCCAACACCCGCTGACGCG
CCCTGACGGGCTTGTCTGCTCCCGGCATCCGCTTACAGACAAGCTGTGACCGTCTCCGGGAGCTGCATGTGTCAGAGG
TTTTACCGTCATCACCGAAACGCGCGAGACGAAAGGGCCTCGTGATACGCCTATTTTTTATAGGTTAATGTCATGATA
25 ATAATGGTTTCTTAGACGTCAGGTGGCACTTTTCGGGGAAATGTGCGCGGAACCCCTATTTGTTTATTTTTCTAAATA
CATTCAAATATGTATCCGCTCATGAGACAATAACCCTGATAAATGCTTCAATAATATTGAAAAAGGAAGAGTATGAGT
ATTCAACATTTCCGTGTGCCCCCTTATTCCCTTTTTTGCGGCATTTTGCTTCCCTGTTTTTGCTCACCCAGAAACGCTG
GTGAAAGTAAAAGATGCTGAAGATCAGTTGGGTGCACGAGTGGGTACATCGAACTGGATCTCAACAGCGGTAAGATC
CTTGAGAGTTTTCGCCCCGAAGAAGCTTTTCCAATGATGAGCACTTTTAAAGTTCTGCTATGTGGCGCGGTATTATCC
30 CGTATTGACGCCGGGCAAGAGCAACTCGGTGCGGCATACACTATTCTCAGAATGACTTGGTTGAGTACTACCAGTC
ACAGAAAAGCATCTTACGGATGGCATGACAGTAAGAGAATTATGCAGTGCTGCCATAACCATGAGTGATAACACTGCG
GCCAACTTACTTCTGACAACGATCGGAGGACCGAAGGAGCTAACCCTTTTTTGACAAACATGGGGGATCATGTAACCT
CGCCTTGATCGTTGGGAACCGGAGCTGAATGAAGCCATACCAAACGACGAGCGTGACACCACGATGCCTGTAGCAATG
GCAACAACGTTGCGCAAACTATTAACCTGGCGAACTACTTACTCTAGCTTCCCGGCAACAATTAATAGACTGGATGGAG
35 GCGGATAAAGTTGCAGGACCACTTCTGCGCTCGGCCCTTCCGGCTGGCTGGTTTATTGCTGATAAATCTGGAGCCGGT
GAGCGTGGGTCTCGCGGTATCATTGCAGCACTGGGGCCAGATGGTAAGCCCTCCCGTATCGTAGTTATCTACACGACG
GGGAGTCAGGCAACTATGGATGAACGAAATAGACAGATCGCTGAGATAGGTGCCTCACTGATTAAGCATTGGTAACCTG
TCAGACCAAGTTTACTCATATATACTTTAGATTGATTTAAACTTCATTTTTAATTTAAAAGGATCTAGGTGAAGATC
CTTTTTGATAATCTCATGACCAAAATCCCTTAACGTGAGTTTTCGTTCCACTGAGCGTCAGACCCCGTAGAAAAGATC
40 AAAGGATCTTCTTGAGATCCTTTTTTTCTGCGCGTAATCTGCTGCTTGCAAACAAAAAAACCACCGCTACCAGCGGTG
GTTTGTTTGCCGGATCAAGAGCTACCAACTCTTTTTCCGAAGGTAACCTGGCTTCAGCAGAGCGCAGATACCAAATACT
GTTCTTCTAGTGTAGCCGTAGTTAGGCCACCACTTCAAGAACTCTGTAGCACCGCCTACATACCTCGCTCTGCTAATC
CTGTTACCAGTGGCTGCTGCCAGTGGCGATAAGTCGTGTCTTACCGGGTTGGACTCAAGACGATAGTTACCGGATAAG
GCGCAGCGGTGCGGCTGAACGGGGGGTTCTGTGCACACAGCCCAGCTTGGAGCGAACGACCTACACCGAACTGAGATAC

CTACAGCGTGAGCTATGAGAAAGCGCCACGCTTCCCGAAGGGAGAAAGGCGGACAGGTATCCGGTAAGCGGCAGGGTC
 GGAACAGGAGAGCGCACGAGGGAGCTTCCAGGGGGAAACGCCTGGTATCTTTATAGTCCTGTCGGGTTTCGCCACCTC
 TGACTIONGAGCGTCGATTTTTGTGATGCTCGTCAGGGGGGCGGAGCCTATGGAAAAACGCCAGCAACGCGGCCTTTTTTA
 CGGTTCCCTGGCCTTTTGCTGGCCTTTTGCTCACATGTTCTTTCTGCGTTATCCCCTGATTCTGTGGATAACCGTATT
 5 ACCGCCTTTGAGTGAGCTGATACCGCTCGCCGCAGCCGAACGACCGAGCGCAGCGAGTCAGTGAGCGAGGAAGCGGAA
 G

[SEQ ID No: 17]

Preferably, the first expression vector comprises a nucleic acid sequence substantially
 10 as set out in SEQ ID No: 17, or a fragment or variant thereof.

The following sequence, referred to herein as SEQ ID No: 18 and shown in Figure 7,
 depicts a vector comprising a CBh promoter operably linked to a GCH-1 coding
 sequence:

15 AGCGCCCAATACGCAAACCGCCTCTCCCCGCGCGTTGGCCGATTCATTAATGCAGCTGGCACGACAGGTTTCCCGACT
 GGAAAGCGGGCAGTGAGCGCAACGCAATTAATGTGAGTTAGCTCACTCATTAGGCACCCCAGGCTTTACACTTTATGC
 TTCCGGCTCGTATGTTGTGTGGAATTGTGAGCGGATAACAATTTACACAGGAAACAGCTATGACCATGATTACGCCA
 AGCTCTCGAGATCTAGAAAGCTTCCCGGGGGGATCTGGGCCACTCCCTCTCTGCGCGCTCGCTCGCTCACTGAGGCCG
 20 GGCGACCAAAGGTCGCCCCGACGCCCGGGCTTTGCCCGGGCGGCCTCAGTGAGCGAGCGAGCGCGCAGAGAGGGAGTG
 CCAACTCCATCACTAGGGGTTCTTGAGGGGTGGAGTCGTGACCTAGGCAACTTTGTATAGAAAAGTTGCGTTACATA
 ACTTACGGTAAATGGCCCGCCTGGCTGACCGCCCAACGACCCCCGCCATTGACGTCAATAGTAACGCCAATAGGGAC
 TTTCCATTGACGTCAATGGGTGGAGTATTTACGGTAAACTGCCCACTTGGCAGTACATCAAGTGTATCATATGCCAAG
 TACGCCCCCTATTGACGTCAATGACGGTAAATGGCCCGCCTGGCATTGTGCCCAGTACATGACCTTATGGGACTTTCC
 25 TACTTGGCAGTACATCTACGTATTAGTCATCGCTATTACCATGGTCGAGGTGAGCCCCACGTTCTGCTTCACTCTCCC
 CATCTCCCCCCCCCTCCCCACCCCCAATTTTGTATTTATTTATTTTAAATTATTTTGTGCAGCGATGGGGGCGGGGG
 GGGGGGGGGGCGCGCGCCAGGCGGGGCGGGGCGGGGCGAGGGGCGGGGCGGGGCGAGGCGGAGAGGTGCGGCGGCAGC
 CAATCAGAGCGGCGCGCTCCGAAAGTTTCCTTTTATGGCGAGGCGGCGGCGGCGGCCCTATAAAAAGCGAAGCGC
 GCGGCGGGGCGGGAGTCGCTGCGCGCTGCCTTCGCCCCGTGCCCCGCTCCGCCGCCGCTCGCGCCGCCCGCCCCGGCT
 30 CTGACTGACCGCGTTACTCCACAGGTGAGCGGGCGGGACGGCCCTTCTCCTCCGGGCTGTAATTAGCTGAGCAAGAG
 GTAAGGGTTTAAGGGATGGTTGGTTGGTGGGGTATTAATGTTTAATTACCTGGAGCACCTGCCTGAAATCACTTTTTT
 TCAGGTTGGCAAGTTTGTACAGCCACCATGGAGAAGCCGCGGGGTGTAAGGTGCACCAATGGGTTCGCCGAGCGGGAG
 CTGCCGCGGCCCGGGGCCAGCCGACCTGCCGAGAAGTCCCGGCCGCCCGAGGCCAAGGGCGCACAGCCAGCCGACGCC
 TGGAAGGCAGGGCGGCCCCGCAGCGAGGAGGATAACGAGCTGAACCTCCCCAACCTGGCGGCCGCTTACTCGTCCATC
 35 CTGCGCTCGCTGGGCGAGGACCCCCAGCGGCAGGGGCTGCTCAAGACGCCCTGGAGGGCGGCCACCGCCATGCAGTTC
 TTCACCAAGGGATACCAGGAGACCATCTCAGATGTCTGAACGATGCTATATTTGATGAGGACCATGACGAGATGGTG
 ATTGTGAAGGACATTGACATGTTTTCCATGTGTGAGCATCACCTGGTCCCATTGTGGGAAGGGTCCATATTGTTTAT
 CTTCTAACAAGCAAGTCCTTGGTCTCAGCAAACCTTGCCAGGATTGTGGAAATCTACAGTAGAAGACTACAAGTTCAA
 GAACGCCTTACCAAACAGATTGCAGTGGCCATCACAGAAGCCTTGACGCCTGCTGGCGTCGGGGTAGTGATTGAAGCA
 40 ACACACATGTGTATGGTCATGCGAGGTGTGCAGAAAATGAACAGCAAGACTGTCCTAGCACCATGCTAGGCGTGTTT
 CGGGAAGACCCAAAGACTCGGGAGGAGTTCTCACACTCATCAGGAGCTGAAATCAACCTCTGGATTACAAAATTTGT
 GAAAGATTGACTGGTATTCTTAACATATGTTGCTCCTTTTACGCTATGTGGATACGCTGCTTTAATGCCTTTGTATCAT

GCTATTGCTTCCCGTATGGCTTTCATTTTCTCCTCCTTGTATAAATCCTGGTTAGTTCTTGCCACGGCGGAACTCATC
 GCCGCCTGCCTTGCCCGCTGCTGGACAGGGGCTCGGCTGTTGGGCACTGACAATTCCGTGGTGTTTATTTGTGAAATT
 TGTGATGCTATTGCTTTATTTGTAACCATCTAGCTTTATTTGTGAAATTTGTGATGCTATTGCTTTATTTGTAACCAT
 TATAAGCTGCAATAAACAAGTTAACAACAACAATTGCATTCATTTTATGTTTTCAGGTTTCAGGGGGAGAGACTAGTCCA
 5 CTCCCTCTCTGCGCGCTCGCTCGCTCACTGAGGCCGGGCGACCAAAGGTCGCCCCGACGCCCGGGCTTTGCCCGGGCGG
 CCTCAGTGAGCGAGCGAGCGCGCAGAGAGGGACAGATCCGGGCCCCGCATGCGTCGACAATTCCTGGCCGTCGTTTTA
 CAACGTCGTGACTGGGAAAACCCTGGCGTTACCCAACTTAATCGCCTTGACGACATCCCCCTTTGCCAGCTGGCGT
 AATAGCGAAGAGGCCCGCACCGATCGCCCTTCCCAACAGTTGCGCAGCCTGAATGGCGAATGGCGCCTGATGCGGTAT
 TTTCTCCTTACGCATCTGTGCGGTATTTACACCGCATATGGTGCCTCTCAGTACAATCTGCTCTGATGCCGCATAG
 10 TTAAGCCAGCCCCGACACCCGCCAACACCCGCTGACGCGCCCTGACGGGCTTGTCTGCTCCCGGCATCCGCTTACAGA
 CAAGCTGTGACCGTCTCCGGGAGCTGCATGTGTCAGAGGTTTTACCGTCATACCGAAACGCGCGAGACGAAAGGGC
 CTCGTGATACGCCTATTTTTATAGGTTAATGTCATGATAATAATGGTTTTCTTAGACGTCAGGTGGCACTTTTCGGGGA
 AATGTGCGCGGAACCCCTATTTGTTTTATTTTTCTAAATACATTCAAATATGTATCCGCTCATGAGACAATAACCCTGA
 TAAATGCTTCAATAATATTGAAAAAGGAAGAGTATGAGTATTCAACATTTCCGTGTGCCCTTATTCCCTTTTTTGCG
 15 GCATTTTGCTTTCCTGTTTTTGCTCACCCAGAAACGCTGGTGAAAGTAAAAGATGCTGAAGATCAGTTGGGTGCACGA
 GTGGGTACATCGAACTGGATCTCAACAGCGGTAAGATCCTTGAGAGTTTTCGCCCCGAAGAACGTTTTCCAATGATG
 AGCACTTTTAAAGTTCTGCTATGTGGCGCGGTATTATCCCGTATTGACGCCGGGCAAGAGCAACTCGGTGCGCGCATA
 CACTATTCTCAGAATGACTTGGTTGAGTACTCACCAGTCACAGAAAAGCATCTTACGGATGGCATGACAGTAAGAGAA
 TTATGCAGTGCTGCCATAACCATGAGTGATAAACTGCGGCCAACTTACTTCTGACAACGATCGGAGGACCGAAGGAG
 20 CTAACCGCTTTTTTGACACAACATGGGGGATCATGTAACCTGCCTTGATCGTTGGGAACCGGAGCTGAATGAAGCCATA
 CCAAACGACGAGCGTGACACCACGATGCCTGTAGCAATGGCAACAACGTTGCGCAAACTATTAAGTGGCGAACTACTT
 ACTCTAGCTTCCCGGCAACAATTAATAGACTGGATGGAGGCGGATAAAGTTGCAGGACCACTTCTGCGCTCGGCCCTT
 CCGGCTGGCTGGTTTTATTGCTGATAAATCTGGAGCCGGTGAGCGTGGGTCTCGCGGTATCATTGCAGCACTGGGGCCA
 GATGGTAAGCCCTCCCGTATCGTAGTTATCTACACGACGGGGAGTCAGGCAACTATGGATGAACGAAATAGACAGATC
 25 GCTGAGATAGGTGCCTCACTGATTAAGCATTGGTAACTGTCAGACCAAGTTTACTCATATATACTTTAGATTGATTTA
 AAACCTTCATTTTTAATTTAAAAGGATCTAGGTGAAGATCCTTTTTGATAATCTCATGACCAAAAATCCCTTAACGTGAG
 TTTTCGTTCCACTGAGCGTCAGACCCCGTAGAAAAGATCAAAGGATCTTCTTGAGATCCTTTTTTTCTGCGCGTAATC
 TGCTGCTTGCAAACAAAAAAACCACCGCTACCAGCGGTGGTTTTGTTTGCCGGATCAAGAGCTACCAACTCTTTTTCCG
 AAGGTAACCTGGCTTCAGCAGAGCGCAGATACCAAATACTGTTCTTCTAGTGTAGCCGTAGTTAGGCCACCACTTCAAG
 30 AACTCTGTAGCACCGCTACATACCTCGCTCTGCTAATCCTGTTACCAGTGGCTGCTGCCAGTGGCGATAAGTCGTGT
 CTTACCGGGTTGGACTCAAGACGATAGTTACCGGATAAGGCGCAGCGGTGCGGCTGAACGGGGGGTTCTGTCACACAG
 CCCAGCTTGGAGCGAACGACCTACACCGAACTGAGATACCTACAGCGTGAGCTATGAGAAAGCGCCACGCTTCCCGAA
 GGGAGAAAGGCGGACAGGTATCCGGTAAGCGGCAGGGTCGGAACAGGAGAGCGCACGAGGGAGCTTCCAGGGGGAAAC
 GCCTGGTATCTTTATAGTCTGTGCGGTTTCGCCACCTCTGACTTGAGCGTCGATTTTTGTGATGCTCGTCAGGGGGG
 35 CGGAGCCTATGGAAAAACGCCAGCAACGCGGCCTTTTTACGGTTCCTGGCCTTTTGCTGGCCTTTTGCTCACATGTTT
 TTTCTGCGTTATCCCTGATTCTGTGGATAACCGTATTACCGCCTTTGAGTGAGCTGATACCGCTCGCCGCAGCCGA
 ACGACCGAGCGCAGCGAGTCAGTGAGCGAGGAAGCGGAAG

[SEQ ID No: 18]

40 Preferably, the second expression vector comprises a nucleic acid sequence
 substantially as set out in SEQ ID No: 18, or a fragment or variant thereof.

The following sequence, referred to herein as SEQ ID No: 19 and shown in Figure 8, depicts a vector (i.e. the first expression vector of the composition of the first aspect) comprising a SYN1 promoter operably linked to a htTH coding sequence:

```

5  GGCCACTCCCTCTCTGCGCGCTCGCTCGCTCACTGAGGCCGGGCGACCAAAGGTCGCCCCGACGCCCGGGCTTTGCCCC
   GGCGGCCTCAGTGAGCGAGCGAGCGCGCAGAGAGGGAGTGGCCAACTCCATCACTAGGGGTTCTTGAGGGGTGGAGT
   CGTGACCTAGGCAACTTTGTATAGAAAAGTTGCTGCAGAGTGCAAGTGGGTTTTAGGACCAGGATGAGGCGGGGTGGG
   GGTGCCTACCTGACGACCGACCCCGACCCACTGGACAAGCACCCAACCCCATTCGCCAAATTGCGCATCCCCTATCA
   GAGAGGGGGAGGGGAAACAGGATGCGGCGAGGCGCGTGCGCACTGCCAGCTTCAGCACCGCGGACAGTGCTTCGCCC
10  CCGCCTGGCGGCGCGCGCCACCGCCGCCTCAGCACTGAAGGCGCGCTGACGTCACCTCGCCGGTCCCCCGCAAACCTCCC
   CTTCCCGGCCACCTTGGTCGCGTCCGCGCCGCGCCGGGCCAGCCGGACCGCACACGCGAGGCGCGAGATAGGGGGG
   CACGGGCGCGACCATCTGCGCTGCGGCGCCGGCGACTCAGCGCTGCCTCAGTCTGCGGTGGGCAGCGGAGGAGTCTGTG
   TCGTGCTGAGAGCGCAGGCCACCATGAGCCCCGCGGGGCCCAAGGTCCCCTGGTTCCCAAGAAAAGTGTGAGAGCTG
   GACAAGTGTATCATCCTGGTCACCAAGTTCGACCCTGACCTGGACTTGGACCACCCGGGCTTCTCGGACCAGGTGTAC
15  CGCCAGCGCAGGAAGCTGATTGCTGAGATCGCCTTCCAGTACAGGCACGGCGACCCGATTCCCCGTGTGGAGTACACC
   GCCGAGGAGATTGCCACCTGGAAGGAGGTCTACACCACGCTGAAGGGCCTCTACGCCACGCACGCCTGCGGGGAGCAC
   CTGGAGGCCTTTGCTTTGCTGGAGCGCTTCAGCGGCTACCGGGAAGACAATATCCCCAGCTGGAGGACGTCTCCCGC
   TTCCTGAAGGAGCGCACGGGCTTCCAGCTGCGGCCTGTGGCCGGCCTGCTGTCCGCCCGGGACTTCCTGGCCAGCCTG
   GCCTTCCGCGTGTTCAGTGCACCCAGTATATCCGCCACGCGTCCTCGCCCATGCACTCCCCTGAGCCGGAAGTCTGTC
20  CACGAGCTGCTGGGGCACGTGCCCATGCTGGCCGACCGCACCTTCGCGCAGTTCTCGCAGGACATTGGCCTGGCGTCC
   CTGGGGGCCTCGGATGAGGAAATTGAGAAGCTGTCCACGCTGTACTGGTTCACGGTGGAGTTCGGGCTGTGTAAGCAG
   AACGGGGAGGTGAAGGCCTATGGTGCCGGGCTGCTGTCTCTCTACGGGGAGCTCCTGCACTGCCTGTCTGAGGAGCCT
   GAGATTCGGGCCTTCGACCCTGAGGCTGCGGCCGTGCAGCCCTACCAAGACCAGACGTACCAGTCAGTCTACTTCGTG
   TCTGAGAGCTTCAGTGACGCCAAGGACAAGCTCAGGAGCTATGCCTCACGCATCCAGCGCCCCCTTCTCCGTGAAGTTC
25  GACCCGTACACGCTGGCCATCGACGTGCTGGACAGCCCCCAGGCCGTGCGGCGCTCCCTGGAGGGTGTCCAGGATGAG
   CTGGACACCCTTGCCCATGCGCTGAGTGCCATTGGCTAAAATCAACCTCTGGATTACAAAATTTGTGAAAGATTGACT
   GGTATTCTTAACATATGTTGCTCCTTTTACGCTATGTGGATACGCTGCTTTAATGCCTTTGTATCATGCTATTGCTTCC
   CGTATGGCTTTCATTTTCTCCTCCTTGTATAAATCCTGGTTAGTTCTTGCCACGGCGGAACCTCATCGCCGCCTGCCTT
   GCCCGCTGCTGGACAGGGGCTCGGCTGTTGGGCACTGACAATCCGTGGTGTGTTATTTGTGAAATTTGTGATGCTATT
30  GCTTTATTTGTAACCATCTAGCTTTATTTGTGAAATTTGTGATGCTATTGCTTTATTTGTAACCATTATAAGCTGCAA
   TAAACAAGTTAACAACAACAATTGCATTCATTTTATGTTTCAGGTTTCAGGGGGAGAGCAATTGCATTCATTTTATGTT
   TCAGGTTTCAGGGGGAGGTGTGGGAGGTTTTTTTAAAGCAAGTAAAACCTCTACAAATGTGGTAACTAGTCCACTCCCTC
   TCTGCGCGCTCGCTCGCTCACTGAGGCCGGGCGACCAAAGGTCGCCCCGACGCCCGGGCTTTGCCCGGGCGGCCTCAGT
   GAGCGAGCGAGCGCGCAGAGAGGGACAGATCCGGGCCCCGCATGCGTCGACAATCACTGGCCGTCGTTTTACAACGTC
35  GTGACTGGGAAAACCCTGGCGTTACCCAACCTTAATCGCCTTGACGACATCCCCCTTTCGCCAGCTGGCGTAATAGCG
   AAGAGGCCCGCACCGATCGCCCTTCCCAACAGTTGCGCAGCCTGAATGGCGAATGGCGCCTGATGCGGTATTTTCTCC
   TTACGCATCTGTGCGGTATTTACACCGCATATGGTGCACTCTCAGTACAATCTGCTCTGATGCCGCATAGTTAAGCC
   AGCCCCGACACCCGCCAACACCCGCTGACGCGCCCTGACGGGCTTGTCTGCTCCCGGCATCCGCTTACAGACAAGCTG
   TGACCGTCTCCGGGAGCTGCATGTGTGAGAGGTTTTACCGTTCATACCGAAACGCGCGAGACGAAAGGGCCTCGTGA
40  TACGCCTATTTTTATAGGTTAATGTCATGATAATAATGGTTTCTTAGACGTCAGGTGGCACTTTTCGGGGAAATGTGC
   GCGGAACCCCTATTTGTTTATTTTTCTAAATACATTCAAATATGTATCCGCTCATGAGACAATAACCCTGATAAATGC
   TTCAATAATATTGAAAAGGAAGAGTATGAGTATTCAACATTTCCGTGTCGCCCTTATTCCTTTTTTTCGGGCATTTT
   GCCTTCCTGTTTTTGTCTACCCAGAAACGCTGGTGAAAGTAAAAGATGCTGAAGATCAGTTGGGTGCACGAGTGGGT

```

ACATCGAACTGGATCTCAACAGCGGTAAGATCCTTGAGAGTTTTCGCCCCGAAGAACGTTTTCCAATGATGAGCACTT
 TTAAAGTTCTGCTATGTGGCGCGGTATTATCCCGTATTGACGCCGGGCAAGAGCAACTCGGTGCGCGCATACACTATT
 CTCAGAACTGACTTGGTTGAGTACTCACCAGTCACAGAAAAGCATCTTACGGATGGCATGACAGTAAGAGAATTATGCA
 GTGCTGCCATAACCATGAGTGATAACACTGCGGCCAACTTACTTCTGACAACGATCGGAGGACCGAAGGAGCTAACCG
 5 CTTTTTTGCACAACATGGGGGATCATGTAACCTCGCCTTGATCGTTGGGAACCGGAGCTGAATGAAGCCATACCAAACG
 ACGAGCGTGACACCACGATGCCTGTAGCAATGGCAACAACGTTGCGCAAACCTATTAACCTGGCGAACTACTTACTCTAG
 CTTCCCGGCAACAATTAATAGACTGGATGGAGGCGGATAAAGTTGCAGGACCACTTCTGCGCTCGGCCCTTCCGGCTG
 GCTGGTTTTATTGCTGATAAATCTGGAGCCGGTGAGCGTGGGTCTCGCGGTATCATTGCAGCACTGGGGCCAGATGGTA
 AGCCCTCCCGTATCGTAGTTATCTACACGACGGGGAGTCAGGCAACTATGGATGAACGAAATAGACAGATCGCTGAGA
 10 TAGGTGCCTCACTGATTAAGCATTGGTAACTGTCAGACCAAGTTTACTCATATATACTTTAGATTGATTTAAAACCTC
 ATTTTTAATTTAAAAGGATCTAGGTGAAGATCCTTTTTGATAATCTCATGACCAAAATCCCTTAACGTGAGTTTTTCGT
 TCCACTGAGCGTCAGACCCCGTAGAAAAGATCAAAGGATCTTCTTGAGATCCTTTTTTTCTGCGCGTAATCTGCTGCT
 TGCAAACAAAAAAACCACCGCTACCAGCGGTGGTTTTGTTTGCCGGATCAAGAGCTACCAACTCTTTTTCCGAAGGTAA
 CTGGCTTCAGCAGAGCGCAGATACCAAATACTGTTCTTCTAGTGTAGCCGTAGTTAGGCCACCACTTCAAGAACTCTG
 15 TAGCACCGCCTACATACCTCGCTCTGCTAATCCTGTTACCAGTGGCTGCTGCCAGTGGCGATAAGTCGTGTCTTACCG
 GGTGGACTCAAGACGATAGTTACCGGATAAGGCGCAGCGGTCGGGCTGAACGGGGGGTTCGTGCACACAGCCCAGCT
 TGGAGCGAACGACCTACACCGAACTGAGATACCTACAGCGTGAGCTATGAGAAAGCGCCACGCTTCCCGAAGGGAGAA
 AGGCGGACAGGTATCCGGTAAGCGGCAGGGTCGGAACAGGAGAGCGCACGAGGGAGCTTCCAGGGGGAAACGCCTGGT
 ATCTTTATAGTCCTGTGCGGTTTTCGCCACCTCTGACTTGAGCGTCGATTTTTGTGATGCTCGTCAGGGGGGCGGAGCC
 20 TATGGAAAAACGCCAGCAACGCGGCCTTTTTACGGTTCCTGGCCTTTTGCTGGCCTTTTGCTCACATGTTCTTTCCTG
 CGTTATCCCCTGATTCTGTGGATAACCGTATTACCGCCTTTGAGTGAGCTGATACCGCTCGCCGCAGCCGAACGACCG
 AGCGCAGCGAGTCAGTGAGCGAGGAAGCGGAAGAGCGCCCAATACGCAAACCGCCTCTCCCCGCGCGTTGGCCGATTC
 ATTAATGCAGCTGGCACGACAGGTTTCCCGACTGGAAAGCGGGCAGTGAGCGCAACGCAATTAATGTGAGTTAGCTCA
 CTCATTAGGCACCCAGGCTTTACACTTTATGCTTCCGGCTCGTATGTTGTGTGGAATTGTGAGCGGATAACAATTTG
 25 ACACAGGAAACAGCTATGACCATGATTACGCCAAGCTCTCGAGATCTAGAAAGCTTCCCGGGGGGATCTG

[SEQ ID No: 19]

The following sequence, referred to herein as SEQ ID No: 20 and shown in Figure 9,
 depicts a vector (i.e. the second expression vector of the composition of the first aspect)
 30 comprising a SYN1 promoter operably linked to a GCH-1 coding sequence:

GGCCACTCCCTCTCTGCGCGCTCGCTCGCTCACTGAGGCCGGGCGACCAAAGGTCGCCCAGCGCCGGGCTTTGCCCCG
 GGCGGCCTCAGTGAGCGAGCGAGCGCGCAGAGAGGGAGTGGCCAACTCCATCACTAGGGGTTCTTGAGGGGTGGAGT
 CGTGACCTAGGCAACTTTGTATAGAAAAGTTGCTGCAGAGTGCAAGTGGGTTTTAGGACCAGGATGAGGCGGGGTGGG
 35 GGTGCCTACCTGACGACCGACCCGACCCACTGGACAAGCACCCAACCCCATTTCCCAAATTGCGCATCCCCATCA
 GAGAGGGGGAGGGGAAACAGGATGCGGCGAGGCGCGTGCGCACTGCCAGCTTCAGCACCGCGGACAGTGCTTCGCCC
 CCGCCTGGCGGCGCGCGCCACCGCCGCCTCAGCACTGAAGGCGCGCTGACGTCACTCGCCGGTCCCCGCAAACTCCC
 CTTCCCGGCCACCTTGGTGCGGTCCGCGCCGCGCCGGCCGAGCCGACCGCACCGAGGCGCGAGATAGGGGGG
 CACGGGCGCGACCATCTGCGCTGCGGCGCCGGCGACTCAGCGCTGCCTCAGTCTGCGGTGGGCAGCGGAGGAGTCGTG
 40 TCGTGCCCTGAGAGCGCAGGCCACCATGGAGAAGCCGCGGGGTGTAAGGTGCACCAATGGGTTCCCCGAGCGGGAGCTG
 CCGCGGCCCGGGGCCAGCCGACCTGCCGAGAAGTCCCGGCCGCCCAGGGCCAAGGGCGCACAGCCAGCCGACGCCTGG
 AAGGCAGGGCGGCCCCGCGAGCGAGGAGGATAACGAGCTGAACCTCCCCAACCTGGCGGGCGCTTACTCGTCCATCCTG

CGCTCGCTGGGCGAGGACCCCCAGCGGCAGGGGCTGCTCAAGACGCCCTGGAGGGCGGGCCACCGCCATGCAGTTCTTC
ACCAAGGGATACCAGGAGACCATCTCAGATGTCCTGAACGATGCTATATTTGATGAGGACCATGACGAGATGGTGATT
GTGAAGGACATTGACATGTTTTCCATGTGTGAGCATCACCTGGTCCCATTTGTGGGAAGGGTCCATATTGGTTATCTT
CCTAACAAGCAAGTCCTTGGTCTCAGCAAACCTTGCCAGGATTGTGGAAATCTACAGTAGAAGACTACAAGTTCAAGAA
5 CGCCTTACCAAACAGATTGCAGTGGCCATCACAGAAGCCTTGACGCCCTGCTGGCGTCGGGGTAGTGATTGAAGCAACA
CACATGTGTATGGTCATGCGAGGTGTGCAGAAAATGAACAGCAAGACTGTCACTAGCACCATGCTAGGCGTGTTCCGG
GAAGACCCAAAGACTCGGGAGGAGTTCCTCACACTCATCAGGAGCTGAAATCAACCTCTGGATTACAAAATTTGTGAA
AGATTGACTGGTATTCTTAACATATGTTGCTCCTTTTACGCTATGTGGATACGCTGCTTTAATGCCCTTTGTATCATGCT
ATTGCTTCCCGTATGGCTTTTCATTTTCTCCTCCTTGTATAAATCCTGGTTAGTTCTTGCCACGGCGGAACCTCATCGCC
10 GCCTGCCCTTGCCCGCTGCTGGACAGGGGCTCGGCTGTTGGGCACTGACAATTCCGTGGTGTTTATTTGTGAAATTTGT
GATGCTATTGCTTTATTTGTAACCATCTAGCTTTATTTGTGAAATTTGTGATGCTATTGCTTTATTTGTAACCATTAT
AAGCTGCAATAAACAAGTTAACAACAACAATTGCATTCATTTTTATGTTTCAGGTTTCAGGGGGAGAGCAATTGCATTCA
TTTTATGTTTCAGGTTTCAGGGGGAGGTGTGGGAGGTTTTTTTAAAGCAAGTAAAACCTCTACAAATGTGGTAACTAGTC
CACTCCCTCTCTGCGCGCTCGCTCGCTCACTGAGGCCGGGCGACCAAAGGTCGCCCGACGCCCGGGCTTTGCCCGGGC
15 GGCCTCAGTGAGCGAGCGAGCGCGCAGAGAGGGACAGATCCGGGCCCCGCATGCGTCGACAATTCAGTGGCCGTCGTTT
TACAACGTCGTGACTGGGAAAACCTGGCGTTACCCAACCTTAATCGCCTTGACGACATCCCCCTTTGCCAGCTGGC
GTAATAGCGAAGAGGCCCGCACCGATCGCCCTTCCCAACAGTTGCGCAGCCTGAATGGCGAATGGCGCCTGATGCGGT
ATTTTCTCCTTACGCATCTGTGCGGTATTTACACCCGCATATGGTGCCTCTCAGTACAATCTGCTCTGATGCCGCAT
AGTTAAGCCAGCCCCGACACCCGCCAACACCCGCTGACGCGCCCTGACGGGCTTGTCTGCTCCCGGCATCCGCTTACA
20 GACAAGCTGTGACCGTCTCCGGGAGCTGCATGTGTGAGAGGTTTTACCGTGCATACCGAAACGCGCGAGACGAAAGG
GCCTCGTGATACGCTATTTTTATAGGTAAATGTCATGATAATAATGGTTTTCTTAGACGTCAGGTGGCACTTTTCGGG
GAAATGTGCGCGGAACCCCTATTTGTTTATTTTTCTAAATACATTCAAATATGTATCCGCTCATGAGACAATAACCCCT
GATAAATGCTTCAATAATATTGAAAAAGGAAGAGTATGAGTATTCAACATTTCCGTGTGCCCCTTATTCCCTTTTTTG
CGGCATTTTGCCTTCCTGTTTTTGTCTACCCAGAAACGCTGGTGAAAGTAAAAGATGCTGAAGATCAGTTGGGTGCAC
25 GAGTGGGTTACATCGAACTGGATCTCAACAGCGGTAAGATCCTTGAGAGTTTTCGCCCCGAAGAACGTTTTCCAATGA
TGAGCACTTTTAAAGTTCTGCTATGTGGCGCGGTATTATCCCGTATTGACGCCGGGCAAGAGCAACTCGGTGCGCGCA
TACACTATTCTCAGAATGACTTGGTTGAGTACTACCCAGTACAGAAAAGCATCTTACGGATGGCATGACAGTAAGAG
AATTATGCAGTGCTGCCATAACCATGAGTGATAACACTGCGGCCAACTTACTTCTGACAACGATCGGAGGACCGAAGG
AGCTAACCGCTTTTTTGCACAACATGGGGGATCATGTAACCTCGCCTTGATCGTTGGGAACCGGAGCTGAATGAAGCCA
30 TACCAAACGACGAGCGTGACACCACGATGCCTGTAGCAATGGCAACAACGTTGCGCAAACCTATTAAGTGGCGAACTAC
TACTCTAGCTTCCCGGCAACAATTAATAGACTGGATGGAGGCGGATAAAGTTGCAGGACCACTTCTGCGCTCGGCCC
TTCCGGCTGGCTGGTTTTATTGCTGATAAATCTGGAGCCGGTGAGCGTGGGTCTCGCGGTATCATTGCAGCACTGGGGC
CAGATGGTAAGCCCTCCCGTATCGTAGTTATCTACACGACGGGGAGTCAGGCAACTATGGATGAACGAAATAGACAGA
TCGCTGAGATAGGTGCCTCACTGATTAAGCATTGGTAACTGTCAGACCAAGTTTACTCATATATACTTTAGATTGATT
35 TAAAACTTCATTTTTAAATTTAAAAGGATCTAGGTGAAGATCCTTTTTGATAATCTCATGACCAAAATCCCTTAACGTG
AGTTTTTCGTTCCACTGAGCGTCAGACCCCGTAGAAAAGATCAAAGGATCTTCTTGAGATCCTTTTTTTCTGCGCGTAA
TCTGCTGCTTGCAAACAAAAAAACCACCGCTACCAGCGGTGGTTTTGTTTGCCGGATCAAGAGCTACCAACTCTTTTTTC
CGAAGGTAACCTGGCTTCAGCAGAGCGCAGATACCAAATACTGTTCTTCTAGTGTAGCCGTAGTTAGGCCACCACTTCA
AGAACTCTGTAGCACCGCCTACATACTCGCTCTGCTAATCCTGTTACCAGTGGCTGCTGCCAGTGGCGATAAGTCGT
40 GTCTTACCGGGTTGGACTCAAGACGATAGTTACCGGATAAGGCGCAGCGGTGCGGCTGAACGGGGGGTTTCGTGCACAC
AGCCCAGCTTGGAGCGAACGACCTACACCGAACTGAGATACCTACAGCGTGAGCTATGAGAAAGCGCCACGCTTCCCG
AAGGGAGAAAGGCGGACAGGTATCCGGTAAGCGGCAGGGTCGGAACAGGAGAGCGCACGAGGGAGCTTCCAGGGGGAA
ACGCTTGGTATCTTTATAGTCTGTGCGGTTTTCGCCACCTCTGACTTGAGCGTCGATTTTTGTGATGCTCGTCAGGGG
GGCGGAGCCTATGAAAAACGCCAGCAACGCGGCCTTTTTACGGTTCCTGGCCTTTTGCTGGCCTTTTGCTCACATGT

TCTTTCCTGCGTTATCCCCTGATTCTGTGGATAACCGTATTACCGCCTTTGAGTGAGCTGATACCGCTCGCCGCAGCC
 GAACGACCGAGCGCAGCGAGTCAGTGAGCGAGGAAGCGGAAGAGCGCCCAATACGCAAACCGCCTCTCCCCGCGCGTT
 GGCCGATTCATTAATGCAGCTGGCACGACAGGTTTCCCGACTGGAAAGCGGGCAGTGAGCGCAACGCAATTAATGTGA
 GTTAGCTCACTCATTAGGCACCCCAGGCTTTACACTTTATGCTTCCGGCTCGTATGTTGTGTGGAATTGTGAGCGGAT
 5 AACAAATTCACACAGGAAACAGCTATGACCATGATTACGCCAAGCTCTCGAGATCTAGAAAGCTTCCCGGGGGGATCT
 G

[SEQ ID No: 20]

The invention preferably provides a composition comprising:-

- 10 (i) a first self-complementary adeno-associated virus (scAAV) vector comprising a promoter operably linked to a coding sequence, which encodes tyrosine hydroxylase (TH), optionally human truncated TH lacking the regulatory domain; and
- (ii) a second self-complementary adeno-associated virus (scAAV) vector
 15 comprising a promoter operably linked a coding sequence, which encodes GTP cyclohydrolase 1 (GCH1).

According to a second aspect, there is provided a pharmaceutical composition comprising the composition according to the first aspect, and a pharmaceutically
 20 acceptable vehicle.

The composition comprising the recombinant vectors of the first aspect, and the pharmaceutical composition of the second aspect are particularly suitable for therapy.

25 Hence, according to a third aspect, there is provided the composition according to the first aspect, or the pharmaceutical composition according to the second aspect, for use as a medicament or in therapy.

Treatment of Parkinson's disease, DOPA responsive dystonia, vascular parkinsonism,
 30 side effects associated with L-DOPA treatment for Parkinson's disease, L-DOPA induced dyskinesia, Segawa syndrome, or genetic dopamine receptor abnormalities are especially envisaged.

Thus, in a fourth aspect of the invention, there is provided the composition according to
 35 the first aspect, or the pharmaceutical composition according to the second aspect, for use in treating, preventing, or ameliorating Parkinson's disease, DOPA responsive dystonia, vascular parkinsonism, side effects associated with L-DOPA treatment for

Parkinson's disease, L-DOPA induced dyskinesia, Segawa syndrome, or genetic dopamine receptor abnormalities.

5 The skilled person will appreciate that the therapeutic use of the first and second vectors means that they do not necessarily need to be provided in the same composition or formulation.

10 Hence, in yet another aspect, there is provided a first expression vector comprising a promoter operably linked to a self-complementary coding sequence, which encodes tyrosine hydroxylase (TH), and a second expression vector comprising a promoter operably linked to a coding sequence, which encodes GTP cyclohydrolase 1 (GCH1), for use in therapy.

15 In yet another aspect, there is provided a first expression vector comprising a promoter operably linked to a self-complementary coding sequence, which encodes tyrosine hydroxylase (TH), and a second expression vector comprising a promoter operably linked to a coding sequence, which encodes GTP cyclohydrolase 1 (GCH1), for use in treating, preventing, or ameliorating Parkinson's disease, DOPA responsive dystonia, vascular parkinsonism, side effects associated with L-DOPA treatment for Parkinson's
20 disease, L-DOPA induced dyskinesia, Segawa syndrome, or genetic dopamine receptor abnormalities.

The first and second expression vectors used herein are as described in relation to the first aspect.

25 Preferably, the uses described herein comprise the use of a first self-complementary adeno-associated virus (scAAV) vector comprising a promoter operably linked to a coding sequence, which encodes tyrosine hydroxylase (TH), optionally human truncated TH lacking the regulatory domain.

30 Preferably, the uses described herein comprise the use of a second self-complementary adeno-associated virus (scAAV) vector comprising a promoter operably linked a coding sequence, which encodes GTP cyclohydrolase 1 (GCH1).

35 According to a fifth aspect, there is provided a method of treating, preventing, or ameliorating Parkinson's disease, DOPA responsive dystonia, vascular parkinsonism,

side effects associated with L-DOPA treatment for Parkinson's disease, L-DOPA induced dyskinesia, Segawa syndrome, or genetic dopamine receptor abnormalities in a subject, the method comprising administering, to a subject in need of such treatment, a therapeutically effective amount of the composition according to the first aspect, or the
5 composition according to the second aspect.

In yet another aspect, there is provided a method of treating, preventing, or ameliorating Parkinson's disease, DOPA responsive dystonia, vascular parkinsonism, side effects associated with L-DOPA treatment for Parkinson's disease, L-DOPA
10 induced dyskinesia, Segawa syndrome, or genetic dopamine receptor abnormalities in a subject, the method comprising administering, to a subject in need of such treatment, a therapeutically effective amount of a first expression vector comprising a promoter operably linked to a self-complementary coding sequence, which encodes tyrosine hydroxylase (TH), and a second expression vector comprising a promoter operably
15 linked to a coding sequence, which encodes GTP cyclohydrolase 1 (GCH1).

Preferably, the first and second vectors or compositions according to the invention are used in a gene therapy technique.

20 In embodiment, the disorder to be treated is selected from the group consisting of Parkinson's disease, DOPA responsive dystonia, vascular parkinsonism, side effects associated with L-DOPA treatment for Parkinson's disease, L-DOPA induced dyskinesia, Segawa syndrome, or genetic dopamine receptor abnormalities.

25 In a most preferred embodiment, the disease to be treated is Parkinson's disease.

The disclosed gene therapy technique leads to a constant level of production of L-DOPA in the striatum. This removes or reduces the need for oral L-DOPA and so results in reduced peak to trough variation. Hence, the disclosed gene therapy can be used for
30 the treatment of side effects associated with L-DOPA treatment of Parkinson's disease and of L-DOPA-induced dyskinesia.

The disclosed gene therapy technique may be used for the treatment of Segawa syndrome. Although it would be possible to treat Segawa syndrome with a gene
35 therapy delivering only GCH1, or only TH (depending on the cause of the Segawa syndrome) the additional inclusion of TH or GCH1 (respectively) is not expected to be

prejudicial and may be beneficial. The disclosed treatment is especially advantageous as, due to the rareness of Segawa syndrome, it may not be commercially attractive or viable to develop a treatment solely for this indication. Production of the disclosed invention for this indication as well as Parkinson's disease, will reduce the unit cost of the therapy.

In a preferred embodiment, medicaments according to the invention (i.e. the first and second expression vectors) may be administered to a subject by injection into the blood stream, the cerebrospinal fluid, a nerve, or directly into a site requiring treatment. For instance, the expression vectors may be delivered to the brain. The vector may be delivered bilaterally or unilaterally. Specific regions of the brain may be targeted, such as striatum. The putamen or caudate nucleus may be targeted. Alternatively, only the putamen may be targeted. The treatment may be centred on the dopaminergic neurons of the pars compacta region in the substantia nigra.

The delivery method may be direct injection. Methods for injection into the brain (for instance the striatum) are well known in the art (Bilang-Bleuel et al (1997) Proc. Acad. Nati. Sci. USA 94:8818-8823; Choi-Lundberg et al (1998) Exp. Neurol.154:261 -275; Choi-Lundberg et al (1997) Science 275:838-841; and Mandel et al (1997)) Proc. Acad. Natl. Sci. USA 94:14083-14088). Alternatively, or in addition, the vector chosen may have a tropism that is targeted towards a specific desired tissue, such as a neuron.

Modifications of the vector capsid properties could enable targeting of the vector to the striatal region also after intrathecal (IT) injection or injection into the cerebral ventricles (ICV). Injections into the ventricles, such that the resulting L-DOPA or dopamine is elevated, may be transmitted to the striatum by diffusion through CSF or axonal transfer. An alternative approach is to generate chimeric AAV serotypes that would inherit different binding properties from the two serotypes mixed.

Preferably, however, the vector and compositions according to the invention may be administered to a subject by injection into the striatum.

The gene therapy vectors may be produced by any technique known in the art. For instance, the AAV vectors may be produced using classic triple transfection methodology. Methods for the production of adeno-associated virus vectors are

disclosed in Matsushita *et al.* (Matsushita *et al.*, Adeno-associated virus vectors can be efficiently produced without helper virus. *Gene Therapy* (1998) 5, 938–945).

5 It will be appreciated that the amount of the composition of the invention and amount of each of the two vectors within the mixture or provided separately that is required is determined by the biological activity and bioavailability of the two vectors in the mixture (or separately) which in turn depends on the mode of administration, the physiochemical properties of the vectors and whether the composition is being used as a monotherapy or combined with other therapies. Optimal dosages to be administered
10 may be determined by those skilled in the art, and will vary with the particular expression vectors in use, the strength of the composition and pharmaceutical composition, the mode of administration, and the advancement of the neurodegenerative disorder being treated. Additional factors depending on the particular subject being treated will result in a need to adjust dosages, including subject
15 age, weight, gender, diet, and time of administration.

The dose of composition of the invention delivered may be 300 µl to 20,000 µl, 300 µl to 10,000 µl, 300 µl to 5,000 µl, 300 µl to 4500 µl, 400 µl to 4000 µl, 500 µl to 3500 µl, 600 µl to 3000 µl, 700 µl to 2500 µl, 750 µl to 2000 µl, 800 µl to 1500 µl, 850 µl to
20 1000 µl, or approximately 900 µl.

If administered as a mixture of AAV vectors, the titre of each AAV may be 1E8 to 5E14, 1E9 to 1E14, 1E10 to 5E13, 1E11 to 1E13, 1E12 to 8E12, 4E12 to 6E12, or roughly 5E12 genome copies per ml (GC/ml).

25

If administered as a mixture of naked DNA plasmid vectors, the dose of each DNA plasmid vector may be 50, 100, 200, 300, 400, 500, 600, 700, 800, 900, 1000, 1250, 1500, 1750 or 2000 micrograms (µg) per brain hemisphere.

30 The composition may be administered during or after onset of the disorder. Doses may be given as a single administration, or multiple doses may be given over the course of the treatment. A dose may be administered to a patient, and the patient may be monitored in order to assess the necessity for a second or further doses. Repeat use delivery of the same genomes within AAV vectors may be facilitated by the switching
35 the AAV capsid serotype to reduce the probability of interference by an antibody or cell mediated immune response induced by the previous treatment.

In some embodiments, the therapeutic methods may include, prior to gene therapy treatment, a test infusion of L-DOPA. The test infusion may be used to demonstrate that a subject is responsive to L-DOPA and benefits from reduced peak to trough variation in plasma and or brain L-DOPA levels, and so may allow the selection of subjects most likely to benefit from gene therapy treatment. The L-DOPA test infusion may be by any means capable of creating a steady blood level over hours or days. Examples of suitable infusion methods include by nasogastric tube, i.v. infusion, infusion via a pump, by the use of DuoDOPA, or any other suitable means.

It will be appreciated that the first and second expression vectors on their own, or the composition according to the first aspect, or the pharmaceutical composition of the second aspect may be used in a medicament, which may be used as a monotherapy (i.e. use of vector composition according to the first aspect or the composition according to the second aspect of the invention), for treating, ameliorating, or preventing any disorder as disclosed herein. Alternatively, the vectors on their own or the composition according to the invention may be used as an adjunct to, or in combination with, known therapies for treating, ameliorating, or preventing any disorder as disclosed herein. In some cases, vectors may be used as an adjunct to, in combination with, or alongside a treatment designed to improve the gene therapy. For instance, the vectors may be used in combination with an immunosuppressive treatment, in order to reduce, prevent, or control an immune response induced by the gene therapy itself. For example, the immunosuppressive treatment may prevent, reduce, or control an immune response directed to a capsid of a gene therapy vector, a genome comprised within a gene therapy vector, or a product produced by a gene therapy vector during therapy. The immunosuppressive regime may include a general immunosuppressant, such as a steroid. The immunosuppressive regime may include more targeted immunosuppression designed to reduce specific immune responses, such as immunotherapy to specific antigens found within, or produced by, a gene therapy construct. Alternatively, the composition comprising the vectors may be administered or used in combination with an agent intended to increase the efficiency of uptake of the vectors by the target cells, or increase the efficiency of transfection or transduction or prevent down-regulation or silencing of expression.

The compositions according to the invention may be combined in compositions having a number of different forms depending, in particular, on the manner in which the

composition is to be used. Thus, for example, the compositions may be in the form of a powder, liquid, micellar solution, liposome suspension or any other suitable form that may be administered to a person or animal in need of treatment. It will be appreciated that the vehicle of medicaments according to the invention should be one which is well-tolerated by the subject to whom it is given. Preferably, the composition is in the form of an injectable liquid.

Known procedures, such as those conventionally employed by the pharmaceutical industry (e.g. *in vivo* experimentation, clinical trials, etc.), may be used to form specific formulations of the composition according to the invention and precise therapeutic regimes.

According to a sixth aspect, there is provided a method of preparing the pharmaceutical composition according to the second aspect, the method comprising contacting the composition according to the first aspect, and a pharmaceutically acceptable vehicle.

A “subject” may be a vertebrate, mammal, or domestic animal. Hence, compositions and medicaments according to the invention may be used to treat any mammal, for example livestock (e.g. a horse), pets, or may be used in other veterinary applications. Most preferably, however, the subject is a human being.

A “therapeutically effective amount” of the vector or the composition is any amount which, when administered to a subject, is the amount of the aforementioned that is needed to treat the disorder.

A “pharmaceutically acceptable vehicle” as referred to herein, is any known compound or combination of known compounds that are known to those skilled in the art to be useful in formulating pharmaceutical compositions.

In a preferred embodiment, the pharmaceutically acceptable vehicle may be such as to allow injection of the composition directly into a subject. For instance, the vehicle may be suitable for allowing the injection of the composition into the striatum.

In one embodiment, the pharmaceutically acceptable vehicle may be a solid, and the composition may be in the form of a powder, or suspension. A solid pharmaceutically acceptable vehicle may include one or more substances which may also act as,

lubricants, solubilisers, suspending agents, dyes, fillers, glidants, compression aids, inert binders, preservatives, dyes, coatings, or solid-disintegrating agents. The vehicle may also be an encapsulating material. In powders, the vehicle is a finely divided solid that is in admixture with the finely divided active agents according to the invention. In
5 another embodiment, the pharmaceutical vehicle may be a gel or the like.

However, the pharmaceutical vehicle may be a suspension or a liquid, and the pharmaceutical composition is in the form of a suspension or a solution. Liquid pharmaceutical compositions, which are sterile solutions or suspensions, can be
10 utilized by, for example, intrathecal, epidural, intravenous and particularly direct injection into the target area of brain, such as the striatum. The first and second vectors may be prepared as a suspension or as sterile solid or dry composition that may be dissolved or suspended at the time of administration using sterile water, saline, Dulbecco's Phosphate Buffered Saline (dPBS) with MgCl₂ and CaCl₂, artificial
15 cerebrospinal fluid or other appropriate sterile injectable medium.

In one embodiment, the composition of the first and second aspects of the invention may be supplied as a single pre-mixed formulation (e.g. in a vial or syringe). In another embodiment, however, the composition comprises the two expression vectors supplied
20 individually (e.g. in two vials or two syringes), but in a kit, and mixed immediately prior to, or at the time of, administration.

Thus, in a seventh aspect, there is provided a kit of parts comprising the first and second expression vectors as defined in accordance with the first aspect, and optionally,
25 instructions for use.

The kit of parts may comprise a first container in which the first expression vector is contained. The kit of parts may comprise a second container in which the second expression vector is contained. The first and/or second container may be a vial, syringe, Eppendorf, or the like. For example, the syringe may be a pre-loaded syringe. The kit
30 may comprise a mixing vessel in which the vectors may be mixed prior to administration. Alternatively, one vector may be transferred to the container holding the other vector, where they may be mixed. Alternatively, the vectors may be administered separately, but sufficiently contemporaneously such that they are
35 simultaneously therapeutically active in the subject. The instructions for use preferably describe how to mix the vectors, if appropriate, and dosages.

The ratio of the first expression vector to second expression vector may preferably be about 50:50, but could be 5:95, 10:90, 20:80, 30:70 60:40, 40:60, 70:30, 80:20, 90:10 or 95:5.

5

It will be appreciated that the kit of the seventh aspect can be used in therapy, and preferably for treating, preventing, or ameliorating Parkinson's disease, DOPA responsive dystonia, vascular parkinsonism, side effects associated with L-DOPA treatment for Parkinson's disease, L-DOPA induced dyskinesia, Segawa syndrome, or
10 genetic dopamine receptor abnormalities.

In another aspect, there is provided a composition comprising first and second expression vectors, wherein the first expression vector comprises a promoter operably linked to a self-complementary coding sequence, which encodes tyrosine hydroxylase
15 (TH), and the second expression vector comprises a coding sequence, which encodes GTP cyclohydrolase 1 (GCH1).

It will be appreciated that the invention extends to any nucleic acid or peptide or variant, derivative or analogue thereof, which comprises substantially the amino acid or
20 nucleic acid sequences of any of the sequences referred to herein, including variants or fragments thereof. The terms "substantially the amino acid/nucleotide/peptide sequence", "variant" and "fragment", can be a sequence that has at least 40% sequence identity with the amino acid/nucleotide/peptide sequences of any one of the sequences referred to herein, for example 40% identity with the sequence identified as SEQ ID
25 No:1-29 and so on.

Amino acid/polynucleotide/polypeptide sequences with a sequence identity which is greater than 65%, more preferably greater than 70%, even more preferably greater than 75%, and still more preferably greater than 80% sequence identity to any of the
30 sequences referred to are also envisaged. Preferably, the amino acid/polynucleotide/polypeptide sequence has at least 85% identity with any of the sequences referred to, more preferably at least 90% identity, even more preferably at least 92% identity, even more preferably at least 95% identity, even more preferably at least 97% identity, even more preferably at least 98% identity and, most preferably at
35 least 99% identity with any of the sequences referred to herein.

The skilled technician will appreciate how to calculate the percentage identity between two amino acid/polynucleotide/polypeptide sequences. In order to calculate the percentage identity between two amino acid/polynucleotide/polypeptide sequences, an alignment of the two sequences must first be prepared, followed by calculation of the sequence identity value. The percentage identity for two sequences may take different values depending on:- (i) the method used to align the sequences, for example, ClustalW, BLAST, FASTA, Smith-Waterman (implemented in different programs), or structural alignment from 3D comparison; and (ii) the parameters used by the alignment method, for example, local vs global alignment, the pair-score matrix used (e.g. BLOSUM62, PAM250, Gonnet etc.), and gap-penalty, e.g. functional form and constants.

Having made the alignment, there are many different ways of calculating percentage identity between the two sequences. For example, one may divide the number of identities by: (i) the length of shortest sequence; (ii) the length of alignment; (iii) the mean length of sequence; (iv) the number of non-gap positions; or (v) the number of equivalenced positions excluding overhangs. Furthermore, it will be appreciated that percentage identity is also strongly length dependent. Therefore, the shorter a pair of sequences is, the higher the sequence identity one may expect to occur by chance.

Hence, it will be appreciated that the accurate alignment of protein or DNA sequences is a complex process. The popular multiple alignment program ClustalW (Thompson *et al.*, 1994, Nucleic Acids Research, 22, 4673-4680; Thompson *et al.*, 1997, Nucleic Acids Research, 24, 4876-4882) is a preferred way for generating multiple alignments of proteins or DNA in accordance with the invention. Suitable parameters for ClustalW may be as follows: For DNA alignments: Gap Open Penalty = 15.0, Gap Extension Penalty = 6.66, and Matrix = Identity. For protein alignments: Gap Open Penalty = 10.0, Gap Extension Penalty = 0.2, and Matrix = Gonnet. For DNA and Protein alignments: ENDGAP = -1, and GAPDIST = 4. Those skilled in the art will be aware that it may be necessary to vary these and other parameters for optimal sequence alignment.

Preferably, calculation of percentage identities between two amino acid/polynucleotide/polypeptide sequences may then be calculated from such an alignment as $(N/T) \times 100$, where N is the number of positions at which the sequences share an identical residue, and T is the total number of positions compared including

gaps and either including or excluding overhangs. Preferably, overhangs are included in the calculation. Hence, a most preferred method for calculating percentage identity between two sequences comprises (i) preparing a sequence alignment using the ClustalW program using a suitable set of parameters, for example, as set out above; and
5 (ii) inserting the values of N and T into the following formula:- Sequence Identity = $(N/T)*100$.

Alternative methods for identifying similar sequences will be known to those skilled in the art. For example, a substantially similar nucleotide sequence will be encoded by a
10 sequence which hybridizes to DNA sequences or their complements under stringent conditions. By stringent conditions, we mean the nucleotide hybridises to filter-bound DNA or RNA in 3x sodium chloride/sodium citrate (SSC) at approximately 45°C followed by at least one wash in 0.2x SSC/0.1% SDS at approximately 20-65°C. Alternatively, a substantially similar polypeptide may differ by at least 1, but less than 5,
15 10, 20, 50 or 100 amino acids from the sequences shown in, for example, in the amino acid sequence that are included within SEQ ID Nos: 1-29.

Due to the degeneracy of the genetic code, it is clear that any nucleic acid sequence described herein could be varied or changed without substantially affecting the
20 sequence of the protein encoded thereby, to provide a functional variant thereof. Suitable nucleotide variants are those having a sequence altered by the substitution of different codons that encode the same amino acid within the sequence, thus producing a silent change. Other suitable variants are those having homologous nucleotide sequences but comprising all, or portions of, sequence, which are altered by the
25 substitution of different codons that encode an amino acid with a side chain of similar biophysical properties to the amino acid it substitutes, to produce a conservative change. For example, small non-polar, hydrophobic amino acids include glycine, alanine, leucine, isoleucine, valine, proline, and methionine. Large non-polar, hydrophobic amino acids include phenylalanine, tryptophan and tyrosine. The polar
30 neutral amino acids include serine, threonine, cysteine, asparagine and glutamine. The positively charged (basic) amino acids include lysine, arginine and histidine. The negatively charged (acidic) amino acids include aspartic acid and glutamic acid. It will therefore be appreciated which amino acids may be replaced with an amino acid having similar biophysical properties, and the skilled technician will know the nucleotide
35 sequences encoding these amino acids.

All of the features described herein (including any accompanying claims, abstract and drawings), and/or all of the steps of any method or process so disclosed, may be combined with any of the above aspects in any combination, except combinations where at least some of such features and/or steps are mutually exclusive.

5

For a better understanding of the invention, and to show how embodiments of the same may be carried into effect, reference will now be made, by way of example, to the accompanying Figures, in which: -

10

Figure 1 is a plasmid map of one embodiment of a single-stranded ssAAV-SYN1-hGCH-SYN1-EGFP-WPRE-pA vector (construct A).

Figure 2 is a plasmid map of one embodiment of a self-complementary plasmid pscAAV-CBh-EGFP-WPRE-SV4opA vector (construct B).

15

Figure 3 is a plasmid map of one embodiment of a self-complementary plasmid pscAAV-SYN1-EGFP-WPRE-SV4opA vector (construct C).

20

Figure 4 is a plasmid map of one embodiment of a single-stranded plasmid sspAAV-SYN1-EGFP-T2A-GCH-WPRE-pA vector (construct D).

Figure 5 is a plasmid map of one embodiment of an pAAV[TetOn]TRE-EGFP-rev(SYN1-tTS-T2A-rtTA) vector (construct E).

25

Figure 6 is a plasmid map of one embodiment of a vector comprising a CBh promoter operably linked to a htTH coding sequence.

Figure 7 is a plasmid map of one embodiment of a vector comprising a CBh promoter operably linked to a GCH-1 coding sequence.

30

Figure 8 is a plasmid map of one embodiment of a vector comprising a SYN1 promoter operably linked to a htTH coding sequence.

35

Figure 9 is a plasmid map of one embodiment of a vector comprising a SYN1 promoter operably linked to a GCH-1 coding sequence.

Figure 10A shows qualitative analysis by Western blot of expression of the reporter gene EGFP of a number of constructs, A, B and C. The blot shows the correct molecular weight of EGFP of 37KDa; and **Figure 10B** shows quantitative DAB colorimetric detection of expression of the reporter gene EGFP.

5

Figure 11A shows a second data set of qualitative analysis by Western blot of expression of the reporter gene EGFP of constructs, A, B and C. The blot shows the correct molecular weight of EGFP of 37KDa, and **Figure 11B** shows quantitative DAB colorimetric detection of expression of the reporter gene EGFP. The results confirm
10 that the B construct shows the highest dose dependent expression of EGFP.

Figure 12 shows the expression levels of GFP for the tested constructs 48 hours post transfection.

15 **Figure 13** shows the average number of GFP cells plotted over time with a maximum signal at about 48 hours.

Figure 14 shows the GFP expression in cells transfected with 200ng of DNA after 48 hours.

20

Figure 15 shows the GFP expression in cells transfected with 100ng of DNA after 48 hours.

Figure 16 shows the GFP expression in cells transfected with 50ng of DNA after 48
25 hours.

Figure 17 shows a coronal section of MPTP-lesioned macaque brain stained with mouse anti-TH antibody (x 2 magnification).

30 **Figure 18** shows a coronal section of MPTP-lesioned macaque brain stained with mouse anti-TH antibody (x 10 magnification).

Figure 19 shows a coronal section of MPTP-lesioned macaque brain stained with mouse anti-TH antibody (x 20 magnification).

35

Figure 20 shows a monkey movement analysis panel (mMAP; from Gash et al, 1999).

Figure 21 shows results of monkey analysis panel experiments, i.e. the change in mMAP Pre vs Post treatment.

5 **Examples**

Background

 The inventors set out to determine an optimum expression cassette (and vector harbouring the cassette) for *in vivo* expression of TH and GCH1. The objective of the study was to transfect SH-SY5Y (human neuronal cells) *in vitro* with five different
10 plasmids at three different concentrations and analyse the expression of a reporter gene EGFP. In these constructs, the sequence for TH was substituted for EGFP to enable comparison of transduction efficiency by measurement of GFP fluorescence.

Example 1

15 **Materials and Methods**

 The SH-SY5Y cells were obtained at P13 from Sigma-Aldrich, cultured in 10% FBS DMEM:F12 containing 2mM L-Glutamine and banked at P15. A total of five transfection experiments were conducted to optimise the conditions. In brief, SH-SY5Y cells were plated directly from frozen in 96 well plates at 20,000 cells per well
20 and cultured for 24hr. The medium was removed and transfection was carried out using TransFast reagent in a 1:1 ratio of TransFast reagent to plasmid DNA in basal medium DMEM:F12 with no serum. Plasmids were assigned codes A-E as shown in Table 1 below. The transfection was carried out according to the instructions provided for the TransFast reagent using the equivalent of 0.5ug, 0.75ug and 1.0ug per 24 well.
25 Note that the Even et al publication used 0.75ug. A total of 40ul of TransFast plasmid mixture was added to each well of a 96 well plate and incubated for 1hr. The calculation for the transfection reagent plasmid mixture is shown in Table 2 below. After 1hr the TransFast plasmid mixture was removed and 200ul of 10% FBS DMEM:F12 growth medium added and incubated for 2 days.

30

Table 1 – Plasmid constructs

Code	Plasmid ID	Construct
A	VB200507-3049fzk	pAAV[Exp]SYN1>hGCH1[NM_000161.3](TAAstop)-SYN1>EGFP
B	VB200507-1054ety	pscAAV[Exp]CBh>EGFP:WPR E3/SV40
C	VB200507-1050huy	pscAAV[Exp]SYN1>EGFP:WP RE3/SV40 pA

D	VB200510-1139ssd	pAAV[Exp]SYN1>EGFP(ns):T2A:rGch1[NM_024356.1]:WPRE
E	VB200519-1235vjq	pAAV[TetOn]TRE>EGFP-rev(SYN1>tTS:T2A:rtTA)

Constructs A and D were single-stranded AAV plasmids.

Constructs B and C were self-complementary AAV plasmids.

5

Referring to Figures 1-9, there are shown plasmid maps of different embodiments of the constructs described herein. Figure 6 (SEQ ID No: 17) illustrates a plasmid map for one preferred embodiment of the first expression vector which encodes human truncated TH, and Figure 7 (SEQ ID No: 18) shows the map for the second expression vector which encodes human GCH-1.

10

Table 2 – Transfection calculations

Transfection Calculations													
	A	A1	A2	A3	B	B1	B2	B3	C	C1	C2	C3	
Four Conditions/24 well	0	0.5	0.75	1	0	0.5	0.75	1	0	0.5	0.75	1	
Total DNA	0	0.875	1.312	1.75	0	0.875	1.312	1.75	0	0.875	1.313	1.75	
Concentration DNA ug/ul	0	2.677	2.677	2.677	0	0.196	0.196	0.196	0	0.342	0.342	0.342	
1-1 DNA ul	0.0	0.3	0.5	0.7	0.0	4.5	6.7	8.9	0.0	2.6	3.8	5.1	
TransFast	0.0	2.6	3.9	5.3	0.0	2.6	3.9	5.3	0.0	2.6	3.9	5.3	
Medium	0.0	347.0	345.6	344.1	0.0	342.9	339.4	335.8	350.0	344.8	342.2	339.6	
1-1 Total	350.0	350.0	350.0	350.0	350.0	350.0	350.0	350.0	350.0	350.0	350.0	350.0	
	D	D1	D2	D3	E	E1	E2	E3					
Conditions/24 well	0	0.5	0.75	1	0	0.5	0.75	1					
Total DNA	0	0.875	1.3125	1.75	0	0.875	1.3125	1.75					
Concentration DNA ug/ul	0	0.502	0.502	0.502	0	0.444	0.444	0.444					
2-1 DNA ul	0.0	1.7	2.6	3.5	0.0	2.0	3.0	3.9					
TransFast	0.0	2.6	3.9	5.3	0.0	2.6	3.9	5.3					
Medium	350.0	345.6	343.4	341.3	350.0	345.4	343.1	340.8					
1-1 Total	350.0	350.0	350.0	350.0	350.0	350.0	350.0	350.0					

15

A total of 8 wells were transfected per condition. After two days incubation, the cells were gently washed 1 x 200ul with warm PBS. Two wells per condition (top two rows of each 96 well plate) were fixed with 4% Paraformaldehyde containing 4% sucrose in PBS for 15min. The wells were then washed 1 x 200ul with PBS and stored in 100ul PBS. Fluorescent plate analysis was conducted by scanning the top two rows of the 96 well plate with a Tecan plate reader using excitation filter 485nm and emission filter

20

535nm. Data is shown by subtracted the non-transfected well signals from the transfected wells (n=2).

5 All other wells were lysed with 1X SDS PAGE sample buffer (NuPage, Invitrogen) by adding 30ul per well and pipetting up and down to lyse genomic DNA. The six wells for each condition were combined in one tube and boiled for 5min before loading 50ul of the cell lysate to a 4-12% NuPage Bis-Tris gel and separated by electrophoresis in MES running buffer. Western blotting of the gel was performed onto Nitrocellulose membrane in Novex Mini blot module using Bolt transfer buffer and 10% methanol. A
10 prestained molecular weight marker was used to confirm transfer (EZ-Run prestained marker Fisher). In brief, the membrane was dried over night and blocked with 5% non-fat dried milk in PBS containing 0.05% Tween 20 (PBST). The membrane was probed for 1hr with rabbit anti-egfp polyclonal antibody (Invitrogen CAB4211) at a dilution of 1:250 in PBST and then washed 3 x 5min in PBST. The membrane was incubated in
15 secondary anti-rabbit IgG HRP (Invitrogen cat #31460) at a dilution of 1:2500 for 1hr and then washed 3 x 5min in PBST. The western blots were then developed using a colorimetric DAB Substrate Kit from Thermo Fisher Cat# 34002 for 15min.

Results

20 *First data set*

As shown in Figure 10A, the Western blot shows bands of the correct apparent molecular weight of EGFP of 37KDa. Bands are clearly visible in plasmid construct B from 0.5ug to 1.0ug. Note that condition E1 was not run on the gel as there was only 10 wells per gel. A, B and C are control non-transfected cells. Levels of GFP expression
25 were also determined using a fluorescence plate reader (Figure 10B).

Second data set

The second data set confirm the findings of the first data set, as shown in Figure 11A and B. Namely, the B construct (plasmid ID: VB200507-1054ety Construct:
30 pscAAV[Exp]CBh>EGFP:WPR E3/SV40) shows the highest and dose dependent expression of EGFP and construct C (pscAAV[Exp]SYN1>EGFP:WP RE3/SV40 pA) showing a much lower but detectable expression of EGFP. Note in this experiment, the entire plate was scanned (n=8) as opposed to only the top two rows that were scanned in the first experiment (n=2). There was detectable expression in construct A but no
35 expression was found in construct E incubating with 1ug/ml doxycycline.

The Western blot analysis was loaded with a higher amount of sample than the first to increase the signal. In addition, TMB was used to develop the blot as it images much better. In the Western blot, expression is strongly detected in construct B and construct C, as shown in Figure 11A. However, detection of expression was just above background in construct E incubated with 1ug/ml doxycycline. It may be that a higher concentration of doxycycline is required but this would require a toxicity experiment as doxycycline is toxic >2ug/ml in many cell lines. With the higher loading and TMB detection, expression of EGFP in construct A is just visible above background. No expression of EGFP is detected in construct D. (Con is Control, MW is Molecular Weight Marker).

Summary

The objective of the study was to transfect SH-SY5Y (human neuronal cells) *in vitro* with five different plasmids at three different concentrations and analyse the expression of a reporter gene EGFP to determine the best expression cassette for *in vivo* study and therapy. The SH-SY5Y were transfected at passage 15 (P15) with TransFast Reagent at 0.5µg, 0.75µg and 1µg (equivalence to 24 well) in 96 well plates and analysed both qualitatively by Western Blot and quantitatively by fluorescence plate reader.

The results show that self-complementary plasmid ID: VB200507-1054ety Construct: pscAAV[Exp]CBh>EGFP:WPR E3/SV40 (construct B) had the highest expression of EGFP all five plasmids tested. Moreover, by both Western Blot and fluorescence plate reader, the expression of EGFP was dose dependant and increased from 0.5µg to 1µg. Expression of EGFP was observed at a lower level by only one other plasmid, i.e. self-complementary pscAAV[Exp]SYN1>EGFP:WP RE3/SV40 pA.

Example 2 - Pilot Study – Assess the ability of AAV-TH/GCH1 on the expression of tyrosine hydroxylase in a MPTP-lesioned macaque

Study outline

The study was a non-GLP study to assess the ability of AAV-TH/GCH1 to increase TH expression in the putamen following administration over 3 sites in the putamen.

MPTP is 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine and induces Parkinsonian syndrome. On Day 1 (D-7) of the study, a single female cynomolgus macaque previously

lesioned by systemic MPTP and shows significant motor deficits that are reversible by L-DOPA, received a T1-weighted MRI for the purpose of imaging the anatomy from which to derive surgical targets.

- 5 On D0, the animal underwent stereotaxic surgery to administer AAV-TH/GCH1 over 3-sites within the right putamen. The left putamen received vehicle.

On D28, the animal was deeply sedated using pentobarbital and killed via exsanguination with heparinised saline.

10

Following rapid removal, the brain paraffin embedded before being placed ventral side up into a stainless steel brain matrix. The brain was blocked at 4 mm intervals to obtain slabs throughout the entire striatum. Slides from each brain slab were processed for TH-IHC and imaged on a 40x slide scanner.

15

All in-life components were conducted at Atuka's non-human primate facility at 1336 Wuzhong Avenue, Suzhou, Jiangsu Province, PRC.

Methods and Materials

20

Constructs

The constructs of the invention, i.e. scAAV-TH/CGH1, were stored at -80 °C.

Vehicle

- 25 The vehicle used to formulate AAV-TH/CGH1 was PBS with 5% sorbitol.

Animal husbandry

- 30 The study was conducted under an approved IACUC. The macaque was obtained from Suzhou Xishan Zhongke Laboratory Animal Company (Xishan island, Jiangsu province, PRC). The animal was group housed with 2-3 animals per cage. The cage sizes exceeded UK, EU, NIH and CCAC minimum size recommendations, 152 (w) x 136 (d) x 192 (h) cm. The housing room was subject to a 12-hour light-dark cycle (lights on 7 a.m.), temperature 20-26°C in a room containing only animals of the same sex. Fresh fruit, primate pellets and water was available *ad libitum*.

35

The animal was handled by technical staff and transferred from home caging to

observation caging on a regular basis. The animal ID was identified via individually inscribed metalcollar tags and also by a subcutaneously implanted transponder encoded with the animal ID (Plexx,model IPTT-300). The animal was weighed weekly throughout the duration of the study.

5

Surgical delivery of viral vectors

MRI

For the purpose of calculating surgical coordinates for each animal and for each
10 target, T1 weighted 3T MRI was performed. Animals were anesthetized with Zoletil
(4-6 mg/kg, IM) /atropine 0.04 mg/kg, IM). Once sufficiently sedated, animals were
mounted onto the surgical frame and coordinates recorded in order to place the
animal back into the frame at the same orientation for surgery. Once in the frame the
animal was placed into the MRI scanner and 0.3mm thick horizontal slices was
15 obtained throughout the brain. Images were stored on external hard drives and
submitted to Osirix imaging software for viewing and derivation of surgical targets.
Part of this process included a qualitative inspection of the brain to note any
abnormal neuroanatomical presentations (e.g. tumor, abnormal asymmetry).

Surgery (Do)

Stereotaxic injection of the AAV vector was performed under isoflurane anaesthesia in
sterile conditions. All cranial injections were performed with the animal in a
stereotaxic head holder. Precise stereotaxic coordinates for all surgeries were
calculated prior to surgery from each individual animal MRI scan. Following sterile
25 preparation, incisions were made in the scalp over the target area and skin, muscle and
fascia retracted to expose the cranial surface. Single large bilateral burr holes were
made over the target areas. A small incision was then be made in the dura above the
desired injection sites and the tip of a Hamilton syringe (26G) was lowered to the
desired site for microinjection. Injections containing the AAV were made at a speed of
30 1.0 µL/min and a volume of 15 µL each into 3 sites of each hemisphere of the putamen
(AC+1, AC-2 and AC-5 mm). At each site, 2 deposits were made at 2 different depths.
The needle was maintained in place for an additional 5 min after each injection before
being withdrawn very slowly and moved to the next site. Following injection, the
exposed dura was covered with Gelfoam and the incision was closed with an
35 interrupted 6-0 monofilament suture. Animals received antibiotic treatment just prior
to surgery (ampicillin, 160 mg/kg, IM) and 2x/day thereafter for 3 days.

Postoperatively, for pain control, animals received meloxicam for 5 days (1/day, 0.1 mg/kg, PO). The animals were carefully monitored during the post operative period (see details below).

5 **Treatments**

The experiment contained 1 animal. Details can be found in the table below,

Treatment group	Surgery, right putamen (Day 0)	Surgery, left putamen (Day 0)	Necropsy
1	AAV-TH/GCH1	vehicle	Day 28

Brain tissue preparation

10 On D28, the animal was removed from their home cage, administered NSD1015 (dose and route to be determined) 30 minutes prior to necropsy. The animal was then deeply sedated by overdose with sodium pentobarbital (50 mg/kg, IV).

15 The thoracic cavity was quickly opened and a 14G catheter was inserted into the ascending aorta, the descending aorta was clamped behind the heart and an incision made into the right atrium to allow efflux of returning venous blood. Using a perfusion pump approximately 200 ml of ice-cold heparinised 0.9% saline (10 000 IU / L) was perfused at a rate of 100 ml/min. The brains were then removed and placed ventral side up, into a pre-chilled ice-cold brain matrix. Brain slabs of 4 mm thickness
20 were made spanning the entire striatum and from one of the slabs, single punches of putamen were taken from both hemispheres and stored at -80°C. Slabs of tissue were then immersed in 10% formalin for 48 hrs before being subjected to paraffin embedding. Tissues were then sectioned onto glass slides for immunohistochemistry.

25 **Postmortem measures**

Tyrosine hydroxylase histology

From 5 um thick paraffin-embedded sections from both hemispheres, mounted on glass slides, slides were deparaffinized and rehydrated as follows: twice in 100% Xylene (5 minutes each), twice in 100% Ethanol (3 minutes each), once in 95%
30 Ethanol (1 minute), once in 70% Ethanol (1 minute), twice in double distilled water (3

minutes each). Heat induced antigen retrieval was performed by incubating slides in Citrate Buffer for 20 minutes, followed by cooling at room temperature for approximately 20 minutes. Following three washes in PBS, endogenous peroxidase was quenched in 0.6% hydrogen peroxide solution and background staining was inhibited in a 10% normal goat serum/2% bovine serum albumin 0.1% Triton PBS solution. Tissue was then incubated with primary antibody overnight: Mouse anti-TH antibody (1:50, ThermoFisher. No. 185). After three washes in PBS, sections were sequentially incubated in biotinylated goat anti-mouse IgG (1:500, Jackson Immuno Research Laboratories, West Grove, PA, Cat. No. 111-065-144) for 1 hour at room temperature. Following 3 washes in PBS, sections were incubated with the Elite avidin-biotin complex (ABC kit, Vector, Burlingame, Ca, Cat. No. PK-6101) for 30 minutes. Immunostaining was visualized following a 15 minute reaction with 3, 3-diaminobenzidine (DAB kit, Vector, Burlingame, Ca, Cat. No. SK-4100). Sections were allowed to dry, dehydrated through graded alcohols (70%, 95%, 100%), cleared in xylenes and coverslipped with DEPEX mounting medium (Electron Microscopy Sciences, Hatfield, PA, Cat. No. 13514). Each slide was digitally scanned at 40x magnification (Aperio XT, Leica) and images will be provided.

Results

Referring to Figures 17-19, there are shown coronal sections of MPTP-lesioned macaque brain stained with Mouse anti-TH antibody (1:50, ThermoFisher. No. 185). TH-expressing fibres and cell bodies are stained brown. Expression of TH is demonstrated in the area where a combination of scAAV-hTH and scAAV-GCH1 was injected.

Discussion

This study was conducted as previous attempts by others to transduce sufficient TH expression to be detected by immunohistochemistry in the MPTP macaque model of PD by transduction with a bicistronic vector failed, i.e. Cederfjäll, E. et al. Continuous DOPA synthesis from a single AAV: dosing and efficacy in models of Parkinson's disease. Sci Rep-uk 3, (2013), in which the authors state "The reason for the lack of transgenic TH expression by histology and lack of DOPA and dopamine production by microdialysis remains unclear at this time. However, this problem requires a solution prior to the initiation of clinical trials utilizing this approach."

In contrast, the study described herein demonstrates that the claimed invention resulted in sufficient expression of TH in the MPTP-lesioned macaque putamen to be easily detected using equivalent immunohistochemistry detection.

5

Example 3 - Assessment of the effects of 1:1 combination of scAAV5-htTH and scAAV5-GCH1 on behaviour in the MPTP-lesioned macaque

Objective

10 The purpose of this study was to assess the ability of a 1:1 mixture of scAAV-TH and scAAV-GCH1 administered unilaterally to the putamen to improve contralateral motor performance on a reaching task in animals with an existing motor disability from MPTP exposure.

15 ***Animal Welfare***

The study was conducted according to CCAC guidelines and under IACUC-approved Animal Use Protocols (AUPs).

Study outline

20 The animals selected for the study had been previously lesioned via systemic administration of MPTP and show stable bilateral motor deficits that are sensitive to L-DOPA therapy. The behavioural tasks examined included a reaching task (monkey movement assessment panel, mMAP) and, independently, observation cage measures of general locomotor activity
25 (assessed via passive infra-red activity monitors during a 2-hour period and by use of Actical over a 24 hour period).

Behavioural assessments (mMAP and activity) was made twice weekly prior to surgery for 3 weeks (for a total of 6 observations) and twice weekly, every two
30 weeks post-surgery for a period of 3 months post-surgery (for a total of 12 observations).

On Day D-20 of the Study, all animals will received a T1-weighted MRI for the purpose of imaging the anatomy from which to derive surgical targets.

35

On D1, the animals will underwent stereotaxic surgery to administer 1:1

mixture of AAV-TH and AAV-GCH1 over 3-sites within the right putamen.

Methods and Materials

The scAAV-TH and scAAV-GCH1 were stored at -80 and were
5 brought to room temperature before co-infusion in PBS with 5%
sorbitol.

The macaques were obtained from Suzhou Xishan Zhongke Laboratory
Animal Company (Xishan island, Jiangsu province, PRC). Animals were
10 acclimatised to the experimental setting. The animals will had been rendered
parkinsonian by once daily subcutaneous injection of 0.2 mg/kg MPTP,
administered for 8-12 days, until the first appearance of parkinsonian
symptoms. After this time, a parkinsonian syndrome reached a moderate to
marked level, over approximately 30 days, and stabilized. Additional
15 administrations of MPTP were given to some animals to titrate to similar
degrees of parkinsonism in individuals across the group. The macaques were
allowed to recover for a minimum of further 30 days until their parkinsonism
was demonstrated as being stable.

20 Sixty days after commencing MPTP administration, L-DOPA (25 mg/kg) was
administered orally twice daily for at least two months. L-DOPA is given with
the decarboxylase inhibitor benserazide (as Madopar™). This treatment leads
to the development of motor fluctuations, including dyskinesia. Once selected
for the current study animals received no further regular L-DOPA
25 administration.

For the purpose of calculating surgical coordinates for each animal and for each
target, T1 weighted 3T MRI was performed. Animals were anesthetized with
Zoletil (4-6 mg/kg, IM / atropine 0.04 mg/kg, IM). Once sufficiently sedated,
30 animals were mounted onto the surgical frame and coordinates recorded in
order to place the animal back into the frame at the same orientation for
surgery. Once in the frame the animal was placed into the MRI scanner and
0.3 mm thick horizontal slices will be obtained throughout the brain. Images
were stored on external hard drives and submitted to Osirix imaging software
35 for viewing and derivation of surgical targets.

5 Stereotaxic injection of the AAV vectors was performed under isoflurane anesthesia in sterile conditions. Injections containing the mixture of two AAV vectors will be made by an infusion pump at a speed of 2.0 uL/min (Pump 11 Elite Nanomite Programmable Syringe Pump, Harvard Apparatus). The
10 needle was based on the construction described in WIPO Patent number WO2006/042090 AI (Kankiewicz and Sommer). Two stacked deposits, each of 15 µL of AAV mixture will be equally spaced along three tracks. The three tracks will be positioned pre-commissural, commissural and post-commissural in the putamen. Thus, a total of 90 µL of the AAV mixture will be deposited in the right putamen of each animal. The needle tip was positioned at the target site for the proximal deposit (1 minute wait time) followed by cannula advancement and infusion at the distal deposit (5 minute wait time).

15 Animals received antibiotic treatment just prior to surgery (ampicillin, 160 mg/kg, IM) and 2x/day thereafter for 3 days. Postoperatively, for pain control, animals will receive meloxicam for 5 days (1/day, 0.1 mg/kg, PO).

Surgery Right Putamen	Behaviour Right and left arm mMAP and activity counts	Number of animals
1:1 scAAV-TH: scAAV-GCH1 mixture	mMAP reach times, twice per week at weeks -3, -2, and -1 prior to surgery and twice every 2 weeks post-surgery for 3 months (all tests without L-DOPA/benserazide)	4

Behaviour

20 The primary endpoint of the study was fine motor function of the right and left upper limb assessed, in the animal's home cage, using a reaching task. Prior to commencing the study, animals were been trained to retrieve a positive reinforcer (candy), using the right and left hands from the monkey movement analysis panel as illustrated in Figure 20 (mMAP; essentially equivalent to
25 that described by Gash DM, et al., J Neurosci Methods. 1999; 89:111-7. KoW Ltd, Mississauga, ON, Canada).

The trial began when the experimenter places the candy (Lifesaver) in the

mMAP located outside the animal's home cage within reach of the animal. The time taken for the animal to retrieve the candy ("Retrieval Time") and return its arm to within the home cage, with a maximum cut off of 45 seconds, was assessed *post-hoc* by analysis of video recordings by an observer blinded to the treatment given. The ability of the animal to perform at three ascending levels of difficulty was assessed whereby the Lifesaver treat is either placed on the floor of the mMAP receptacle (Level B), on a straight pin within the receptacle (C) or, and most challengingly, on a curved hook (D) within the receptacle. The MAP tests were videoed in such a way that the resulting digital video file will allow a third-party rater blinded to treatment allocation or side of surgery to independently repeat the measurement of retrieval time.

Results

Referring to Figure 21, there is shown the change in mMAP Pre vs Post treatment. As can be seen, treatment resulted in a significantly ($p=0.018$) greater reduction in the reach time as a percent of baseline reach time in the contralateral arm compared to the ipsilateral arm. The reduction in reach time for the contralateral arm is consistent with increased L-DOPA production within the lesioned hemisphere. (The observed increase in reach time in the ipsilateral arm is unexplained and could be due to chance or could reflect some reversal of the increased dopamine D2 receptors known to occur in untreated MPTP lesioned animals. The present reduction in reach time would approach significance ($p=0.052$) even if no change was assumed in the ipsilateral arm.)

Overall Conclusions

It is known that Parkinson's disease symptoms arise due to a lack have the production of dopamine in the striatum of the brain. Three enzymes are necessary to produce dopamine, namely tyrosine hydroxylase [TH], GTP cyclohydrolase 1 [GCH] and amino acid decarboxylase [AADC]. Multiple attempts, including preclinical and clinical studies, have attempted to provide symptomatic relief of Parkinson's disease by using gene therapy to restore production of dopamine in the striatum by introducing one, two, or three of the genes to produce these enzymes. To date, however, none of these attempts has resulted in an optimal solution.

The invention described herein embodies co-administration of preferably two self-complementary AAV viral vectors encoding transduction of tyrosine hydroxylase and GTP cyclohydrolase 1 into intraparenchymal injection into the striatum. In contrast to

the only published study using a transducing just TH and GCH1 (without AADC) into the putamen of the MPTP NHP model of PD the invention resulted in expression of TH detectable by immunohistochemistry. Despite many previous published studies in which one or both genes have been injected into the striatum of animal models or patients to reduce the motor symptoms of Parkinson's disease, the composition described herein has never been described previously. Importantly, the novel co-administration of two monocistronic self-complementary AAV vectors has not been viewed as an obvious strategy. The enhanced efficacy and reduced cost of goods resulting from the invention are surprising and clinically important.

10

The inventor has found no reference to the co-administration of two self-complementary AAV vectors as a treatment for Parkinson's disease in the published literature are any other publicly available source.

15 The efficacy and economic advantages of the invention are advantageous and surprising for the following reasons:

(i) Two previously published approaches have coadministered TH and GCH in combination with AADC the resultant improvement in the motor symptoms of animal models of Parkinson's disease. While both these approaches have incorporated coadministration of TH and GCH neither has demonstrated that the use of TH and GCH in the absence of coadministration with AADC is effective. This is important because separate studies in non-human primates and in humans have emphasized the importance off loss of AADC in the evolution of clinical Parkinson's disease and have demonstrated significant symptomatic improvement in Parkinson's disease following intraparenchymal injection into the striatum of AADC alone. Based on the publications in which all three genes have been coadministered either as three monocistronic AAV vectors or as a single tricistronic lenti vector, it is not possible to predict the efficacy of TH and GCH administered in the absence of AADC.

30

(ii) A series of preclinical studies demonstrated that coadministration of single-stranded monocistronic AAV vectors carrying the transgenes for TH and GCH resulted in an improved motor performance when administered directly into the striatum of 6 hydroxy dopamine lesioned rats. However, this approach was not investigated further in larger animals or man, the

35

researchers reasoning that it “has a number of limitations, as transduction of efficacy and transgene expression is difficult to predict by in vitro assays clinical production would become very troublesome.” Secondly, although at the global scale the expression pattern over the two genes might look similar, the number of copies of the two vectors in an individual cell might vary dramatically, thus resulting in varying grade of DOPA synthesis. In addition, the effect might be aggravated with many cells receiving none or only one of the genes and therefore displaying limited DOPA synthesis if any. Furthermore, co-administration of different vectors carrying the same serotype was postulated to risk competition between the vectors for the same binding site on the target cell. Finally, and importantly, it was also reasoned that the cost of goods for a therapy requiring two individual AAV vectors would be significantly higher than a therapy requiring a single bicistronic vector. For these reasons, investigators switched to developing a bicistronic vector delivering both TH and GCH.

(iii) A series of studies subsequently demonstrated that administration of TH and GCH in a bicistronic single stranded [i.e., not self-complementary] AAV vector improved Parkinson disease motor symptoms in rat. Although this approach produced complete reversal of motor symptoms in the six hydroxy dopamine rat model of Parkinson's disease, it produced only modest improvement when scaled up to the non-human primate model. This was consistent with low barely discernible expression (assessed by immunohistochemistry) of TH in the striatum of treated non-human primates. As these findings were observed at the highest feasible dose of the bicistronic vector, development of this product was terminated and not advanced into clinical trials. Indeed, in a resulting publication, the authors state “The reason for the lack of transgenic TH expression by histology and lack of DOPA and dopamine production by microdialysis remains unclear at this time. However, this problem requires a solution prior to the initiation of clinical trials utilizing this approach.” Since these findings, no further studies implying that dual use of only TH and GCH have been published and the approach seems to have been abandoned as not sufficiently efficacious.

(iv) Co-administration of two self-complementary AAV vectors for this indication is novel and results in markedly enhanced transduction of

tyrosine hydroxylase to an extent that could not have been predicted. Clear evidence of efficacy in MPTP lesioned non-human primates has been demonstrated following co-administration of the two self-complementary monocistronic vectors.

5

- (v) The invention uses a CBh promoter that has never been applied to vectors intended to treat Parkinson's disease. The CBh promoter offers the following advantages over promoters used in previous vectors intended to treat Parkinson's disease, i.e. (1) its short length enables accommodation of the promoter trans gene combination within a self-complementary AAV construct. (2) It is less prone to silencing than the CMV promoter widely used in previous monocistronic constructs. (3) Its lack of neuronal specificity enables transduction of astrocytes and glia increasing the potential for additional production of DOPA by these cells within the striatum (4), the CBh promoter contains both a truncated chicken beta-actin intron and a minute virus of mouse (MVM) intron, which, together, act as a spacer, thereby increasing gene expression.

10

15

20

- (vi) Importantly, the increase in efficacy observed along human primates with the invention is such that the dose of the two individual self-complementary vectors is more than 50% lower than the [moderately] effective dose of the previously researched bicistronic factor. This surprising finding has significant potential beneficial impact on the cost of goods for the resulting therapeutic product.

25

Claims

1. A composition comprising first and second expression vectors, wherein the first expression vector comprises a promoter operably linked to a self-complementary
5 coding sequence, which encodes tyrosine hydroxylase (TH), and the second expression vector comprises a promoter operably linked to a coding sequence, which encodes GTP cyclohydrolase 1 (GCH1).
2. A composition according to claim 1, wherein the first expression vector and/or
10 the second expression vector is a naked DNA vector.
3. A composition according to any preceding claim, wherein the first expression vector and/or the second expression vector is an AAV vector.
- 15 4. A composition according to any preceding claim, wherein the second expression vector is a single-stranded AAV (ssAAV) vector.
5. A composition according to any preceding claim, wherein the second expression vector is a self-complementary AAV vector.
20
6. A composition according to any preceding claim, wherein the first expression vector is self-complementary AAV vector, and the second expression vector is a ssAAV or naked DNA vector.
- 25 7. A composition according to any preceding claim, wherein the first and/or second expression vector is derived from AAV-1, AAV-2, AAV-3A, AAV-3B, AAV-4, AAV-5, AAV-6, AAV-7, AAV-8, AAV-9, AAV-10, and/or AAV-11.
8. A composition according to any preceding claim, wherein the first and/or
30 second expression vector is derived from AAV1, AAV5, or AAV9, and more preferably, AAV5.
9. A composition according to any preceding claim, wherein the composition does not comprise a vector, which encodes aromatic amino acid decarboxylase (AADC).

10. A composition according to any preceding claim, wherein the coding sequence encoding TH comprises a nucleotide sequence substantially as set out in SEQ ID No: 1 or 21, or a fragment or variant thereof, or wherein the coding sequence encoding TH comprises a nucleotide sequence encoding an amino acid sequence substantially as set out in SEQ ID No: 2 or 22, or a fragment or variant thereof.
11. A composition according to any preceding claim, wherein the coding sequence encoding TH comprises a nucleotide sequence encoding truncated TH lacking the regulatory domain of TH, optionally wherein the coding sequence encoding TH comprises a nucleotide sequence substantially as set out in SEQ ID No: 3 or 23, or a fragment or variant thereof, or wherein the coding sequence encoding TH comprises a nucleotide sequence encoding an amino acid sequence substantially as set out in SEQ ID No: 4 or 24, or a fragment or variant thereof.
12. A composition according to any preceding claim, wherein the coding sequence encoding GCH1 comprises a nucleotide sequence substantially as set out in SEQ ID No: 6, or a fragment or variant thereof, or wherein the coding sequence encoding GCH1 comprises a nucleotide sequence encoding an amino acid sequence substantially as set out in SEQ ID No: 7, or a fragment or variant thereof.
13. A composition according to any preceding claim, wherein the promoter in the first and/or second expression vector is one that permits high expression in a subject's neurons, or in the subject's glial cells, or in the subject's neurons and glial cells, or in the subject's neurons and ependymal cells lining the cerebral ventricles, or in the subject's neurons and glial cells and ependymal cells.
14. A composition according to any preceding claim, wherein the promoter in the first and/or second expression vector is the CBh promoter, or a fragment or variant thereof, optionally wherein the promoter in the first and second vectors comprises the CBh promoter.
15. A composition according to claim 14, the promoter sequence in the first and/or second expression vector comprises a nucleotide sequence substantially as set out in SEQ ID No: 8, or a fragment or variant thereof.

16. A composition according to any preceding claim, wherein the promoter in the first and/or second expression vector is a human synapsin promoter, or the chicken beta actin promoter with a cytomegalovirus enhancer (CB7), or a Tetracycline-responsive element (TRE) promoter, and optionally is not the CMV promoter, or the
5 CMV enhancer/promoter.

17. A composition according to claim 16, wherein the promoter comprises a nucleotide sequence substantially as set out in SEQ ID No: 9, 10, 11, or 25, or a fragment or variant thereof.

10

18. A composition according to any preceding claim, wherein the first expression vector and/or the second expression vector comprises an intron disposed between its promoter and the nucleotide encoding TH1 or GCH1, respectively, optionally wherein
15 (i) the intron is at least 25, 50, 75, or 100 nucleotides in length;
(ii) the intron is at least 125, 150, 175, or 200 nucleotides in length; or
(iii) the intron is at least 225, 250, 275, or 300 nucleotides in length.

19. A composition according to claim 18, wherein the intron is selected from a group of introns consisting of: the human growth hormone (hGH) intron; the beta-actin intron; the minute virus of mouse (MVM) intron; the SV40 intron; and the EF-1
20 alpha intron

20. A composition according to claim 19, wherein the intron is the MVM intron, preferably wherein the intron comprises a nucleotide sequence substantially as set out
25 in SEQ ID No: 27, or a fragment or variant thereof.

21. A composition according to any one of claims 18-20, wherein :
(i) the first and/or second expression vector comprises a SYN1 promoter followed by an intron, which is either the MVM intron (SEQ ID No: 27) or the human
30 growth hormone (hGH) intron (SEQ ID No: 26);
(ii) the first and/or second expression vector comprises a chicken beta actin promoter with a cytomegalovirus enhancer (CB7) followed by an intron, which is either the MVM intron or the human growth hormone (hGH) intron;
(iii) the first and/or second expression vector comprises a Tetracycline-
35 responsive element (TRE) promoter followed by an intron, which is either the MVM intron or the human growth hormone (hGH) intron; or

(iv) the first and/or second expression vector comprises a CMV promoter followed by an intron, which is either the MVM intron or the human growth hormone (hGH) intron.

5 22. A composition according to any preceding claim, wherein second expression vector further comprises a nucleotide sequence encoding Woodchuck Hepatitis Virus Post-transcriptional Regulatory Element (WPRE), optionally wherein the WPRE coding sequence is disposed 3' of GCH1 coding sequence, and/or wherein the WPRE comprises a nucleic acid sequence substantially as set out in SEQ ID No: 12 or 13, or a fragment or
10 variant thereof.

23. A composition according to any preceding claim, wherein the first and/or second expression vector comprises a nucleotide sequence encoding a polyA tail, wherein:

15 (i) the polyA tail comprises the simian virus SV40 polyA tail, optionally comprising a nucleic acid sequence substantially as set out in SEQ ID No: 14, or a fragment or variant thereof; and/or

(ii) the polyA tail comprises the bovine growth hormone (BGH) poly A tail, optionally comprising a nucleic acid sequence substantially as set out in SEQ ID No: 15,
20 or a fragment or variant thereof.

24. A composition according to any preceding claim, wherein the first expression vector and/or the second expression vector comprises a nucleotide sequence encoding a 3' untranslated region (3' UTR), optionally wherein the first expression vector
25 comprises a 3' UTR coding sequence comprising a nucleic acid sequence substantially as set out in SEQ ID No: 28, or a fragment or variant thereof.

25. A composition according to any preceding claim, wherein the first and/or second expression vector comprises a left and/or a right Inverted Terminal Repeat sequences (ITRs), optionally wherein the first and/or second expression vector
30 comprises one Inverted Terminal Repeat (ITR) sequence and one modified ITR sequence in which the terminal resolution site is deleted, optionally comprising an ITR comprising a nucleic acid sequence substantially as set out in SEQ ID No: 16, or a fragment or variant thereof.

35

26. A composition according to any preceding claim, wherein the first expression vector comprises a nucleic acid sequence substantially as set out in SEQ ID No: 17, or a fragment or variant thereof.
- 5 27. A composition according to any preceding claim, wherein the second expression vector comprises a nucleic acid sequence substantially as set out in SEQ ID No: 18, or a fragment or variant thereof.
28. A composition according to any preceding claim, wherein the composition
10 comprises:-
(i) a first self-complementary adeno-associated virus (scAAV) vector comprising a promoter operably linked to a coding sequence, which encodes tyrosine hydroxylase (TH), optionally truncated TH lacking the regulatory domain; and
15 (ii) a second self-complementary adeno-associated virus (scAAV) vector comprising a promoter operably linked a coding sequence, which encodes GTP cyclohydrolase 1 (GCH1).
29. A pharmaceutical composition comprising the composition according to any
20 one of claims 1-28, and a pharmaceutically acceptable vehicle.
30. The composition according to any one of claims 1-28, or the pharmaceutical composition according to claim 29, for use as a medicament or in therapy.
- 25 31. The composition according to any one of claims 1-28, or the pharmaceutical composition according to claim 29, for use in treating, preventing, or ameliorating Parkinson's disease, DOPA responsive dystonia, vascular parkinsonism, side effects associated with L-DOPA treatment for Parkinson's disease, L-DOPA induced dyskinesia, Segawa syndrome, or genetic dopamine receptor abnormalities.
- 30 32. The composition or the pharmaceutical composition, for use according to claim 31, for administration into the blood stream, the cerebrospinal fluid, a nerve, or the brain.

33. The composition or the pharmaceutical composition, for use according to claim 31, for administration into the striatum, the putamen or caudate nucleus, dopaminergic neurons of the pars compacta region in the substantia nigra.

5 34. The composition or the pharmaceutical composition, for use according to any one of claims 31-33, wherein the dose of the composition delivered is 300 µl to 20,000 µl, 300 µl to 10,000 µl, 300 µl to 5,000 µl, 300 µl to 4500 µl, 400 µl to 4000 µl, 500 µl to 3500 µl, 600 µl to 3000 µl, 700 µl to 2500 µl, 750 µl to 2000 µl, 800 µl to 1500 µl, 850 µl to 1000 µl, or approximately 900 µl.

10

35. The composition or the pharmaceutical composition, for use according to any one of claims 31-34, wherein if administered as a mixture of AAV vectors, the titre of each AAV is 1E8 to 5E14, 1E9 to 1E14, 1E10 to 5E13, 1E11 to 1E13, 1E12 to 8E12, 4E12 to 6E12, or roughly 5E12 genome copies per ml (GC/ml).

15

36. The composition or the pharmaceutical composition, for use according to any one of claims 30-34, wherein if administered as a mixture of naked DNA plasmid vectors, the dose of each DNA plasmid vector is 50, 100, 200, 300, 400, 500, 600, 700, 800, 900, 1000, 1250, 1500, 1750 or 2000 micrograms (µg) per brain hemisphere.

20

37. A first expression vector comprising a promoter operably linked to a self-complementary coding sequence, which encodes tyrosine hydroxylase (TH), and a second expression vector comprising a promoter operably linked to a coding sequence, which encodes GTP cyclohydrolase 1 (GCH1), for use in therapy,

25 optionally for use in treating, preventing, or ameliorating Parkinson's disease, DOPA responsive dystonia, vascular parkinsonism, side effects associated with L-DOPA treatment for Parkinson's disease, L-DOPA induced dyskinesia, Segawa syndrome, or genetic dopamine receptor abnormalities.

30 38. A first expression and a second expression vector, for use according to claim 37, wherein the first and second expression vectors are as defined in any one of claims 1-28.

35 39. A kit of parts comprising the first and second expression vectors as defined in any one of claims 1-28, and optionally, instructions for use.

40. The kit of parts according to claim 39, wherein the kit comprises a first container in which the first expression vector is contained, and a second container in which the second expression vector is contained, optionally wherein the first and/or second container is a vial, syringe, Eppendorf, or the like.

Figure 1




Figure 2




Figure 3




Figure 4




Figure 5




Figure 6




Figure 7




Figure 8




Figure 9




Figure 10A




Figure 10B




Figure 11A




Figure 11B




Figure 12




Figure 13




Figure 14




Figure 15




Figure 16




Figure 17






Figure 18**Figure 19**

Figure 20





Fig. 1. (A) A diagram of the mblAP illustrating the location of the left arm portal (X) on the main frame attached to the home cage. The left receptacle portal (Y) is also labeled. The bank of three photodiodes to detect movement can be seen around each portal. (B) A diagram of the clear Lexan mblAP attached to the doorway of the home cage, allowing the animal to see and view the reward in the receptacle chamber during testing.

Figure 21



SEQUENCE LISTING

<110> MaavRx Ltd

<120> Expression Vector

<130> 98015PCT1

<150> 2019286.0

<151> 2020-12-08

<160> 29

<170> PatentIn version 3.5

<210> 1

<211> 1494

<212> DNA

<213> Homo sapiens

<400> 1

atgcccaccc ccgacgccac cagccacag gccaaagggt tccgcagggc cgtgtctgag	60
ctggacgcca agcaggcaga ggccatcatg tccccgcggt tcattgggcg caggcagagc	120
ctcatcgagg acgcccgcaa ggagcgggag gcggcggtgg cagcagcggc cgctgcagtc	180
ccctcggagc ccggggaccc cctggaggct gtggcctttg aggagaagga ggggaaggcc	240
gtgctaaacc tgctcttctc cccgagggcc accaagccct cggcgctgtc ccgagctgtg	300
aagggtgtttg agacgtttga agccaaaatc caccatctag agaccgggcc cgcccagagg	360
ccgcgagctg gggggcccca cctggagtac ttctgtgcgc tcgaggtgag ccgaggggac	420
ctggccgccc tgctcagtgg tgtgcgccag gtgtcagagg acgtgcgcag ccccgcgggg	480
cccaagggtcc cctggttccc aagaaaagtg tcagagctgg acaagtgtca tcacctggtc	540
accaagtctg accctgacct ggacttggac caccggggt tctcggacca ggtgtaccgc	600
cagcgcagga agctgattgc tgagatcgcc ttccagtaca ggcacggcga cccgattccc	660
cgtgtggagt acaccgccga ggagattgcc acctggaagg aggtctacac cagctgaag	720
ggcctctacg ccacgcacgc ctgcggggag cacctggagg cttttgcttt gctggagcgc	780
ttcagcggct accgggaaga caatatcccc cagctggagg acgtctcccg cttcctgaag	840
gagcgcacgg gcttccagct gcggcctgtg gccggcctgc tgtccgcccg ggacttcctg	900

```

gccagcctgg ccttccgctg gttccagtgc acccagtata tccgccacgc gtcctcgccc      960
atgcactccc ctgagccgga ctgctgccac gagctgctgg ggcacgtgcc catgctggcc      1020
gaccgcacct tcgcgcagtt ctgcgaggac attggcctgg cgtccctggg ggcctcggat      1080
gaggaaattg agaagctgtc cacgctgtac tggttcacgg tggagttcgg gctgtgtaag      1140
cagaacgggg aggtgaaggc ctatggtgcc gggctgctgt cctcctacgg ggagctcctg      1200
cactgcctgt ctgaggagcc tgagattcgg gccttcgacc ctgaggctgc ggccgtgcag      1260
ccctaccaag accagacgta ccagtcagtc tacttcgtgt ctgagagctt cagtgcgcc      1320
aaggacaagc tcaggagcta tgcctcacgc atccagcgcc ctttctccgt gaagttcgac      1380
ccgtacacgc tggccatcga cgtgctggac agccccagg ccgtgcggcg ctccctggag      1440
ggtgtccagg atgagctgga cacccttgcc catgcgctga gtgccattgg ctag          1494

```

```

<210> 2
<211> 497
<212> PRT
<213> Homo sapiens

```

```

<400> 2

```

```

Met Pro Thr Pro Asp Ala Thr Thr Pro Gln Ala Lys Gly Phe Arg Arg
1           5           10          15

```

```

Ala Val Ser Glu Leu Asp Ala Lys Gln Ala Glu Ala Ile Met Ser Pro
          20          25          30

```

```

Arg Phe Ile Gly Arg Arg Gln Ser Leu Ile Glu Asp Ala Arg Lys Glu
          35          40          45

```

```

Arg Glu Ala Ala Val Ala Ala Ala Ala Ala Ala Val Pro Ser Glu Pro
          50          55          60

```

```

Gly Asp Pro Leu Glu Ala Val Ala Phe Glu Glu Lys Glu Gly Lys Ala
65          70          75          80

```

```

Val Leu Asn Leu Leu Phe Ser Pro Arg Ala Thr Lys Pro Ser Ala Leu

```

85

90

95

Ser Arg Ala Val Lys Val Phe Glu Thr Phe Glu Ala Lys Ile His His
 100 105 110

Leu Glu Thr Arg Pro Ala Gln Arg Pro Arg Ala Gly Gly Pro His Leu
 115 120 125

Glu Tyr Phe Val Arg Leu Glu Val Arg Arg Gly Asp Leu Ala Ala Leu
 130 135 140

Leu Ser Gly Val Arg Gln Val Ser Glu Asp Val Arg Ser Pro Ala Gly
 145 150 155 160

Pro Lys Val Pro Trp Phe Pro Arg Lys Val Ser Glu Leu Asp Lys Cys
 165 170 175

His His Leu Val Thr Lys Phe Asp Pro Asp Leu Asp Leu Asp His Pro
 180 185 190

Gly Phe Ser Asp Gln Val Tyr Arg Gln Arg Arg Lys Leu Ile Ala Glu
 195 200 205

Ile Ala Phe Gln Tyr Arg His Gly Asp Pro Ile Pro Arg Val Glu Tyr
 210 215 220

Thr Ala Glu Glu Ile Ala Thr Trp Lys Glu Val Tyr Thr Thr Leu Lys
 225 230 235 240

Gly Leu Tyr Ala Thr His Ala Cys Gly Glu His Leu Glu Ala Phe Ala
 245 250 255

Leu Leu Glu Arg Phe Ser Gly Tyr Arg Glu Asp Asn Ile Pro Gln Leu
 260 265 270

Glu Asp Val Ser Arg Phe Leu Lys Glu Arg Thr Gly Phe Gln Leu Arg
 275 280 285

Pro Val Ala Gly Leu Leu Ser Ala Arg Asp Phe Leu Ala Ser Leu Ala
290 295 300

Phe Arg Val Phe Gln Cys Thr Gln Tyr Ile Arg His Ala Ser Ser Pro
305 310 315 320

Met His Ser Pro Glu Pro Asp Cys Cys His Glu Leu Leu Gly His Val
325 330 335

Pro Met Leu Ala Asp Arg Thr Phe Ala Gln Phe Ser Gln Asp Ile Gly
340 345 350

Leu Ala Ser Leu Gly Ala Ser Asp Glu Glu Ile Glu Lys Leu Ser Thr
355 360 365

Leu Tyr Trp Phe Thr Val Glu Phe Gly Leu Cys Lys Gln Asn Gly Glu
370 375 380

Val Lys Ala Tyr Gly Ala Gly Leu Leu Ser Ser Tyr Gly Glu Leu Leu
385 390 395 400

His Cys Leu Ser Glu Glu Pro Glu Ile Arg Ala Phe Asp Pro Glu Ala
405 410 415

Ala Ala Val Gln Pro Tyr Gln Asp Gln Thr Tyr Gln Ser Val Tyr Phe
420 425 430

Val Ser Glu Ser Phe Ser Asp Ala Lys Asp Lys Leu Arg Ser Tyr Ala
435 440 445

Ser Arg Ile Gln Arg Pro Phe Ser Val Lys Phe Asp Pro Tyr Thr Leu
450 455 460

Ala Ile Asp Val Leu Asp Ser Pro Gln Ala Val Arg Arg Ser Leu Glu
465 470 475 480

Gly Val Gln Asp Glu Leu Asp Thr Leu Ala His Ala Leu Ser Ala Ile

Gly

<210> 3

<211> 1029

<212> DNA

<213> Homo sapiens

<400> 3

atgagccccg cggggcccaa ggtcccctgg ttcccaagaa aagtgtcaga gctggacaag	60
tgtcatcacc tggtcaccaa gttcgaccct gacctggact tggaccaccc gggcttctcg	120
gaccaggtgt accgccagcg caggaagctg attgctgaga tcgccttcca gtacaggcac	180
ggcgacccga ttccccgtgt ggagtacacc gccgaggaga ttgccacctg gaaggaggtc	240
tacaccacgc tgaagggcct ctacgccacg cagcctgcg gggagcacct ggaggccttt	300
gctttgctgg agcgcttcag cggctaccgg gaagacaata tccccagct ggaggacgtc	360
tcccgcttcc tgaaggagcg cacgggcttc cagctgcggc ctgtggccgg cctgctgtcc	420
gcccgggact tcctggccag cctggccttc cgcgtgttcc agtgcacca gtatatccgc	480
cacgcgtcct cgcccatgca ctcccctgag ccgactgct gccacgagct gctggggcac	540
gtgcccattgc tggccgaccg caccttcgcg cagttctcgc aggacattgg cctggcgtcc	600
ctggggggcct cggatgagga aattgagaag ctgtccacgc tgtactgggtt cacggtggag	660
ttcgggctgt gtaagcagaa cggggaggtg aaggcctatg gtgccgggct gctgtcctcc	720
tacggggagc tcctgcactg cctgtctgag gagcctgaga ttcgggcctt cgaccctgag	780
gctgcggccg tgcagcccta ccaagaccag acgtaccagt cagtctactt cgtgtctgag	840
agcttcagtg acgccaagga caagctcagg agctatgcct cacgcatcca gcgccccttc	900
tccgtgaagt tcgaccgta cacgctggcc atcgacgtgc tggacagccc ccaggccgtg	960
cggcgctccc tggagggtgt ccaggatgag ctggacaccc ttgcccatgc gctgagtgcc	1020
attggctag	1029

<210> 4
<211> 342
<212> PRT
<213> Homo sapiens

<400> 4

Met Ser Pro Ala Gly Pro Lys Val Pro Trp Phe Pro Arg Lys Val Ser
1 5 10 15

Glu Leu Asp Lys Cys His His Leu Val Thr Lys Phe Asp Pro Asp Leu
20 25 30

Asp Leu Asp His Pro Gly Phe Ser Asp Gln Val Tyr Arg Gln Arg Arg
35 40 45

Lys Leu Ile Ala Glu Ile Ala Phe Gln Tyr Arg His Gly Asp Pro Ile
50 55 60

Pro Arg Val Glu Tyr Thr Ala Glu Glu Ile Ala Thr Trp Lys Glu Val
65 70 75 80

Tyr Thr Thr Leu Lys Gly Leu Tyr Ala Thr His Ala Cys Gly Glu His
85 90 95

Leu Glu Ala Phe Ala Leu Leu Glu Arg Phe Ser Gly Tyr Arg Glu Asp
100 105 110

Asn Ile Pro Gln Leu Glu Asp Val Ser Arg Phe Leu Lys Glu Arg Thr
115 120 125

Gly Phe Gln Leu Arg Pro Val Ala Gly Leu Leu Ser Ala Arg Asp Phe
130 135 140

Leu Ala Ser Leu Ala Phe Arg Val Phe Gln Cys Thr Gln Tyr Ile Arg
145 150 155 160

His Ala Ser Ser Pro Met His Ser Pro Glu Pro Asp Cys Cys His Glu
165 170 175

Leu Leu Gly His Val Pro Met Leu Ala Asp Arg Thr Phe Ala Gln Phe
180 185 190

Ser Gln Asp Ile Gly Leu Ala Ser Leu Gly Ala Ser Asp Glu Glu Ile
195 200 205

Glu Lys Leu Ser Thr Leu Tyr Trp Phe Thr Val Glu Phe Gly Leu Cys
210 215 220

Lys Gln Asn Gly Glu Val Lys Ala Tyr Gly Ala Gly Leu Leu Ser Ser
225 230 235 240

Tyr Gly Glu Leu Leu His Cys Leu Ser Glu Glu Pro Glu Ile Arg Ala
245 250 255

Phe Asp Pro Glu Ala Ala Ala Val Gln Pro Tyr Gln Asp Gln Thr Tyr
260 265 270

Gln Ser Val Tyr Phe Val Ser Glu Ser Phe Ser Asp Ala Lys Asp Lys
275 280 285

Leu Arg Ser Tyr Ala Ser Arg Ile Gln Arg Pro Phe Ser Val Lys Phe
290 295 300

Asp Pro Tyr Thr Leu Ala Ile Asp Val Leu Asp Ser Pro Gln Ala Val
305 310 315 320

Arg Arg Ser Leu Glu Gly Val Gln Asp Glu Leu Asp Thr Leu Ala His
325 330 335

Ala Leu Ser Ala Ile Gly
340

<210> 5
<211> 792
<212> DNA
<213> Mus musculus

<400> 5
 ggtgggttttc ctttgaaaaa cacgatgata atatggccac aaccgcggcc gtagatcccc 60
 ggaccatgga gaagccgcgg ggagtcaggt gcaccaatgg gttctccgag cgggagctgc 120
 cgcggccccg ggccagcccc cctgccgaga agtcccggcc gcccgaggcc aagggcgcac 180
 agccggccga cgcctggaag gcagggcggc accgcagcga ggaggaaaac caggtgaacc 240
 tccccaaact ggaggctgct tactcgtcca ttctgctctc gctgggagag gacccccagc 300
 ggagggggct gctcaagacg ccctggaggg cggccaccgc catgcagtac ttcaccaagg 360
 gataccagga gaccatctca gatgtcctga atgatgctat atttgatgaa gatcatgacg 420
 agatggtgat tgtgaaggac atagatatgt tctccatgtg tgagcatcac cttgttccat 480
 ttgtaggaag ggtccatatt ggctatcttc ctaacaagca agtccttggc ctcagtaaac 540
 ttgccaggat ttagaaaatc tacagtagac gactacaagt tcaagagcgc ctcaccaaac 600
 agattgcggg ggccatcaca gaagccttgc agcctgctgg cgttgagta gtgattgaag 660
 cgacacacat gtgcatgta atgcgaggcg tgcagaaaat gaacagcaag actgtcacta 720
 gcaccatgct gggcgtgttc cgggaagacc ccaagactcg ggaggagttc ctcacactaa 780
 tcaggagctg ag 792

<210> 6
 <211> 753
 <212> DNA
 <213> Homo sapiens

<400> 6
 atggagaagg gccctgtgcg ggcaccggcg gagaagccgc ggggcgccag gtgcagcaat 60
 gggttccccg agcgggatcc gccgcggccc gggcccagca ggccggcgga gaagcccccg 120
 cggcccagg ccaagagcgc gcagcccgcg gacggctgga agggcgagcg gccccgcagc 180
 gaggaggata acgagctgaa cctccctaac ctggcagccg cctactcgtc catcctgagc 240
 tcgctgggcg agaaccccc a gcggcaagg ctgctcaaga cgccctggag ggcggcctcg 300
 gccatgcagt tcttcaccaa gggctaccag gagaccatct cagatgtcct aaacgatgct 360
 atatttgatg aagatcatga tgagatggtg attgtgaagg acatagacat gttttccatg 420

tgtgagcatc acttggttcc atttggttga aaggtccata ttggttatct tcctaacaag	480
caagtccttg gcctcagcaa acttgcgagg attgtagaaa tctatagtag aagactacaa	540
gttcaggagc gccttacaaa acaaattgct gtagcaatca cggaagcctt gcggcctgct	600
ggagtcgggg tagtggttga agcaacacac atgtgtatgg taatgcgagg tgtacagaaa	660
atgaacagca aaactgtgac cagcacaatg ttgggtgtgt tccgggagga tccaaagact	720
cgggaagagt tcctgactct cattaggagc tga	753

<210> 7
 <211> 250
 <212> PRT
 <213> Homo sapiens

<400> 7

Met	Glu	Lys	Gly	Pro	Val	Arg	Ala	Pro	Ala	Glu	Lys	Pro	Arg	Gly	Ala
1				5					10					15	

Arg	Cys	Ser	Asn	Gly	Phe	Pro	Glu	Arg	Asp	Pro	Pro	Arg	Pro	Gly	Pro
			20					25					30		

Ser	Arg	Pro	Ala	Glu	Lys	Pro	Pro	Arg	Pro	Glu	Ala	Lys	Ser	Ala	Gln
		35					40					45			

Pro	Ala	Asp	Gly	Trp	Lys	Gly	Glu	Arg	Pro	Arg	Ser	Glu	Glu	Asp	Asn
	50					55					60				

Glu	Leu	Asn	Leu	Pro	Asn	Leu	Ala	Ala	Ala	Tyr	Ser	Ser	Ile	Leu	Ser
65					70					75				80	

Ser	Leu	Gly	Glu	Asn	Pro	Gln	Arg	Gln	Gly	Leu	Leu	Lys	Thr	Pro	Trp
			85						90					95	

Arg	Ala	Ala	Ser	Ala	Met	Gln	Phe	Phe	Thr	Lys	Gly	Tyr	Gln	Glu	Thr
			100					105					110		

Ile	Ser	Asp	Val	Leu	Asn	Asp	Ala	Ile	Phe	Asp	Glu	Asp	His	Asp	Glu
		115					120					125			

Met Val Ile Val Lys Asp Ile Asp Met Phe Ser Met Cys Glu His His
130 135 140

Leu Val Pro Phe Val Gly Lys Val His Ile Gly Tyr Leu Pro Asn Lys
145 150 155 160

Gln Val Leu Gly Leu Ser Lys Leu Ala Arg Ile Val Glu Ile Tyr Ser
165 170 175

Arg Arg Leu Gln Val Gln Glu Arg Leu Thr Lys Gln Ile Ala Val Ala
180 185 190

Ile Thr Glu Ala Leu Arg Pro Ala Gly Val Gly Val Val Val Glu Ala
195 200 205

Thr His Met Cys Met Val Met Arg Gly Val Gln Lys Met Asn Ser Lys
210 215 220

Thr Val Thr Ser Thr Met Leu Gly Val Phe Arg Glu Asp Pro Lys Thr
225 230 235 240

Arg Glu Glu Phe Leu Thr Leu Ile Arg Ser
245 250

<210> 8
<211> 798
<212> DNA
<213> Artificial Sequence

<220>
<223> CBh promoter

<400> 8
cgttacataa cttacggtaa atggcccgcc tggctgaccg cccaacgacc cccgccatt 60
gacgtcaata gtaacgcaa tagggacttt ccattgacgt caatgggtgg agtatttacg 120
gtaaactgcc cacttggcag tacatcaagt gtatcatatg ccaagtacgc cccctattga 180
cgtcaatgac ggtaaattggc cgcctggca ttgtgccag tacatgacct tatgggactt 240

tcctacttgg cagtacatct acgtattagt catcgctatt accatggtcg aggtgagccc	300
cacgttctgc ttactctcc ccatctcccc cccctcccca cccccaattt tgtattttatt	360
tatttttttaa ttattttgtg cagcgatggg ggcggggggg gggggggggc gcgcgccagg	420
cggggcgggg cggggcgagg ggcggggcgg ggcgaggcgg agaggtgcgg cggcagccaa	480
tcagagcggc gcgctccgaa agtttccttt tatggcgagg cggcggcggc ggcggcccta	540
taaaaagcga agcgcgcggc gggcgggagt cgctgcgcgc tgccttcgcc ccgtgccccg	600
ctccgccgcc gcctcgcgcc gcccgcgccg gctctgactg accgcgttac tcccacaggt	660
gagcgggcgg gacggccctt ctctccggg ctgtaattag ctgagcaaga ggtaagggtt	720
taagggatgg ttggttggtg gggтатаат gttaattac ctggagcacc tgcctgaaat	780
cacttttttt caggttgg	798

<210> 9
 <211> 469
 <212> DNA
 <213> Homo sapiens

<400> 9	
ctgcagaggg ccctgcgtat gagtgcagt gggtttttagg accaggatga ggcgggggtgg	60
gggtgcctac ctgacgaccg accccgacc actggacaag caccacaacc ccattcccca	120
aattgcgcat cccctatcag agaggggggag gggaaacagg atgcggcgag gcgcgtgcgc	180
actgccagct tcagcaccgc ggacagtgcc ttcgcccccg cctggcggcg gcgcgccaccg	240
ccgcctcagc actgaaggcg cgctgacgtc actcgccggt ccccgcaaa ctccccttcc	300
cggccacctt ggtcgcgtcc gcgccgccgc cggcccagcc ggaccgcacc acgcgaggcg	360
cgagataggg gggcacgggc gcgacctct gcgctgcggc gccggcgact cagcgctgcc	420
tcagtctgcg gtgggcagcg gaggagtcgt gtcgtgcctg agagcgag	469

<210> 10
 <211> 659
 <212> DNA
 <213> Artificial Sequence

<220>

<223> Chicken beta actin promoter with a cytomegalovirus enhancer (CB7)

<400> 10

gacattgatt attgactagt tattaatagt aatcaattac ggggtcatta gttcatagcc	60
catatatgga gttccgcgtt acataactta cggtaaatgg cccgcctggc tgaccgcca	120
acgacccccg cccattgacg tcaataatga cgtatgttcc catagtaacg ccaataggga	180
ctttccattg acgtcaatgg gtggagtatt tacggtaaac tgcccacttg gcagtacatc	240
aagtgtatca tatgccaagt acgcccccta ttgacgtcaa tgacggtaaa tggccgcct	300
ggcattatgc ccagtacatg accttatggg actttcctac ttggcagtac atctacgtat	360
tagtcatcgc tattaccatg gtcgaggatga gcccacggtt ctgcttcact ctccccatct	420
cccccccctc cccacccccca attttgtatt tatttatttt ttaattattt tgtgcagcga	480
tgggggcgagg ggggggggggg gggcgcgcg caggcggggc ggggcggggc gagggcgagg	540
gcggggcgag gcggagaggt gcggcggcag ccaatcagag cggcgcgctc cgaaagtttc	600
cttttatggc gaggcggcgg cggcggcggc cctataaaaa gcgaagcgcg cggcgggcg	659

<210> 11

<211> 663

<212> DNA

<213> Artificial Sequence

<220>

<223> TRE promoter

<400> 11

acgcgtggag ctagttatta atagtaatca attacggggt cattagttca tagcccatat	60
atggagttcc gcgttacata acttacggta aatggcccg ctaggctgacc gcccaacgac	120
ccccgcccac tgacgtcaat aatgacgtat gttcccatag taacgtcaat agggactttc	180
cattgacgtc aatgggtgga gtatttacgg taaactgccc acttggcagt acatcaagtg	240
tatcatatgc caagtacgcc ccctattgac gtcaatgacg gttaaaggcc cgcctggcat	300
tatgcccagt acatgacctt atgggacttt cctacttggc agtacatcta cgtattagtc	360
atcgctatta ccatggtgat gcggttttgg cagtacatca atgggcgtgg atagcggttt	420

gactcacggg gatttccaag tctccacccc attgacgtca atgggagttt gttttgcacc	480
aaaatcaacg ggactttcca aaatgtcgta acaactccgc cccattgacg caaatgggag	540
gtaggcgtgt acgggtgggag gtctatataa gcagagctcg tttagtgaac cgtcagatcg	600
cctggagacg ccatccacgc tgttttgacc tccatagaag acaccgggac cgatccagcc	660
tcc	663

<210> 12
 <211> 592
 <212> DNA
 <213> Woodchuck hepatitis B virus

<400> 12	
aatcaacctc tggattacaa aatttgtgaa agattgactg gtattcttaa ctatgttgct	60
ccttttacgc tatgtggata cgctgcttta atgcctttgt atcatgctat tgcttcccgt	120
atggctttca ttttctcctc cttgtataaa tcctggttgc tgtctcttta tgaggagttg	180
tggcccgttg tcaggcaacg tggcgtggtg tgcactgtgt ttgctgacgc aacccccact	240
ggttggggca ttgccaccac ctgtcagctc ctttccggga ctttcgcttt cccctccct	300
attgccacgg cggaactcat cgccgcctgc cttgcccgt gctggacagg ggctcggctg	360
ttgggcactg acaattccgt ggtgttgctg gggaagctga cgtcctttcc atggctgctc	420
gcctgtgttg ccacctggat tctgcgcggg acgtccttct gctacgtccc ttcggccctc	480
aatccagcgg accttcctc ccgcggcctg ctgccggctc tgcggcctct tccgcgtctt	540
cgccttcgcc ctacagacgag tcggatctcc ctttgggccg cctccccgcc tg	592

<210> 13
 <211> 247
 <212> DNA
 <213> Woodchuck hepatitis B virus

<400> 13	
aatcaacctc tggattacaa aatttgtgaa agattgactg gtattcttaa ctatgttgct	60
ccttttacgc tatgtggata cgctgcttta atgcctttgt atcatgctat tgcttcccgt	120
atggctttca ttttctcctc cttgtataaa tcctggttag ttcttgccac ggcggaactc	180

atcgccgcct gccttgcccg ctgctggaca ggggctcggc tgttgggcac tgacaattcc 240
gtggtgt 247

<210> 14
<211> 224
<212> DNA
<213> Simian virus 40

<400> 14
agcagacatg ataagataca ttgatgagtt tggacaaacc acaactagaa tgcagtgaaa 60
aaaatgcttt atttgtgaaa tttgtgatgc tattgcttta tttgtaacca ttataagctg 120
caataaaciaa gttaacaaca acaattgcat tcattttatg tttcaggttc agggggaggt 180
gtgggaggtt ttttaaagca agtaaacct ctacaaatgt ggta 224

<210> 15
<211> 208
<212> DNA
<213> Bos taurus

<400> 15
ctgtgccctt tagttgccag ccatctgttg tttgccctc ccccgctgcct tccttgaccc 60
tggaagggtg cactcccact gtcctttcct aataaaatga ggaaattgca tcgcattgtc 120
tgagtaggtg tcattctatt ctgggggggtg ggggtggggca ggacagcaag ggggaggatt 180
gggaagagaa tagcaggcat gctgggga 208

<210> 16
<211> 113
<212> DNA
<213> Artificial Sequence

<220>
<223> ITR sequence

<400> 16
ccactccctc tctgcgcgct cgctcgctca ctgaggccgg gcgaccaaag gtcgcccgcac 60
gcccgggctt tgcccgggcg gcctcagtga gcgagcgagc gcgcagagag gga 113

<210> 17

<211> 5071
<212> DNA
<213> Artificial Sequence

<220>

<223> Expression vector comprising a CBh promoter operably linked to an htTH coding sequence

<400> 17

agcgcccaat acgcaaaccg cctctccccg cgcgttggcc gattcattaa tgcagctggc	60
acgacaggtt tcccgactgg aaagcgggca gtgagcgcaa cgcaattaat gtgagttagc	120
tcactcatta ggcaccccag gctttacact ttatgcttcc ggctcgtatg ttgtgtggaa	180
ttgtgagcgg ataacaattt cacacaggaa acagctatga ccatgattac gccaagctct	240
cgagatctag aaagcttccc ggggggatct gggccactcc ctctctgcgc gctcgctcgc	300
tcactgaggc cgggcgacca aaggtcgccc gacgcccggg ctttgcccgg gcggcctcag	360
tgagcgagcg agcgcgaga gagggagtgg ccaactccat cactaggggt tcctggaggg	420
gtggagtctg gacctaggca actttgtata gaaaagttgc gttacataac ttacggtaaa	480
tggcccgctt ggctgaccgc ccaacgaccc ccgcccattg acgtcaatag taacgccaat	540
agggactttc cattgacgtc aatgggtgga gtattttacgg taaactgccc acttggcagt	600
acatcaagtg tatcatatgc caagtacgcc ccctattgac gtcaatgacg gtaaattggcc	660
cgcctggcat tgtgcccagt acatgacctt atgggacttt cctacttggc agtacatcta	720
cgtattagtc atcgctatta ccatggtcga ggtgagcccc acgttctgct tcactctccc	780
catctcccc ccctccccac cccaatttt gtattttattt attttttaat tattttgtgc	840
agcgaatgggg gcggggggggg gggggggggcg cgcgccaggc ggggcggggc ggggcgaggg	900
gcggggcggg gcgaggcgga gaggtgcggc ggcagccaat cagagcggcg cgctccgaaa	960
gtttcctttt atggcgaggc ggcggcgggc gcggccctat aaaaagcgaa gcgcgcggcg	1020
ggcgggagtc gctgcgcgt gccttcgccc cgtgccccgc tccgccgccg cctcgcgccg	1080
cccggcccgg ctctgactga ccgcgttact cccacagggt agcgggcggg acggcccttc	1140
tcctccgggc tgtaattagc tgagcaagag gtaagggttt aagggatggt tggttggtgg	1200
ggtattaatg tttaattacc tggagcacct gcctgaaatc actttttttc aggttggcaa	1260

gtttgtacag ccaccatgag ccccgcgggg cccaaggtcc cctggttccc aagaaaagtg	1320
tcagagctgg acaagtgtca tcacctggtc accaagttcg accctgacct ggacttggac	1380
cacccgggct tctcggacca ggtgtaccgc cagcgcagga agctgattgc tgagatcgcc	1440
ttccagtaca ggcacggcga cccgattccc cgtgtggagt acaccgccga ggagattgcc	1500
acctggaagg aggtctacac cacgctgaag ggcctctacg ccacgcacgc ctgcggggag	1560
cacctggagg cttttgcttt gctggagcgc ttacgaggct accgggaaga caatatcccc	1620
cagctggagg acgtctcccg cttcctgaag gagcgcacgg gcttccagct gcggcctgtg	1680
gccggcctgc tgtccgcccc ggacttcttg gccagcctgg ctttccgcgt gttccagtgc	1740
acccagtata tccgccacgc gtcctcgccc atgcactccc ctgagccgga ctgctgccac	1800
gagctgctgg ggcacgtgcc catgctggcc gaccgcacct tcgcgcagtt ctgcaggac	1860
attggcctgg cgtccctggg ggcctcggat gaggaaattg agaagctgtc cacgctgtac	1920
tggttcacgg tggagttcgg gctgtgtaag cagaacgggg aggtgaaggc ctatggtgcc	1980
gggctgctgt cctcctacgg ggagctcctg cactgcctgt ctgaggagcc tgagattcgg	2040
gccttcgacc ctgaggctgc ggccgtgcag ccctaccaag accagacgta ccagtcagtc	2100
tacttcgtgt ctgagagctt cagtgcgcc aaggacaagc tcaggagcta tgcctcacgc	2160
atccagcgcc ctttctccgt gaagttcgac ccgtacacgc tggccatcga cgtgctggac	2220
agccccagg ccgtgcggcg ctccctggag ggtgtccagg atgagctgga cacccttgcc	2280
catgcgctga gtgccattgg ctaacagaca tgataagata cattgatgag tttggacaaa	2340
ccacaactag aatgcagtga aaaaaatgct ttattttgtga aatttgtgat gctattgctt	2400
tattttgtaac cattataagc tgcaataaac aagttaacaa caacaattgc attcatttta	2460
tgtttcaggt tcagggggag gtgtgggagg ttttttaaag caagtaaaac ctctacaaat	2520
gtggtaacta gtccactccc tctctgcgcg ctgcctcgt cactgaggcc gggcgaccaa	2580
aggtcgcccc acgcccgggc tttgcccggg cggcctcagt gagcgagcga gcgcgcagag	2640
agggacagat ccgggccccg atgcgtcgac aattcactgg ccgtcgtttt acaacgtcgt	2700
gactgggaaa accctggcgt tacccaactt aatgccttg cagcacatcc ccctttcgcc	2760

agctggcgta atagcgaaga ggccccgcacc gatcgccctt cccaacagtt gcgcagcctg	2820
aatggcgaat ggcgctgat gcggtathtt ctccttacgc atctgtgcgg tattttcacac	2880
cgcatatggg gcactctcag tacaatctgc tctgatgccg catagttaag ccagccccga	2940
cacccgcca caccgctga cgcgccctga cgggcttgct tgctcccggc atccgcttac	3000
agacaagctg tgaccgtctc cgggagctgc atgtgtcaga ggttttcacc gtcacacccg	3060
aaacgcgcga gacgaaaggg cctcgtgata cgcctathtt tataggttaa tgtcatgata	3120
ataatggttt cttagacgtc aggtggcact tttcggggaa atgtgcgcgg aaccctatt	3180
tgtttathtt tctaaataca ttcaaatac tatccgctca tgagacaata accctgataa	3240
atgcttcaat aatattgaaa aaggaagagt atgagtattc aacatttcg tgctgccctt	3300
attcccthtt ttgcggcatt ttgccttcct gtttttgctc acccagaaac gctggtgaaa	3360
gtaaaagatg ctgaagatca gttgggtgca cgagtgggtt acatcgaact ggatctcaac	3420
agcggtaaga tccttgagag ttttcgcccc gaagaacgtt ttccaatgat gagcacthtt	3480
aaagtctgc tatgtggcgc ggtattatcc cgtattgacg ccgggcaaga gcaactcgg	3540
cgccgcatac actattctca gaatgacttg gttgagtact caccagtcac agaaaagcat	3600
cttacggatg gcatgacagt aagagaatta tgcagtgtg ccataaccat gagtgataac	3660
actgcggcca acttacttct gacaacgatc ggaggaccga aggagctaac cgcttttttg	3720
cacaacatgg gggatcatgt aactcgcctt gatcgttggg aaccggagct gaatgaagcc	3780
ataccaaacg acgagcgtga caccacgatg cctgtagcaa tggcaacaac gttgcgcaaa	3840
ctattaactg gcgaactact tactctagct tcccggcaac aattaataga ctggatggag	3900
gcggataaag ttgcaggacc acttctgcgc tcggcccttc cggctggctg gtttattgct	3960
gataaatctg gagccggtga gcgtgggtct cgcggtatca ttgcagcact ggggccagat	4020
ggtaagccct cccgtatcgt agttatctac acgacgggga gtcaggcaac tatggatgaa	4080
cgaaaatagac agatcgtga gataggtgcc tctactgatta agcattggta actgtcagac	4140
caagtttact catatatact ttagattgat ttaaaacttc atttttaatt taaaaggatc	4200
taggtgaaga tcctttttga taatctcatg accaaaatcc cttaacgtga gttttcgttc	4260

cactgagcgt cagaccccggt agaaaagatc aaaggatctt cttgagatcc tttttttctg	4320
cgcgtaatct gctgcttgca aacaaaaaaaa ccaccgctac cagcgggtggt ttgtttgccg	4380
gatcaagagc taccaactct ttttccgaag gtaactggct tcagcagagc gcagatacca	4440
aatactgttc ttctagtgtg gccgtagtta ggccaccact tcaagaactc tgtagcaccg	4500
cctacatacc tcgctctgct aatcctgtta ccagtggctg ctgccagtgg cgataagtcg	4560
tgtcttaccg ggttggactc aagacgatag ttaccggata aggcgcagcg gtcgggctga	4620
acgggggggtt cgtgcacaca gcccagcttg gagcgaacga cctacaccga actgagatac	4680
ctacagcgtg agctatgaga aagcgccacg cttcccgaag ggagaaaggc ggacaggtat	4740
ccggtaagcg gcaggggtcgg aacaggagag cgcacgaggg agcttccagg gggaaacgcc	4800
tggtatcttt atagtcctgt cgggtttcgc cacctctgac ttgagcgtcg atttttgtga	4860
tgctcgtcag gggggcgagg cctatggaaa aacgccagca acgcggcctt tttacggttc	4920
ctggcctttt gctggccttt tgctcacatg ttctttcctg cgttatcccc tgattctgtg	4980
gataaccgta ttaccgcctt tgagtgagct gataccgctc gccgcagccg aacgaccgag	5040
cgcagcgagt cagtgagcga ggaagcggaa g	5071

<210> 18
 <211> 4954
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Expression vector comprising a CBh promoter operably linked to a GCH-1 coding sequence

<400> 18	
agcgcccaat acgcaaaccg cctctccccg cgcgttggcc gattcattaa tgcagctggc	60
acgacagggt tcccgactgg aaagcgggca gtgagcgcaa cgcaattaat gtgagttagc	120
tcactcatta ggcaccccg gctttacact ttatgcttcc ggctcgtatg ttgtgtggaa	180
ttgtgagcgg ataacaattt cacacaggaa acagctatga ccatgattac gccaaagctct	240
cgagatctag aaagcttccc ggggggatct gggccactcc ctctctgcgc gctcgctcgc	300

tcactgaggc cgggcgacca aaggtcgccc gacggccggg ctttgcccgg gcggcctcag	360
tgagcgagcg agcgcgcaga gagggagtgg ccaactccat cactaggggt tcctggaggg	420
gtggagtcgt gacctaggca actttgtata gaaaagttgc gttacataac ttacggtaaa	480
tggcccgctt ggctgaccgc ccaacgaccc ccgcccattg acgtcaatag taacgccaat	540
agggactttc cattgacgtc aatgggtgga gtatttacgg taaactgccc acttggcagt	600
acatcaagtg tatcatatgc caagtacgcc ccctattgac gtcaatgacg gtaaattggcc	660
cgcctggcat tgtgcccagt acatgacctt atgggacttt cctacttggc agtacatcta	720
cgtattagtc atcgctatta ccatggtcga ggtgagcccc acgtttctgct tcactctccc	780
catctcccc ccctccccac cccaatttt gtattttattt attttttaat tattttgtgc	840
agcgatgggg gcggggggggg gggggggggcg gcgcccaggc ggggcggggc ggggcgaggg	900
gcggggcggg gcgaggcgga gaggtgcggc ggcagccaat cagagcggcg cgctccgaaa	960
gtttcctttt atggcgaggc ggcggcgggc gcggccctat aaaaagcgaa gcgcgcggcg	1020
ggcgggagtc gctgcgcgct gccttcgccc cgtgccccgc tccgccgccg cctcgcgccg	1080
cccgccccgg ctctgactga ccgcgttact cccacaggtg agcgggcggg acggcccttc	1140
tcctccgggc tgtaattagc tgagcaagag gtaagggttt aagggatggt tggttggtgg	1200
ggtattaatg ttttaattacc tggagcacct gcctgaaatc actttttttc aggttggcaa	1260
gtttgtacag ccaccatgga gaagccgcgg ggtgtaaggc gcaccaatgg gttccccgag	1320
cgggagctgc cgcgggccccg ggccagccga cctgccgaga agtcccggcc gcccgaggcc	1380
aagggcgcac agccagccga cgcctggaag gcagggcggc cccgcagcga ggaggataac	1440
gagctgaacc tccccaacct ggcggccgct tactcgtcca tcctgcgctc gctgggcgag	1500
gacccccagc ggcaggggct gctcaagacg ccctggaggg cggccaccgc catgcagttc	1560
ttcaccaagg gataccagga gaccatctca gatgtcctga acgatgctat atttgatgag	1620
gaccatgacg agatggtgat tgtgaaggac attgacatgt tttccatgtg tgagcatcac	1680
ctgggtcccat ttgtgggaag ggtccatatt ggttatcttc ctaacaagca agtccttggt	1740
ctcagcaaac ttgccaggat tgtggaaatc tacagtagaa gactacaagt tcaagaacgc	1800

cttaccaaac agattgcagt ggccatcaca gaagccttgc agcctgctgg cgtcggggta	1860
gtgattgaag caacacacat gtgtatggtc atgcgagggtg tgcagaaaat gaacagcaag	1920
actgtcacta gcaccatgct aggcgtgttc cgggaagacc caaagactcg ggaggagttc	1980
ctcacactca tcaggagctg aaatcaacct ctggattaca aaatttgtga aagattgact	2040
ggatattctta actatgttgc tccttttacg ctatgtggat acgctgcttt aatgcctttg	2100
tatcatgcta ttgcttcccg tatggctttc attttctcct ccttgtataa atcctggtta	2160
gttcttgcca cggcggaact catcgccgcc tgccttgccc gctgctggac aggggctcgg	2220
ctgttgggca ctgacaattc cgtggtgttt atttgtgaaa tttgtgatgc tattgcttta	2280
tttgaacca tctagcttta tttgtgaaat ttgtgatgct attgctttat ttgtaaccat	2340
tataagctgc aataaacaag ttaacaacaa caattgcatt cattttatgt ttcaggttca	2400
gggggagaga ctagtcact ccctctctgc gcgctcgctc gctcactgag gccgggcgac	2460
caaaggctgc ccgacgccc ggctttgccc gggcggcctc agtgagcgag cgagcgcgca	2520
gagagggaca gatccgggcc cgcatgcgtc gacaattcac tggccgtcgt tttacaacgt	2580
cgtgactggg aaaaccctgg cgttaccaa cttaatcgcc ttgcagcaca tcccccttc	2640
gccagctggc gtaatagcga agaggcccgc accgatcgcc cttccaaca gttgcgcagc	2700
ctgaatggcg aatggcgcct gatgcggtat tttctcctta cgcatctgtg cggatatttc	2760
caccgcatat ggtgcactct cagtacaatc tgctctgatg ccgcatagtt aagccagccc	2820
cgacacccgc caacacccgc tgacgcgccc tgacgggctt gtctgctccc ggcattcgct	2880
tacagacaag ctgtgaccgt ctccgggagc tgcattgtgc agaggttttc accgtcatca	2940
ccgaaacgcg cgagacgaaa gggcctcgtg atacgcctat ttttataggt taatgtcatg	3000
ataataatgg tttcttagac gtcagggtggc acttttcggg gaaatgtgcg cggaaccct	3060
atttgtttat ttttctaaat acattcaaat atgtatccgc tcatgagaca ataaccctga	3120
taaatgcttc aataatattg aaaaaggaag agtatgagta ttcaacattt ccgtgtcgcc	3180
cttattccct tttttgcggc attttgcctt cctgtttttg ctcaccaga aacgtgggtg	3240
aaagtaaaag atgctgaaga tcagttgggt gcacgagtgg gttacatcga actggatctc	3300

aacagcggta agatccttga gagttttcgc cccgaagaac gttttccaat gatgagcact	3360
tttaaagttc tgctatgtgg cgcggtatta tcccgtattg acgccgggca agagcaactc	3420
ggtcgccgca tacactattc tcagaatgac ttggttgagt actcaccagt cacagaaaag	3480
catcttacgg atggcatgac agtaagagaa ttatgcagtg ctgccataac catgagtgat	3540
aacactgcgg ccaacttact tctgacaacg atcggaggac cgaaggagct aaccgctttt	3600
ttgcacaaca tgggggatca tgtaactcgc cttgatcggt gggaaccgga gctgaatgaa	3660
gccataccea acgacgagcg tgacaccacg atgcctgtag caatggcaac aacgttgccg	3720
aaactattaa ctggcgaact acttactcta gcttcccggc aacaattaat agactggatg	3780
gaggcgggata aagttgcagg accacttctg cgctcggccc ttccggctgg ctggtttatt	3840
gctgataaat ctggagccgg tgagcgtggg tctcgcggta tcattgcagc actggggcca	3900
gatggtaagc cctcccgtat cgtagttatc tacacgacgg ggagtcaggc aactatggat	3960
gaacgaaata gacagatcgc tgagataggt gcctcactga ttaagcattg gtaactgtca	4020
gaccaagttt actcatatat acttttagatt gatttaaaac ttcattttta atttaaaagg	4080
atctaggtga agatcctttt tgataatctc atgacaaaaa tcccttaacg tgagttttcg	4140
ttccactgag cgtcagaccc cgtagaaaag atcaaaggat cttcttgaga tccttttttt	4200
ctgcgcgtaa tctgctgctt gcaaacaaaa aaaccaccgc taccagcggg ggtttgtttg	4260
ccggatcaag agctaccaac tctttttccg aaggtaactg gcttcagcag agcgcagata	4320
ccaaatactg ttcttctagt gtagccgtag ttaggccacc acttcaagaa ctctgtagca	4380
ccgcctacat acctcgctct gctaatcctg ttaccagtgg ctgctgccag tggcgataag	4440
tcgtgtctta ccgggttgga ctcaagacga tagttaccgg ataaggcgca gcggtcgggc	4500
tgaacggggg gttcgtgcac acagcccagc ttggagcgaa cgacctacac cgaactgaga	4560
tacctacagc gtgagctatg agaaagcgcc acgcttcccg aaggagagaaa ggcggacagg	4620
tatccggtaa gcggcagggt cggaacagga gagcgcacga gggagcttcc agggggaaac	4680
gcctggatatc tttatagtcc tgtcggggtt cgccacctct gacttgagcg tcgatttttg	4740
tgatgctcgt caggggggcg gagcctatgg aaaaacgcca gcaacgcggc ctttttacgg	4800

ttcctggcct tttgctggcc ttttgctcac atgttctttc ctgcgttatc ccctgattct	4860
gtggataacc gtattaccgc ctttgagtga gctgataaccg ctcgccgcag ccgaacgacc	4920
gagcgcagcg agtcagtgag cgaggaagcg gaag	4954

<210> 19
 <211> 4984
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Expression vector comprising a SYN1 promoter operably linked to an htTH coding sequence

<400> 19	
ggccactccc tctctgcgcg ctcgctcgct cactgaggcc gggcgaccaa aggtcgcccc	60
acgcccgggc tttgcccggg cggcctcagt gagcgagcga gcgcgcagag agggagtggc	120
caactccatc actaggggtt cctggagggg tggagtcgtg acctaggcaa ctttgtatag	180
aaaagttgct gcagagtga agtgggtttt aggaccagga tgaggcgggg tgggggtgcc	240
tacctgacga ccgaccccga cccactggac aagcacccaa ccccatctcc ccaaattgcg	300
catcccctat cagagagggg gaggggaaac aggatgcggc gaggcgcgtg cgcactgcca	360
gcttcagcac cgcggacagt gccttcgccc ccgcctggcg gcgcgcgcca ccgccgcctc	420
agcactgaag gcgcgctgac gtcactcgcc ggtccccgc aaactcccct tcccggccac	480
cttggtcgcg tccgcgccgc cgccggccca gccggaccgc accacgcgag gcgcgagata	540
ggggggcacg ggcgcgacca tctgcgctgc ggcgccggcg actcagcgct gcctcagtct	600
gcggtgggca gcggaggagt cgtgtcgtgc ctgagagcgc aggccaccat gagccccgcg	660
gggccaagg tcccctggtt cccaagaaaa gtgtcagagc tggacaagtg tcatcacctg	720
gtcaccaagt tcgaccctga cctggacttg gaccaccgg gcttctcgga ccaggtgtac	780
cgccagcgca ggaagctgat tgctgagatc gccttcagat acaggcacgg cgacccgatt	840
ccccgtgtgg agtacaccgc cgaggagatt gccacctgga aggaggtcta caccacgctg	900
aagggcctct acgccacgca cgcctgcggg gagcacctgg aggcctttgc tttgctggag	960
cgcttcagcg gctaccggga agacaatatc cccagctgg aggacgtctc ccgcttcctg	1020

aaggagcgca cgggcttcca gctgcggcct gtggccggcc tgctgtccgc ccgggacttc	1080
ctggccagcc tggccttccg cgtgttccag tgcacccagt atatccgcca cgcgtcctcg	1140
cccatgcact cccctgagcc ggactgctgc cacgagctgc tggggcacgt gcccatgctg	1200
gccgaccgca ccttcgcgca gttctcgcag gacattggcc tggcgtccct gggggcctcg	1260
gatgaggaaa ttgagaagct gtccacgctg tactggttca cgggtggagt cgggctgtgt	1320
aagcagaacg gggaggtgaa ggcctatggt gccgggctgc tgtcctccta cggggagctc	1380
ctgcactgcc tgtctgagga gcctgagatt cgggccttcg accctgaggc tgcggccgtg	1440
cagccctacc aagaccagac gtaccagtca gtctacttcg tgtctgagag cttcagtgc	1500
gccaaggaca agctcaggag ctatgcctca cgcattccagc gccccttctc cgtgaagttc	1560
gacccgtaca cgctggccat cgacgtgctg gacagcccc aggccgtgcg gcgctccctg	1620
gagggtgtcc aggatgagct ggacaccctt gcccatgcgc tgagtgccat tggctaaaat	1680
caacctctgg attacaaaat ttgtgaaaga ttgactggta ttcttaacta tgttgctcct	1740
tttacgctat gtggatacgc tgctttaatg cttttgtatc atgctattgc ttcccgtatg	1800
gctttcattt tctcctcctt gtataaatcc tggttagttc ttgccacggc ggaactcatc	1860
gccgcctgcc ttgcccgtg ctggacagg gctcggctgt tgggcactga caattccgtg	1920
gtgtttattt gtgaaatttg tgatgctatt gctttatttg taaccatcta gctttatttg	1980
tgaaatttgt gatgctattg ctttatttgt aaccattata agctgcaata aacaagttaa	2040
caacaacaat tgcattcatt ttatgtttca ggttcagggg gagagcaatt gcattcattt	2100
tatgtttcag gttcaggggg aggtgtggga ggttttttaa agcaagtaaa acctctacaa	2160
atgtggtaac tagtcactc cctctctgcg cgctcgtcg ctactgagg ccgggcgacc	2220
aaaggtcgcc cgacggcgg gctttgccc ggcggcctca gtgagcgagc gagcgcgcag	2280
agagggacag atccggggcc gcatgcgtcg acaattcact ggccgtcggt ttacaacgtc	2340
gtgactggga aaaccctggc gttaccaac ttaatgcct tgcagcacat ccccttttcg	2400
ccagctggcg taatagcgaa gaggcccgca ccgatcgccc ttccaacag ttgcgcagcc	2460
tgaatggcga atggcgcctg atgcgttatt ttctccttac gcatctgtgc ggtatttcac	2520

accgcatatg gtgcactctc agtacaatct gctctgatgc cgcatagtta agccagcccc	2580
gacacccgcc aacacccgct gacgcgccct gacgggcttg tctgctcccg gcatccgctt	2640
acagacaagc tgtgaccgtc tccgggagct gcatgtgtca gaggttttca ccgtcatcac	2700
cgaaacgcgc gagacgaaag ggcctcgtga tacgcctatt tttataggtt aatgtcatga	2760
taataatggg ttcttagacg tcaggtggca cttttcgggg aaatgtgcgc ggaaccctta	2820
tttgtttatt tttctaaata cattcaaata tgtatccgct catgagacaa taaccctgat	2880
aaatgcttca ataattatga aaaaggaaga gtatgagtat tcaacatttc cgtgtcgccc	2940
ttattccctt ttttgcgga ttttgccttc ctgtttttgc tcaccagaa acgctgggtga	3000
aagtaaaaga tgctgaagat cagttgggtg cacgagtggg ttacatcgaa ctggatctca	3060
acagcggtaa gatccttgag agttttcgcc ccgaagaacg ttttccaatg atgagcactt	3120
ttaaagtctt gctatgtggc gcggtattat cccgtattga cgccgggcaa gagcaactcg	3180
gtcgccgcat acactattct cagaatgact tggttgagta ctcaccagtc acagaaaagc	3240
atcttacgga tggcatgaca gtaagagaat tatgcagtgc tgccataacc atgagtgata	3300
acactgcggc caacttactt ctgacaacga tcggaggacc gaaggagcta accgcttttt	3360
tgcaaacat gggggatcat gtaactcgcc ttgatcgttg ggaaccggag ctgaatgaag	3420
ccataccaaa cgacgagcgt gacaccacga tgcctgtagc aatggcaaca acgttgcgca	3480
aactattaac tggcgaacta ctactctag cttcccggca acaattaata gactggatgg	3540
aggcggataa agttgcagga ccacttctgc gctcggccct tccggctggc tggttttattg	3600
ctgataaatc tggagccggt gagcgtgggt ctcgcggtat cattgcagca ctggggccag	3660
atggtaagcc ctcccgtatc gtagttatct acacgacggg gagtcaggca actatggatg	3720
aacgaaatag acagatcgct gagatagggt cctcactgat taagcattgg taactgtcag	3780
accaagttta ctcatatata ctttagattg atttaaaact tcatttttaa tttaaaagga	3840
tctaggtgaa gatccttttt gataatctca tgacaaaaat cccttaacgt gagttttcgt	3900
tccactgagc gtcagacccc gtagaaaaga tcaaaggatc ttcttgagat cttttttttc	3960
tgcgcgtaat ctgctgcttg caaacaaaaa aaccaccgct accagcgggtg gtttgtttgc	4020

cggatcaaga gctaccaact ctttttccga aggtaactgg cttcagcaga gcgcagatac	4080
caaatactgt tcttctagt tagccgtagt tagggcacca cttcaagaac tctgtagcac	4140
cgcttacata cctcgctctg ctaatcctgt taccagtggc tgctgccagt ggcgataagt	4200
cgtgtcttac cgggttgac tcaagacgat agttaccgga taaggcgag cggtcgggct	4260
gaacggggggg ttcgtgcaca cagcccagct tggagcgaac gacctacacc gaactgagat	4320
acctacagcg tgagctatga gaaagcgcca cgcttcccga agggagaaaag gcggacaggt	4380
atccggtaaag cggcagggtc ggaacaggag agcgcacgag ggagcttcca gggggaaacg	4440
cctggtatct ttatagtcct gtcgggtttc gccacctctg acttgagcgt cgatTTTTgt	4500
gatgctcgtc agggggggcgg agcctatgga aaaacgccag caacgcggcc tttttacggt	4560
tcctggcctt ttgctggcct tttgctcaca tgttctttcc tgcgttatcc cctgattctg	4620
tggataaccg tattaccgcc tttgagttag ctgataccgc tcgccgcagc cgaacgaccg	4680
agcgagcga gtcagttagc gaggaagcgg aagagcgccc aatacgcaaa ccgcctctcc	4740
ccgcgcgttg gccgattcat taatgcagct ggcacgacag gtttcccgcac tggaaagcgg	4800
gcagttagcg caacgcaatt aatgtgagtt agctcactca ttaggcaccc caggctttac	4860
actttatgct tccggctcgt atgttggtg gaattgtgag cggataacaa tttcacacag	4920
gaaacagcta tgacctgat tacgccaagc tctcgagatc tagaaagctt cccgggggga	4980
tctg	4984

<210> 20

<211> 4681

<212> DNA

<213> Artificial Sequence

<220>

<223> Expression vector comprising a SYN1 promoter operably linked to a GCH-1 coding sequence

<400> 20

ggccactccc tctctgcgcg ctcgctcgct cactgaggcc gggcgaccaa aggtcgccc	60
--	----

acgcccgggc tttgcccggg cggcctcagt gagcgagcga gcgcgcagag agggagtggc	120
---	-----

caactccatc actaggggtt cctggagggg tggagtcgtg acctaggcaa ctttgtatag	180
aaaagttgct gcagagtgca agtggggtttt aggaccagga tgaggcgggg tgggggtgcc	240
tacctgacga ccgaccccga cccactggac aagcacccaa ccccatattcc ccaaattgcg	300
catcccctat cagagagggg gaggggaaac aggatgcggc gaggcgcgtg cgacttgcca	360
gcttcagcac cgcggaacgt gccttcgccc ccgcctggcg gcgcgcgcca ccgccgcctc	420
agcactgaag gcgcgctgac gtcactcgcc ggtccccgc aaactcccct tcccggccac	480
cttggtcgcg tccgcgccgc cgccggccca gccggaccgc accacgcgag gcgcgagata	540
ggggggcacg ggcgcgacca tctgcgctgc ggcgccggcg actcagcgct gcctcagtct	600
gcggtgggca gcggaggagt cgtgtcgtgc ctgagagcgc aggccaccat ggagaagccg	660
cggggtgtaa ggtgcaccaa tgggttcccc gagcgggagc tgccgcggcc cggggccagc	720
cgacctgccg agaagtcccc gccgcccag gagcaaggcg cacagccagc cgacgcctgg	780
aaggcagggc ggccccgcag cgaggaggat aacgagctga acctcccaa cctggcggcc	840
gcttactcgt ccatcctgcg ctcgctgggc gaggaccccc agcggcaggg gctgctcaag	900
acgccctgga gggcgccac cgccatgcag ttcttcacca agggatacca ggagaccatc	960
tcagatgtcc tgaacgatgc tatatttgat gaggaccatg acgagatggt gattgtgaag	1020
gacattgaca tgttttccat gtgtgagcat cacctggtcc ctttgtggg aagggtccat	1080
attggttatc ttcctaaca gcaagtcctt ggtctcagca aacttgccag gattgtggaa	1140
atctacagta gaagactaca agttcaagaa cgccttacca aacagattgc agtggccatc	1200
acagaagcct tgcagcctgc tggcgtcggg gtagtgattg aagcaacaca catgtgtatg	1260
gtcatgcgag gtgtgcagaa aatgaacagc aagactgtca ctagcaccat gctaggcgtg	1320
ttccgggaag acccaaagac tcgggaggag ttccctcacac tcatcaggag ctgaaatcaa	1380
cctctggatt acaaaatttg tgaaagattg actggtattc ttaactatgt tgctcctttt	1440
acgctatgtg gatacgctgc tttaatgcct ttgtatcatg ctattgcttc ccgtatggct	1500
ttcattttct cctccttgta taaatcctgg ttagttcttg ccacggcgga actcatcgcc	1560
gcctgccttg ccgctgctg gacaggggct cggctgttgg gcactgacaa ttccgtggtg	1620

tttattttgtg aaattttgtga tgctattgct ttattttgtaa ccatctagct ttattttgtga	1680
aatattgtgat gctattgctt tattttgtaac cattataagc tgcaataaac aagttaacaa	1740
caacaattgc attcatttta tgtttcaggt tcagggggag agcaattgca ttcatTTTTat	1800
gtttcaggtt cagggggagg tgtgggaggt tttttaagc aagtaaaacc tctacaaatg	1860
tggtaaactag tccactccct ctctgcgcgc tcgctcgctc actgaggccg ggcgacaaaa	1920
ggtcgcccga cgcccgggct ttgcccgggc ggcctcagtg agcgagcgag cgcgcagaga	1980
gggacagatc cgggcccga tgcgtcgaca attcactggc cgtcgtttta caacgtcgtg	2040
actgggaaaa ccctggcggt acccaactta atcgccttg cgcacatccc cttttcgcca	2100
gctggcgtaa tagcgaagag gcccgccacg atcgcccttc ccaacagttg cgcagcctga	2160
atggcgaaatg gcgcctgatg cgggtattttc tccttacgca tctgtgcggt atttcacacc	2220
gcatatgggtg cactctcagt acaatctgct ctgatgccgc atagttaagc cagccccgac	2280
acccgccaac acccgctgac gcgccctgac gggcttgtct gctcccggca tccgcttaca	2340
gacaagctgt gaccgtctcc gggagctgca tgtgtcagag gttttcaccg tcatcaccga	2400
aacgcgcgag acgaaagggc ctcgtgatac gcctatTTTT ataggTTaat gtcataataa	2460
taatggtttc ttagacgtca ggtggcactt ttcggggaaa tgtgcgcgga acccctattt	2520
gtttatTTTT ctaaatacat tcaaatatgt atccgctcat gagacaataa ccctgataaa	2580
tgcttcaata atattgaaaa aggaagagta tgagtattca acatttccgt gtcgccctta	2640
ttccctTTTT tgcggcattt tgccttcctg tttttgctca ccagaaacg ctggtgaaag	2700
taaaagatgc tgaagatcag ttgggtgcac gagtgggtta catcgaactg gatctcaaca	2760
gcggtaagat ccttgagagt tttcgccccg aagaacgttt tccaatgatg agcactttta	2820
aagttctgct atgtggcgcg gtattatccc gtattgacgc cgggcaagag caactcggtc	2880
gccgcataca ctattctcag aatgacttgg ttgagtactc accagtcaca gaaaagcatc	2940
ttacggatgg catgacagta agagaattat gcagtgtgc cataaccatg agtgataaca	3000
ctgcggccaa ctactttctg acaacgatcg gaggaccgaa ggagctaacc gcttttttgc	3060
acaacatggg ggatcatgta actcgccttg atcgttggga accggagctg aatgaagcca	3120

taccaaacga cgagcgtgac accacgatgc ctgtagcaat ggcaacaacg ttgcgcaaac	3180
tattaactgg cgaactactt actctagctt cccggcaaca attaatagac tggatggagg	3240
cggataaagt tgcaggacca cttctgcgct cggcccttcc ggctggctgg tttattgctg	3300
ataaatctgg agccggtgag cgtgggtctc gcggtatcat tgcagcactg gggccagatg	3360
gtaagccctc ccgtatcgta gttatctaca cgacggggag tcaggcaact atggatgaac	3420
gaaatagaca gatcgctgag ataggtgcct cactgattaa gcattggtaa ctgtcagacc	3480
aagtttactc atatatactt tagattgatt taaaacttca tttttaattt aaaaggatct	3540
aggngaagat cctttttgat aatctcatga ccaaaatccc ttaacgtgag ttttcgttcc	3600
actgagcgtc agaccccgtg gaaaagatca aaggatcttc ttgagatcct ttttttctgc	3660
gcgtaatctg ctgcttgcaa aaaaaaaaaac caccgctacc agcgggtggtt tgtttgccgg	3720
atcaagagct accaactctt tttccgaagg taactggctt cagcagagcg cagataccaa	3780
atactgttct tctagtgtag ccgtagttag gccaccactt caagaactct gtagcaccgc	3840
ctacatacct cgctctgcta atcctgttac cagtggctgc tgccagtggc gataagtcgt	3900
gtcttaccgg gttggactca agacgatagt taccggataa ggcgagcgg tcgggctgaa	3960
cgggggggtc gtgcacacag cccagcttgg agcgaacgac ctacaccgaa ctgagatacc	4020
tacagcgtga gctatgagaa agcgccacgc ttcccgaagg gagaaaggcg gacaggtatc	4080
cggtaagcgg cagggctcga acaggagagc gcacgaggga gcttccaggg ggaaacgcct	4140
ggtatcttta tagtcctgtc gggtttcgcc acctctgact tgagcgtcga tttttgtgat	4200
gctcgtcagg ggggcggagc ctatggaaaa acgccagcaa cgcggccttt ttacggttcc	4260
tggccttttg ctggcctttt gtcacatgt tctttcctgc gttatcccct gattctgtgg	4320
ataaccgtat taccgccttt gagtgagctg ataccgctcg ccgcagccga acgaccgagc	4380
gcagcgagtc agtgagcgag gaagcggaag agcgcccaat acgcaaaccg cctctccccg	4440
cgcgttggcc gattcattaa tgcagctggc acgacaggtt tcccactgg aaagcgggca	4500
gtgagcgcaa cgcaattaat gtgagttagc tcactcatta ggcaccccag gctttacact	4560
ttatgcttcc ggctcgtatg ttgtgtggaa ttgtgagcgg ataacaattt cacacaggaa	4620

acagctatga ccatgattac gccaaagctct cgagatctag aaagcttccc ggggggatct	4680
g	4681

<210> 21
 <211> 1494
 <212> DNA
 <213> Homo sapiens

<400> 21	
atgcccaccc ccgacgccac cacgccacag gccaaagggt tccgcagggc cgtgtctgag	60
ctggacgcca agcaggcaga ggccatcatg tccccgcggt tcattgggcg caggcagagc	120
ctcatcgagg acgccccgaa ggagcgggag gcggcggttg cagcagcggc cgctgcagtc	180
ccctcggagc ccggggaccc cctggagggt gtggcctttg aggagaagga ggggaaggcc	240
gtgctaaacc tgctcttctc cccgagggcc accaagccct cggcgctgtc ccgagctgtg	300
aagggtgttg agacgtttga agccaaaatc caccatctag agaccgggc cggccagagg	360
ccgcgagctg ggggccccca cctggagtac ttcgtgcgcc tcgaggtgcg ccgaggggac	420
ctggccgccc tgctcagtgg tgtgcgccag gtgtcagagg acgtgcgcag cccgcgggg	480
cccaagggtcc cctggttccc aagaaaagtg tcagagctgg acaagtgtca tcacctggtc	540
accaagtctg accctgacct ggacttggac caccggggt tctcggacca ggtgtaccgc	600
cagcgcagga agctgattgc tgagatcgcc ttccagtaca ggcacggcga cccgattccc	660
cgtgtggagt acaccgccga ggagattgcc acctggaagg aggtctacac cacgctgaag	720
ggcctctacg ccacgcacgc ctgcggggag cacctggagg cctttgcttt gctggagcgc	780
ttcagcggct accgggaaga caatatcccc cagctggagg acgtctcccg cttcctgaag	840
gagcgcacgg gcttccagct gcggcctgtg gccggcctgc tgtccgcccg ggacttcctg	900
gccagcctgg ccttccgcgt gttccagtgc acccagtata tccgccacgc gtcctcgccc	960
atgcactccc ctgagccgga ctgctgccac gagctgctgg ggcacgtgcc catgctggcc	1020
gaccgcacct tcgcgcagtt ctcgcaggac attggcctgg cgtccctggg ggcctcggat	1080
gaggaaattg agaagctgtc cacgctgtca tggttcacgg tggagttcgg gctgtgtaag	1140
cagaacgggg aggtgaaggc ctatggtgcc gggctgctgt cctcctacgg ggagctcctg	1200

cactgcctgt ctgaggagcc tgagattcgg gccttcgacc ctgaggctgc ggccgtgcag	1260
ccctaccaag accagacgta ccagtcagtc tacttcgtgt ctgagagctt cagtgacgcc	1320
aaggacaagc tcaggagcta tgcctcacgc atccagcgcc ccttctccgt gaagttcgac	1380
ccgtacacgc tggccatcga cgtgctggac agccccagg ccgtgcggcg ctccctggag	1440
ggtgtccagg atgagctgga cacccttgcc catgcgctga gtgccattgg ctag	1494

<210> 22
 <211> 497
 <212> PRT
 <213> Homo sapiens

<400> 22

Met	Pro	Thr	Pro	Asp	Ala	Thr	Thr	Pro	Gln	Ala	Lys	Gly	Phe	Arg	Arg
1				5					10					15	

Ala	Val	Ser	Glu	Leu	Asp	Ala	Lys	Gln	Ala	Glu	Ala	Ile	Met	Ser	Pro
			20					25					30		

Arg	Phe	Ile	Gly	Arg	Arg	Gln	Ser	Leu	Ile	Glu	Asp	Ala	Arg	Lys	Glu
		35					40					45			

Arg	Glu	Ala	Ala	Val	Ala	Ala	Ala	Ala	Ala	Ala	Val	Pro	Ser	Glu	Pro
	50					55						60			

Gly	Asp	Pro	Leu	Glu	Ala	Val	Ala	Phe	Glu	Glu	Lys	Glu	Gly	Lys	Ala
65					70					75					80

Val	Leu	Asn	Leu	Leu	Phe	Ser	Pro	Arg	Ala	Thr	Lys	Pro	Ser	Ala	Leu
			85						90					95	

Ser	Arg	Ala	Val	Lys	Val	Phe	Glu	Thr	Phe	Glu	Ala	Lys	Ile	His	His
			100					105					110		

Leu	Glu	Thr	Arg	Pro	Ala	Gln	Arg	Pro	Arg	Ala	Gly	Gly	Pro	His	Leu
		115					120					125			

Glu Tyr Phe Val Arg Leu Glu Val Arg Arg Gly Asp Leu Ala Ala Leu
130 135 140

Leu Ser Gly Val Arg Gln Val Ser Glu Asp Val Arg Ser Pro Ala Gly
145 150 155 160

Pro Lys Val Pro Trp Phe Pro Arg Lys Val Ser Glu Leu Asp Lys Cys
165 170 175

His His Leu Val Thr Lys Phe Asp Pro Asp Leu Asp Leu Asp His Pro
180 185 190

Gly Phe Ser Asp Gln Val Tyr Arg Gln Arg Arg Lys Leu Ile Ala Glu
195 200 205

Ile Ala Phe Gln Tyr Arg His Gly Asp Pro Ile Pro Arg Val Glu Tyr
210 215 220

Thr Ala Glu Glu Ile Ala Thr Trp Lys Glu Val Tyr Thr Thr Leu Lys
225 230 235 240

Gly Leu Tyr Ala Thr His Ala Cys Gly Glu His Leu Glu Ala Phe Ala
245 250 255

Leu Leu Glu Arg Phe Ser Gly Tyr Arg Glu Asp Asn Ile Pro Gln Leu
260 265 270

Glu Asp Val Ser Arg Phe Leu Lys Glu Arg Thr Gly Phe Gln Leu Arg
275 280 285

Pro Val Ala Gly Leu Leu Ser Ala Arg Asp Phe Leu Ala Ser Leu Ala
290 295 300

Phe Arg Val Phe Gln Cys Thr Gln Tyr Ile Arg His Ala Ser Ser Pro
305 310 315 320

Met His Ser Pro Glu Pro Asp Cys Cys His Glu Leu Leu Gly His Val

325

330

335

Pro Met Leu Ala Asp Arg Thr Phe Ala Gln Phe Ser Gln Asp Ile Gly
 340 345 350

Leu Ala Ser Leu Gly Ala Ser Asp Glu Glu Ile Glu Lys Leu Ser Thr
 355 360 365

Leu Ser Trp Phe Thr Val Glu Phe Gly Leu Cys Lys Gln Asn Gly Glu
 370 375 380

Val Lys Ala Tyr Gly Ala Gly Leu Leu Ser Ser Tyr Gly Glu Leu Leu
 385 390 395 400

His Cys Leu Ser Glu Glu Pro Glu Ile Arg Ala Phe Asp Pro Glu Ala
 405 410 415

Ala Ala Val Gln Pro Tyr Gln Asp Gln Thr Tyr Gln Ser Val Tyr Phe
 420 425 430

Val Ser Glu Ser Phe Ser Asp Ala Lys Asp Lys Leu Arg Ser Tyr Ala
 435 440 445

Ser Arg Ile Gln Arg Pro Phe Ser Val Lys Phe Asp Pro Tyr Thr Leu
 450 455 460

Ala Ile Asp Val Leu Asp Ser Pro Gln Ala Val Arg Arg Ser Leu Glu
 465 470 475 480

Gly Val Gln Asp Glu Leu Asp Thr Leu Ala His Ala Leu Ser Ala Ile
 485 490 495

Gly

<210> 23

<211> 1029

<212> DNA

<213> Homo sapiens

<400> 23

```
atgagccccg cggggcccaa ggtcccctgg ttcccaagaa aagtgtcaga gctggacaag      60
tgtcatcacc tggtcaccaa gttcgaccct gacctggact tggaccaccc gggcttctcg      120
gaccaggtgt accgccagcg caggaagctg attgctgaga tcgccttcca gtacaggcac      180
ggcgacccga ttccccgtgt ggagtacacc gccgaggaga ttgccacctg gaaggaggtc      240
tacaccacgc tgaagggcct ctacgccacg cacgcctgcg gggagcacct ggaggccttt      300
gcttttgctgg agcgcttcag cggctaccgg gaagacaata tccccagct ggaggacgtc      360
tcccgccttc tgaaggagcg cacgggcttc cagctgcggc ctgtggccgg cctgctgtcc      420
gcccgggact tcctggccag cctggccttc cgcgtgttcc agtgcacca gtatatccgc      480
cacgcgtcct cgcccatgca ctcccctgag ccggactgct gccacgagct gctggggcac      540
gtgcccattg tggccgaccg caccttcgcg cagttctcgc aggacattgg cctggcgtcc      600
ctgggggcct cggatgagga aattgagaag ctgtccacgc tgtactggtt cacggtggag      660
ttcgggctgt gtaagcagaa cggggaggtg aaggcctatg gtgccgggct gctgtcctcc      720
tacggggagc tcctgcactg cctgtctgag gagcctgaga ttcgggcctt cgaccctgag      780
gctgcggccg tgcagcccta ccaagaccag acgtaccagt cagtctactt cgtgtctgag      840
agcttcagtg acgccaagga caagctcagg agctatgcct cacgcatcca gcgccccttc      900
tccgtgaagt tcgaccgta cacgctggcc atcgacgtgc tggacagccc ccaggccgtg      960
cggcgctccc tggagggtgt ccaggatgag ctggacaccc ttgcccatgc gctgagtgcc     1020
attggctag                                     1029
```

<210> 24

<211> 342

<212> PRT

<213> Homo sapiens

<400> 24

```
Met Ser Pro Ala Gly Pro Lys Val Pro Trp Phe Pro Arg Lys Val Ser
1          5          10          15
```

Glu Leu Asp Lys Cys His His Leu Val Thr Lys Phe Asp Pro Asp Leu
20 25 30

Asp Leu Asp His Pro Gly Phe Ser Asp Gln Val Tyr Arg Gln Arg Arg
35 40 45

Lys Leu Ile Ala Glu Ile Ala Phe Gln Tyr Arg His Gly Asp Pro Ile
50 55 60

Pro Arg Val Glu Tyr Thr Ala Glu Glu Ile Ala Thr Trp Lys Glu Val
65 70 75 80

Tyr Thr Thr Leu Lys Gly Leu Tyr Ala Thr His Ala Cys Gly Glu His
85 90 95

Leu Glu Ala Phe Ala Leu Leu Glu Arg Phe Ser Gly Tyr Arg Glu Asp
100 105 110

Asn Ile Pro Gln Leu Glu Asp Val Ser Arg Phe Leu Lys Glu Arg Thr
115 120 125

Gly Phe Gln Leu Arg Pro Val Ala Gly Leu Leu Ser Ala Arg Asp Phe
130 135 140

Leu Ala Ser Leu Ala Phe Arg Val Phe Gln Cys Thr Gln Tyr Ile Arg
145 150 155 160

His Ala Ser Ser Pro Met His Ser Pro Glu Pro Asp Cys Cys His Glu
165 170 175

Leu Leu Gly His Val Pro Met Leu Ala Asp Arg Thr Phe Ala Gln Phe
180 185 190

Ser Gln Asp Ile Gly Leu Ala Ser Leu Gly Ala Ser Asp Glu Glu Ile
195 200 205

Glu Lys Leu Ser Thr Leu Ser Trp Phe Thr Val Glu Phe Gly Leu Cys

210

215

220

Lys Gln Asn Gly Glu Val Lys Ala Tyr Gly Ala Gly Leu Leu Ser Ser
 225 230 235 240

Tyr Gly Glu Leu Leu His Cys Leu Ser Glu Glu Pro Glu Ile Arg Ala
 245 250 255

Phe Asp Pro Glu Ala Ala Ala Val Gln Pro Tyr Gln Asp Gln Thr Tyr
 260 265 270

Gln Ser Val Tyr Phe Val Ser Glu Ser Phe Ser Asp Ala Lys Asp Lys
 275 280 285

Leu Arg Ser Tyr Ala Ser Arg Ile Gln Arg Pro Phe Ser Val Lys Phe
 290 295 300

Asp Pro Tyr Thr Leu Ala Ile Asp Val Leu Asp Ser Pro Gln Ala Val
 305 310 315 320

Arg Arg Ser Leu Glu Gly Val Gln Asp Glu Leu Asp Thr Leu Ala His
 325 330 335

Ala Leu Ser Ala Ile Gly
 340

<210> 25
 <211> 589
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> CMV promoter

<400> 25
 tagttattaa tagtaatcaa ttacgggggtc attagttcat agcccatata tggagttccg 60
 cgttacataa cttacggtaa atggcccgcc tggctgaccg cccaacgacc cccgccatt 120
 gacgtcaata atgacgtatg ttcccatagt aacgccaata gggactttcc attgacgtca 180

atgggtggag tatttacggt aaactgccca cttggcagta catcaagtgt atcatatgcc	240
aagtacgccc cctattgacg tcaatgacgg taaatggccc gcctggcatt atgcccagta	300
catgacctta tgggactttc ctacttggca gtacatctac gtattagtca tcgctattac	360
catggtgatg cggttttggc agtacatcaa tgggcgtgga tagcggtttg actcacgggg	420
atttccaagt ctccacccca ttgacgtcaa tgggagtttg ttttggcacc aaaatcaacg	480
ggactttcca aaatgtcgta acaactccgc cccattgacg caaatgggcg gtaggcgtgt	540
acggtgggag gtctatataa gcagagctgg tttagtgaac cgtcagatc	589

<210> 26
 <211> 272
 <212> DNA
 <213> Homo sapiens

<400> 26	
ttcgaacagg taagcgcccc taaaatccct ttgggcacaa tgtgtcctga ggggagaggc	60
agcgacctgt agatgggacg ggggcactaa ccctcaggtt tggggcttct gaatgtgagt	120
atcgccatgt aagcccagta tttggccaat ctcagaaagc tcctgggtccc tggagggatg	180
gagagagaaa aacaaacagc tcctggagca gggagagtgc tggcctcttg ctctccggct	240
ccctctgttg ccctctgggt tctccccagg tt	272

<210> 27
 <211> 82
 <212> DNA
 <213> Mice minute virus

<400> 27	
gtaagggttt aagggtggt tggttggtgg ggtattaatg ttttaattacc tggagcacct	60
gcctgaaatc actttttttc ag	82

<210> 28
 <211> 304
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> 3'UTR coding sequence

<400> 28
 gtgcacggcg tccctgaggg cccttcccaa cctcccctgg tcctgcactg tcccggagct 60
 caggccctgg tgaggggctg ggtcccgggt gcccccatg ccctccctgc tgccaggctc 120
 ccactgcccc tgcacctgct tctcagcgca acagctgtgt gtgcccgtgg tgaggttgtg 180
 ctgcctgtgg tgaggtcctg tcctggctcc cagggtcctg ggggctgctg cactgccctc 240
 cgcccttccc tgacactgtc tgctgccccca atcacgtca caataaaaga aactgtggtc 300
 tcta 304

<210> 29
 <211> 6
 <212> DNA
 <213> Artificial Sequence
 <220>
 <223> 5'UTR coding sequence

<400> 29
 gccacc 6